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Mitochondrial research has made tremendous strides since the 1980/90s when mitochondrial 
DNA mutations were first identified as a primary cause for human diseases and the 
organelle’s role in apoptosis was elucidated.  These mutations of the mitochondrial genome 
have been implicated in a spectrum of clinical disorders especially involving the muscle and 
central nervous system. This makes the mitochondrion a prime candidate for organelle-
specific delivery of exogenous materials such as therapeutic DNA and drugs, for therapy of 
diseases caused by mitochondrial dysfunction. However, reports of mitochondrial targeted 
delivery systems are limited. Hence vector design and development is of paramount 
importance.  The success of liposomes viz. cationic liposomes, in chromosomal gene therapy 
make them potential vectors for mitochondrial gene targeting.   
  
In this investigation novel ‘mitochondriotropic’ liposomes were synthesised to evaluate their 
cellular uptake and mitochondrial localisation activity in vitro using four different 
mammalian cell culture models. Cationic cholesterol derivative, 3β [N-(N’,N’-
dimethylaminopropane)-carbamoyl] cholesterol (CHOL-T) was formulated with 
dioleoylphosphatidylethanolamine (DOPE) to produce cationic liposomes, to which a 
mitochondrial targeting sequence (MTS) and octaarginine (R8) peptides were attached via 
two different novel cholesterol-derived cross-linking agents.  Size, zeta potential, shape and 
lamellarity of liposomes and corresponding lipoplexes were assessed by the innovative 
technique, Nanoparticle Tracking Analysis (NTA) and cryogenic transmission electron 
microscopy.  Their ability to bind, condense and protect plasmid DNA (pCMV-luc), was 
determined using the band shift, dye displacement and nuclease protection assays repectively.  
In vitro cytotoxicity and mechanism of cell death prompted by these novel liposomal 
preparations was determined using the MTT, AlamarBlue
® 
 and acridine orange and ethidium 
bromide (AO/EB) dual staining assays respectively, in the hepatocyte-derived human cell line 
(HepG2), human embryonic kidney cells (HEK293), the human intestinal cell line (Caco-2) 
and human cervical carcinoma (HeLa-Tat luc) cells.  Fluorescently labelled DNA was used to 
determine cellular uptake and mitochondrial targeting and localisation ability of these 
cationic mitochondriotropic liposomal formulations in the target organelles, mitochondria 
using fluorescence microscopy and the quantitative evaluation of fluorescence in the 
mitochondrial fraction of cell homogenate cocktails.  
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These mitochondriotropic liposomes successfully bind, condense and protect plasmid DNA 
in the presence of serum, are fairly well tolerated by all cell lines tested in culture with cell 
death observed to be apoptotic and not necrotic in nature.   The liposomes were shown to 
successfully enhance cellular uptake in all cell culture models tested.  Furthermore, results 
demonstrate positive mitochondrial targeting and localisation activity facilitated by the 
presence of MTS peptide and a combination of MTS and R8 peptides on the liposomal 
surface for all four of these novel liposomal nanovectors. 
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MTS    Mitochondrial Targeting Sequence 
MtDNA   Mitochondrial DNA 
nDNA   Nuclear DNA 
N/P    Amine to phosphate ratio 
NTA    Nanoparticle Tracking Analysis 
OD    Optical density 
OXPHOS   Oxidative phosphorylation system 
PBS    Phosphate buffered saline 
pDNA   Plasmid DNA 
PD    Parkinson's disease 
PEG    Polyethylene glycol 
PEI    Polyethyleneimine 
PLL   Poly-L-lysine 
SD    Standard deviation 
SE    Standard error 
SDS    Sodium dodecyl sulphate 
SP-CHOL    3β-[N-(hydrazino 3-{2-pyridyldithio} propionate)-carbamoyl]   
                                    cholesterol 
SPDP    Succinimidyl 3-(2-pyridyldithio) propionate  
TAT    Trans-activated transcription 
TCA    Cycle tricarboxylic acid cycle 
TLC    Thin layer chromatography 
TIM   Translocator inner membrane 
TOM    Translocator outer membrane 
tRNA    Transfer RNA 
R8    Octaarginine 
RES     Reticuloendothelial system 
ROS     Reactive oxygen species  
TPP    Triphenylphosphonium  
v/v    Volume to volume ratio  
w/v   Weight to volume ratio  
w/w    Weight to weight ratio 
λ    Wavelength (lambda)  
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1.1.  BACKGROUND OF STUDY 
 
The efficient and site-specific distribution of therapeutic agents is a vitally important issue in 
nanotechnology.  Many reports have detailed nanocarriers directed to specific cells and 
tissues however there is a distinct lack of development in nanocarriers that target a specific 
organelle, such as mitochondria, the endoplasmic reticulum and the Golgi apparatus, all of 
which represent promising potential targets for therapeutic agents. Of these organelles, 
mitochondria are of immense interest due to its association with several human diseases, in 
addition to playing a key role in apoptosis in mammalian cells.  Mitochondria are DNA-
containing organelles found in almost all eukaryotic cells.  They contain a small circular 16,6 
kb DNA molecule that resides inside the matrix space and are the prime ATP energy 
generating sites in eukaryotic cells. They are intimately involved in maintaining the 
homeostasis of vital physiological functions, in addition to its array of other functions ranging 
from apoptosis, calcium signalling, intermediary metabolism to aging (D’Souza et al., 2007; 
Scheibye-Knudsen et al., 2014).   
 
Mitochondrial research has made a giant leap since early 1988 and 1990s respectively, when 
mitochondrial DNA mutations were first identified as a primary cause for human diseases 
and the organelle’s role in apoptosis was elucidated (Horobin et al., 2007).  However there is 
much that is still not fully understood about diseases caused by mitochondrial dysfunction.  It 
has been reported by a number of studies that mutations or genetic defects in mitochondrial 
DNA (mtDNA) are linked to mitochondrial diseases or dysfunctions leading to human 
disorders such as diabetes mellitus, increased susceptibility to cancer, and neurodegenerative 
diseases such as Alzheimer’s, Huntington’s and Parkinson’s disease, (Yamada et al., 2015; 
Salvado et al., 2015).  In fact, the prevalence of pathogenic mitochondrial DNA mutations is 
extremely high, and recently estimated to occur in every 1 of 200 adults (Tischner and Wenz, 
2015).  Currently, treatment options for mitochondrial diseases are limited to being palliative 




mitochondrial dysfunction remain elusive as human mitochondria within living cells have 
limited accessibility to direct physical, biochemical and pharmacological manipulation.  
Therefore, incursion of nanotechnologies such as gene therapy into mitochondrial research by 
targeting of genetic material or drugs to the mitochondria could hold the promise of assisting 
to overcome these obstacles, and are promising candidates for the therapeutic treatment of 
mitochondrial diseases.   
 
Presently, there have been reports of numerous systems for delivery of nucleic acids, 
including several successful gene therapies, to the nucleus and cytosol, however, far less 
progress has been made concerning mitochondrial gene delivery nanovectors (Yamada et al., 
2015).  Hence, there has been a paucity of information about mitochondrial targeted delivery 
using nanoparticles, although there have been reports of mitochondrial delivery of various 
biomolecules in isolated mitochondria and cell homogenates (Yamada and Harashima, 2013). 
However, it is significant to note that in respect to successful nuclear gene therapies, 
mitochondrial gene therapy has never been achieved (Yamada et al., 2015).   This is because 
of the lack of an optimal mitochondrial targeting system that can sophistically regulate 
cellular uptake, endosomal escape and mitochondrial targeting.  Thus, it appears that the need 
for an ideal vector for mitochondrial targeting has become a rate-limiting step.   
 
To this end, modification of strategies that made chromosomal gene therapy successful could 
be utilised for mitochondrial targeting.   Although conceptually simple, the translation of 
gene therapy into effective therapies has proven to be extremely challenging, featuring many 
decades of scientific development, failed clinical trials and numerous other setbacks.  
Through this all, gene therapy has still emerged as a new paradigm for the treatment of 
human disease, and is considered by many as a potential revolution in modern day molecular 
medicine.  Until fairly recently, most gene therapy experimental designs have made use of 
viruses as delivery vehicles, however increased inflammatory-type toxicities attributed to the 
activation of adaptive and innate immune responses in hosts in response to the viral-based 
vectors were observed.  This led to non-viral vectors being the delivery vehicle of choice, 
particularly, liposomes.  The success of phospholipid vesicles or liposomes, more specifically 
cationic liposomes, as gene delivery vehicles for chromosomal gene therapy have made them 





This study aims to address the need for a safe and efficient mitochondrial targeted nanovector 
system, by developing a non-toxic, cationic mitochondriotropic liposomal delivery system for 
specific mitochondrial targeting and localisation.  It is hoped that the development of an ideal 
vector system able to successfully target therapeutic genes and agents to the mitochondria in 
a clinical setting will open up a new window into the treatment and possible cure of 
mitochondrial diseases and mitochondrial associated diseases such as cancer,  Parkinson’s 
and Alzheimer’s disease. 
 
 
1.2.  SCOPE OF STUDY  
 
Mitochondrial gene and drug delivery is a field still in its infancy, due in part, to the absence 
of an ideal delivery vehicle to facilitate mitochondrial localisation and subsequent delivery.  
There is currently a search for a model vector system for gene/drug delivery that can 
specifically localise to the site of mitochondria of cells i.e. it is mitochondriotropic.  This 
vector system should ideally be biodegradable, non-toxic, stable to storage, display low 
immunogenicity as well as have high therapeutic efficacy.  To this end, non-viral vectors, 
specifically cationic liposomes, meet all prerequisites for an ideal delivery vehicle which they 
have proven to be with their considerable success in traditional nuclear gene delivery.  
However, their design and application in mitochondrial localisation requires streamlining.  
Accordingly, this study evaluates the ability of four novel cationic mitochondriotropic 
liposomal formulations to improve the efficacy of cellular uptake and mitochondrial 
localisation of plasmid DNA in four different cell line models.   
 
1.2.1.   Hypothesis 
 
Cationic liposome-based delivery systems comprising the cytofectin, 3 β [N-(N’, N’- 
dimethylaminopropane)-carbamoyl] cholesterol (CHOL-T); cross-linking agents, 3β-[N-
(hydrazino 3-{2-pyridyldithio} propionate)-carbamoyl] cholesterol (SP-CHOL) and 3β-[N-
(hydrazino-γ-maleimidobutyryl)-carbamoyl] cholesterol (GM-CHOL); mitochondria 
targeting ligand, mitochondrial targeting sequence (MTS) and octaarginine (R8) peptides 
display minimal toxicity in various cell lines as well as efficiently and effectively enhances 
cellular uptake and mitochondrial localisation of model plasmid DNA in selected mammalian  




1.2.2.  Aim  
 
The main aim of this investigation was the development of mitochondrial targeting vectors in 
the form of four cationic mitochondriotropic liposomal formulations and the evaluation of 
their chemical and biophysical characteristics, cytotoxicity, cellular uptake as well as their 
mitochondrial targeting and localisation activity in four cell lines.   
 
 
1.2.3.  Objectives  
 
The following objectives form the basis to test the hypothesis and achieve the aim: 
 Preparation of four cationic liposomes (CHOL-T), two incorporating the cholesterol-
derived cross-linker, SP-CHOL and two containing GM-CHOL.  Each of these is 
made mitochondriotropic by the addition of the MTS peptide only or a combination of 
MTS and R8 peptides. 
 Preparation of liposome-pDNA complexes and characterisation of these lipoplexes in 
terms of size and zeta potential by Nanoparticle Tracking Analysis (NTA), and 
morphologically utilising cryogenic-transmission electron microscopy (cryo-TEM). 
 Determination of binding capacity and serum stability of resultant lipoplexes using 
gel retardation, nuclease protection and ethidium bromide intercalation assays. 
 Evaluation of cytotoxicity in selected mammalian cell lines in vitro by employing the 
3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) growth 
inhibition and AlamarBlue
® 
assays; detection of apoptosis by acridine orange and 
ethidium bromide (AO/EB)  staining. 
 Determination of cellular uptake and mitochondrial localisation by fluorescent 
microscopy and quantification of mitochondrial targeting activity.   
 
 
1.3.  NOVELTY OF STUDY 
 
The synthetic cationic cholesterol-derived cytofectin, CHOL-T was previously synthesised in 
our laboratory (Singh et al., 2001).  Liposomes were formulated with a constant 50 mol% 
composition of CHOL-T, a varying mole percentage of dioleoylphosphatidylethanolamine 




CHOL or GM-CHOL.  The novelty of these previously synthesized liposomes is that they 
were taken a step further and made mitochondriotropic by the addition of MTS and R8 
peptides.  There have been no previous studies documented involving this novel combination 
of lipids and peptide additives.  Accordingly, this study aims to assess the ability of these 
novel liposomal formulations to facilitate cellular uptake as well as mitochondrial localisation 
and targeting activity in the chosen cell lines.   
 
 
1.4.  OUTLINE OF THESIS 
 
Chapter One  
 
This chapter provides an introduction and background to the study. It highlights the 
challenges of mitochondrial gene delivery and non-viral gene delivery systems.  Additionally, 
it outlines the rationale, scope, aim and objectives of the investigation. 
 
Chapter Two  
 
This chapter reviews in depth the relevant literature.  Firstly, it details non-viral gene delivery 
nanovectors.  Secondly, it highlights the mitochondria, types of mitochondrial diseases and 
their implications.  Lastly, it explores the experimental strategies currently being investigated 
to correct mitochondrial defects and the feasibility thereof. 
 
Chapter Three  
 
The contents of this chapter details the experimental design and describes the laboratory 
methods undertaken.  The syntheses of the cationic cytofectin and the cholesterol-derived 
cross-linkers and their subsequent formulation into cationic liposomes are described.  
Thereafter, the process of attaching the respective peptides to the surface of liposomes to 
generate mitochondriotropic liposomes is discussed, followed by determination of DNA 
binding and nuclease protection by gel retardation, ethidium bromide intercalation and 
nuclease protection assays respectively.  Thereafter, further physical characterisation of 
liposomes and corresponding lipoplexes facilitated by the innovative technique of NTA and 
cryo-TEM is illustrated.  Lastly, in vitro cell culture studies examining the cytotoxicity 








assays in HepG2, HEK293, Caco-2 
and HeLa-Tat luc, cell lines, followed by a description of fluorescent studies used to establish 




Chapter four details all the results acquired, together with a comprehensive discussion on the 
interpretation of these results and their implications providing perspective to this study.  
 
Chapter Five  
 
This final chapter concludes the study by emphasising outcomes which are significant to the 
aim and objectives of the investigation.  Contributions of the study to the area of 
mitochondrial research are documented and assessed, while possible limitations and 
inadequacies of the study are evaluated.  Finally, recommendations for further research to 













2.1.  GENE THERAPY: AN OVERVIEW   
 
The use of nucleic acids as therapeutically useful molecules, offers a fundamental approach 
to the treatment of a variety of diseases of acquired or genetic origin (Smith, 1999; Huang et 
al., 1999).  The concept of gene therapy has provided a new paradigm for the treatment of 
human diseases and is considered by many as a potential revolution in medicine.  This is 
because the ultimate goal of gene therapy is to eliminate the causes of diseases by adding, 
correcting or replacing genes whereas most current treatment of diseases is by simply treating 
the symptoms not the causes (Mountain, 2000; Huang et al., 1999).  Gene therapy is a 
promising therapeutic strategy centred on correcting chronic ailments, such as cancer, and 
other pathogenic diseases through genetic modification.  The basis of this therapy requires the 
introduction of an exogenous nucleic acid molecule, such as DNA, mRNA, miRNA, and 
RNAi molecules, such as siRNA or small hairpin RNAs (shRNA), and antisense 
oligonucleotides (AONs), into the cell to achieve the desired therapeutic benefit with the 
nucleic acid molecule serving as a ‘drug’ (Lasic, 1997; Hill et al., 2016). 
 
The basic ideas for gene therapy were first expressed in the 1960’s when Amos (1961) found 
that the uptake of nucleic acid molecules into cultured cells was enhanced when RNA was 
complexed with protamine  (Huang et al., 1999).  Following that initial discovery, several 
other articles were published which clearly established that complexation of DNA or RNA 
with agents such as gelatin, methylated protein, polylysine and polyarginine increased 
transfection and/or infectivity (Huang et al., 1999).  In 1972, a discussion of gene therapy 
was offered in which it was proposed that a set of ethicoscientific criteria be formulated to 
guide the clinical application and development of gene therapy techniques (Friedmann and 
Roblin, 1972).  Since then a number of advances and discoveries, such as the development of 
retroviral vectors with almost 100% transfection efficiency in 1982, have been made leading 




patients with adenosine deaminase deficiency.  Mullen and co-workers used a retrovirus to 
insert the gene that codes for adenosine deaminase into lymphocytes ex vivo (Mullen et al., 
1996).  A summary of some of the key events in the development of gene therapy is seen in 
Table 2.1.     
 
 
TABLE 2.1:  Summary of key events in the development of gene therapy  




In the last two decades a number of gene therapy trials, involving genetic diseases such as 
cystic fibrosis, acquired diseases such as cancer and infectious diseases such as AIDS, have 
been initiated (Nishikawa and Huang, 2001).  Some examples of diseases targeted by gene 





1944 First description that genetic material is carried in the form of DNA  
1953 Watson and Crick describe the double-helix structure of DNA 
1956 Viral genomes can be permanently incorporated in cell genomes 
1961-2 Foreign DNA can integrate stably into mammalian cellular genomes 
1972 A discussion of gene therapy was offered 
1981-2 
Retroviral vectors were developed to transfer foreign DNA to essentially 
100% of exposed mammalian cells 
1987 Synthesis of cationic lipid, DOTMA 
1990 Adenosine deaminase gene therapy trial was initiated 
1992 First gene therapy trial using DC-CHOL/DOPE cationic liposomes 
1990s Other gene delivery systems were developed 
2003 
China becomes the first country to approve a gene therapy based product for 
clinical use 
2009 First successful gene therapy phase III gene therapy clinical trial in the EU 




TABLE 2.2:  Examples of some disease applications of gene therapy (Lasic, 1997; Hill et  
















Currently, there are more than 1800 approved, ongoing or pending clinical trials worldwide 
(Wirth et al., 2013) (Figure 2.1).  More than 60% of these trials are directed at cancer with 
most of the remainder targeted to monogenetic disorders, cardiovascular and infectious 
diseases. 
 
Figure 2.1: Graphical representation of indications of diseases/disorders addressed by      
                    worldwide gene therapy clinical trials  [The Journal of Gene Medicine, Wiley and    
                    Sons (http://www.abedia.com/wiley/index.html) accessed 03/03/2016].         
DISEASE 
Cystic fibrosis  
Sickle cell anemia  
Gaucher’s disease  
Duchenne muscular dystrophy  
Cancer  
HIV-1 










Almost 50 years after its ‘discovery’, gene therapy has had modest success.  In 2007 
University College London’s Institute of Opthalmology reported a clinical trial for inherited 
retinal disease using a recombinant adeno-associated virus.  The subject showed a moderate 
increase in vision and no apparent side effects (Bainbridge et al., 2008).  China became the 
first country to approve a gene therapy based product for clinical use in 2003 with 
Gendicine
™
, an adenoviral vector with human p53 cDNA for treatment of head and neck 
squamous cell carcinoma.  Oncorine
™
, another adenoviral vector for treatment of late-stage 
refractory nasopharyngeal cancer, was also approved, in China in 2005 (Wirth et al., 2013).  
The European Medicines Agency (EMA) recommended, for the first time, approval of a gene 
therapy product, Glybera, in the EU in July 2012.  Glybera is an adeno-associated viral vector 
manufactured to express lipoprotein lipase in the muscle tissue for the management of severe 
lipoprotein lipase deficiency (Wirth et al., 2013). Other gene delivery based products include 
Rexin G and Neovasculgen (Hill et al., 2016). 
 
Even with this very moderate success, 95% of clinical trials evaluating gene delivery 
technology have failed to progress beyond Phase II trials, demonstrating that there are still 
compelling challenges to producing clinically relevant, effective gene therapies (Hill et al., 
2016).  Some of these include identification of diseases and access to target tissue, gene 
defect identification, stable and prolonged expression of newly introduced genes, immune 
response of the body, long and short term toxicity and probably the most limiting of all, the 
development of a vector that can selectively and efficiently deliver a gene to target cells with 
minimal toxicity (Smith, 1999; Li and Ma, 2001). 
 
The scientific community have been constantly looking into ways of overcoming these 
hurdles and have taken up the challenge to develop a safe and efficient vector that can be 
employed in gene therapy both in vitro and in vivo with no restrictions and side effects.   
Hence to date, a great deal of interest has been focused on basic research into finding an ideal 
gene delivery system. 
 
 
2.2.  GENE DELIVERY VECTORS  
 
In traditional gene therapy, in order for genes to be expressed they must be able to enter the 




for two reasons: large size and repulsion due to their anionic charges (Ropert, 1999; Hill et 
al., 2016).  Hence, the need for a suitable vector to ‘carry/transport’ the nucleic acid or 
biomacromolecule.  An ideal vector is regarded as one that should be safe, stable, easy to 
produce and proficient at achieving efficient, extended and cell or tissue specific gene 
expression (Li and Ma, 2001).  Gene delivery systems generally fall into two categories: viral 
and non-viral.  Viral vectors include all viruses used in the delivery of genes while non-viral 
vectors encompass all other methods of gene delivery.  The advantages and disadvantages of 
these vectors are detailed in Table 2.3. 
 
TABLE 2.3: Summary of advantages and disadvantages of gene delivery systems  
                      (Adapted from Mountain, 2000; Nayerossadat et al., 2012).  
 
Vector Advantages Disadvantages 
Adenovirus 
Very high transfection efficiency ex vivo and in vivo 
Transfects both dividing and non-dividing cells 
Substantial clinical experience 
Characterized by complexity, stability, and integrity 
Acute and strong immune responses 
Transgene  size limit of 7.5 kb 
Manufacture and storage are moderately difficult 
Short duration of expression 
Retrovirus 
Fairly prolonged expression 
High transfection efficiency ex vivo 
Substantial clinical experience 
Low immunogenicity 
 
Low transfection efficiency in vivo 
Transgene size limit of 8 kb 
Transfects only dividing cells 




Efficiently transfects a wide variety of cells in vivo 
Very prolonged expression in vivo 
Low immunogenicity 
High stability, safety and efficacy 
Transgene limit of 4.8 kb 
Manufacture and production  is very difficult 
Little clinical experience 
Safety concern of mutagenesis 
Repeat dosing affected by neutralising antibodies 
Naked DNA 
Manufacture, storage are simple and safe 
Very low immunogenicity 
Very good safety profile 
Clinical efficacy demonstrated in critical limb ischemia 
Very short duration of expression in most tissues 
Very inefficient transfection in vivo 
Retargeting transfection very difficult 
Has to be applied directly 
Cationic liposomes 
Relatively simple manufacture and storage 
Efficient transfection ex vivo and in vitro 
Low immunogenicity and antigenicity 
Good safety profile 
Inefficient transfection in vivo 
Short duration of expression and rapid  clearance by  
Little clinical experience 
Retargeting transfection difficult 
Cationic polymers 
Relatively simple manufacture and storage 
Efficient transfection ex vivo and in vitro 
Low immunogenicity 
Good safety profile 
Retargeted transfection demonstrated 
Inefficient transfection in vivo 
Very short duration of expression 
Non-biodegradable nature of  PEI 






2.2.1.  Viral Vectors   
 
Viral vectors are replication-deficient viruses with part of their viral sequence modified by 
deletion and replaced by therapeutic genes (Li and Ma, 2001).  Generally most viral vectors 
are highly efficient gene transfer vehicles as they contain all of the necessary characteristics 
for successful gene transfer such as cell adhesion, membrane translocation, efficient 
transcription and translation (Cristiano et al., 1993).  In addition, their ability to stably 
integrate exogenous DNA into host chromosomes and their high specificity are among the 
major reasons why viral vectors were employed in more than 90% of clinical gene therapy 
trials (Singh et al., 2006; Walther, 2000; Hill et al., 2016).  However several limitations are 
inherent in their use.  Depending on the type of viral vector, these could include toxicity, high 
immunogenicity, low viral titres, limited transgenic capacity size and provocation of 
mutagenesis and carcinogenesis in hosts (Huang et al., 1999; Liu and Huang, 2002; 
Nayerossadat et al., 2012).  In 1999, the worst case scenario for viral vectors became a reality 
when an 18 year old patient taking part in a gene therapy clinical trial died as a direct result 
of the adenovirus used for the treatment, highlighting safety issues with viral vectors and 
necessitating further investigation regarding overcoming technical limitations and improving 
biosafety (Wirth et al., 2013; Mertena and Gaillet, 2016).   
 
Retroviruses are the most extensively used vectors.  They are single-stranded RNA viruses 
which are constructed into viral vectors by replacing all viral genes required for replication 
with therapeutic genes.  This type of viral vector randomly incorporates the gene directly into 
the host chromosome leading to safety concerns such as mutagenesis and carcinogenesis 
(Lasic, 1997; Smith, 1999).  Adenoviruses are less hazardous as they do not integrate into the 
host chromosome so gene expression is short-lived (Huang et al., 1999).  This vector can be 
produced at high viral titres but suffers in that it often induces an inflammatory response from 
the host making repeat doses impossible (Huang et al., 1999).  These limitations can be 
overcome by the use of ‘gutless’ or ‘helper dependent’ adenoviruses, which lack all viral 
coding sequences (Józkowicz and Dulak, 2005).  Adeno-associated viruses are small non-
pathogenic DNA viruses that require a helper virus to replicate.  They infect both dividing 
and non-dividing cells and like retroviruses, the wild type version can integrate into the host 
chromosome in contrast to the recombinant adeno-associated virus vectors for which 
integration in chromosomes is rare and random (Mertena and Gaillet, 2016).  The major 




than 5 kb and produce low titres (Smith, 1999; Huang et al., 1999; Nayerossadat et al., 2012).   
Other viral vectors include the Herpes simplex viruses (HSV), the main disadvantage of 
which is their cytotoxicity; lentiviruses which suffer from low infectivity and the pox viruses 
which, although possessing a large transgene capacity, have a complex biology and structure, 
are immunogenic and provide only transient expression (Huang et al., 1999; Nayerossadat et 
al., 2012).   
 
As mentioned above, the safety concerns related to the use of these viruses in humans far 
outweigh their advantages making non-viral delivery systems an attractive alternative. 
 
 
2.2.2.  Non-viral Vectors   
 
Advantages of non-viral vectors include their simplicity of use, lack of specific immune 
response, low acute toxicity, no limitation in transgene capacity for most of the vectors and 
ease of large scale production (Li and Huang, 2000; Huang et al., 1999; Nayerossadat et al., 
2012).  These gene delivery vehicles have the potential to provide nucleic acid-based 
therapeutics that strongly resemble traditional pharmaceuticals in that the products may be 
capable of repeat dosages with minimal toxicity, be able to be produced in large quantities at 
an acceptable cost, have high reproducibility and lastly be stable to enable storage (Davis, 
2002).  Non-viral gene delivery vectors can be non-targeted or targeted to a specific cell or 
tissue type (Singh, 1998).  Several non-viral delivery methods exist and they can be broadly 
divided into two categories, naked DNA delivery by a physical method or DNA delivery by 
complexation with a cationic carrier (Nishikawa and Huang, 2001; Nayerossadat et al., 
2012).  These methods will be discussed in brief. 
 
 
2.2.2.1.  Naked DNA Injection  
 
The direct transfer of DNA into the nucleus of cells by microinjection is the simplest system 
for DNA delivery (Nishikawa and Huang, 2001).  The DNA used can be produced on a large 
scale by cultivation of plasmid harbouring Escherichia coli.  Direct DNA transfer by this 
method is not feasible as it is difficult for the naked DNA to enter cells due to their large size, 




only a few tissues i.e. the skeletal muscle, the heart muscle, liver and solid tumours (Singh, 
1998; Huang et al., 1999; Manjila et al., 2013).  However, they are more suitable as ‘DNA 




2.2.2.2.  Gene Gun Method    
 
This method is also referred to as the ballistic method, the particle acceleration method or 
DNA coated particle bombardment (Lasic, 1997; Manjila et al., 2013).  This physical method 
involves shooting gold, tungsten or silver microparticles coated with pDNA into target cells 
or tissues with a gene gun (Nishikawa and Huang, 2001; Manjila et al., 2013).  The gene gun 
method allows for DNA to penetrate directly into the cell thereby bypassing enzymatic 
degradation by the endosomal pathway (Li and Huang, 2000).  A major drawback of this type 
of gene delivery is that the target tissues have to be surgically exposed and there is only low 
level of gene product (Huang et al., 1999; Nishikawa and Huang, 2001).  A possible 




2.2.2.3.  Electroporation and Nucleofection   
 
Electroporation was first described in the 1965 by Coster.  This method involves the 
application of short, intense bursts of controlled electrical pulses to induce transient 
membrane destabilisation of the target cells, thereby allowing the DNA to enter the 
cytoplasm.  After initial permeabilisation, the pores on the membrane close trapping the DNA 
inside the cell (Nishikawa and Huang, 2001; Nayerossadat et al., 2012). To date, this 
technique has been applied to the skin, liver, lung, muscle and in tumour treatment but the 
parameters associated with optimal gene expression differ from tissue to tissue making 
implementation of this method on a large scale difficult (Nishikawa and Huang, 2001).   
 
Nucleofection is a further development of electroporation.  It follows the same principle as 
electroporation however this cell-type specific technique depends on less harmful electrical 







2.2.2.4.  Cationic Polymers  
 
High molecular weight, long chain polymers bearing cationic groups have been used to 
condense DNA via electrostatic interaction and thus facilitate gene transfer (Huang et al., 
1999; Mountain, 2000).  The complexes formed between cationic polymers and DNA are 
referred to as ‘polyplexes’ (Felgner et al., 1997).  The complexation between the polymer and 
DNA protects the nucleic acid molecule from degradation, increases the stability of DNA, 
enhances endocytosis or cellular uptake and enters the nucleus to release the nucleic acid 
molecule (Manjila et al., 2013).  Commonly used polymers include polyethylenimines (PEI), 
poly-L-lysine (PLL), poly-L-ornithine and chitosan (Nishikawa and Huang, 2001; Oku et al., 
2001).  These polymers can be readily chemically synthesised, making them amenable to 
scalable synthesis.  There has recently been a surge in the use of polymer-based vectors, 
possibly due to the growing understanding of polymer gene-delivery mechanisms. 
 
 
2.2.2.5.  Liposomes 
 
Liposomes have been described as vesicular colloidal particles that are composed of self-
assembled amphiphilic molecules (Lasic, 1997).  These ‘liposomal particles’ were first 
developed by Bangham in 1965 and due to their resemblance to cell membranes they have 
been extensively used as  model membrane systems (Smith et al., 1993).  
 
Liposomes are vesicles consisting of one or more concentric bilayers alternating with 
aqueous compartments, within which a variety of lipid soluble or water soluble substances 
can be enclosed (Bangham et al., 1972).  Although, they are usually composed of 
biodegradable, reusable phospholipids, their design and structure is dependent on their 
intended function (Singh, 1998).  Due to their relatively simple design and ease of 
formulation techniques, these vectors are easily synthesised on a large scale.  Prior to their 
application to gene therapy, liposomes were widely used as carriers for a variety of drugs 
(Wang et al., 2006).  These artificial phospholipid vesicles are able to trap hydrophilic drugs 
in the inner aqueous space and lipophilic drugs in the phospholipid bilayer.  Liposome 
research has been the most successful at developing US FDA approved therapeutics such as 
Doxil
®











2009; Durazo and Kompella, 2011).  Additional applications of liposomes include a role in 
cosmetics and the possible use of liposomes in genetic vaccinations (Lasic, 1997; Gregoriadis 
et al., 2002).  As vehicles for the delivery of nucleic acid molecules, liposomes can offer a 
protective, biocompatible and biodegradable delivery system, safe from endogenous 
enzymes, which can further enhance their cellular uptake.  Liposome mediated gene delivery 
is known to exhibit a number of desirable advantages over viral vectors such as lack of 
mutagenesis, reproducibility and ease of use, significant transgene expression and decreased 
immunogenicity and toxicity, thus safety in their use (Koumbi et al., 2006; Percot et al., 
2004; Shim et al., 2013).  Liposomes serving as nanocarriers are currently the most 
represented class of nanoparticles used clinically (Hwang et al., 2015).  
 
Liposomes in general can interact with cells through four different mechanisms (Figure 2.2).  
These can be distinguished as (1) Adsorption, with extracellular release of the liposomal 
contents; (2) Adsorption with lipid exchange; (3) Endocytosis and (4) Fusion of the vesicle 
with the cell membrane (Torchilin, 2003).   The two types of adsorption lead to the contents 
of the liposomes entering the cell without the uptake of the intact liposome.  In the first type, 
the water soluble contents are released into the extracellular environment with the subsequent 
passive or active transport of the molecules into the cell.  The second type involves the 




Figure 2.2: Four mechanisms of liposome-cell interactions by which liposomes can deliver  






The process of fusion involves the complete mixing of the liposomal membrane with the cell 
membrane and, thereby release of the contents of the liposome into the cytoplasm of the cell 
(Torchilin, 2003).  The occurrence of any of these interactions depends largely on the 
characteristics of the liposome, such as size, composition, charge, the presence of targeting 
ligands, and the type of cell (Torchilin, 2003).  Endocytosis has been established as the 
principal mechanism of entry for non-viral nanoparticles.  Endocytosis can further be 
classified into different endocytic routes including phagocytosis, macropinocytosis, clathrin 
dependent endocytosis and clathrin independent endocytosis, which includes caveolae-
mediated internalisation (Figure 2.3).  Clathrin-dependent/-mediated endocytosis is the major 
route of lipoplex entry into cells.  Briefly, upon binding to the cell surface via electrostatic 
interactions; the liposome undergoes endocytotic internalisation followed by possible 
intracellular degradation via the endolysosomal pathway, and subsequent intracellular release 
of the liposomal content.  In order to achieve gene transfer, the DNA has to escape the 
endosome to avoid lysosomal degradation (Hoekstra et al., 2007). This is facilitated by the 
destabilisation of the endosomal membrane by a number of methods but mostly by the 
incorporation of DOPE in the structure of the liposome (Liu and Huang, 2002).  Recently, 
macropinocytosis has received attention as an efficient entry route for gene delivery as it 
displays some expedient features such as an increased uptake of biomolecules, evasion of 
lysosomal degradation and subsequent ease of escape from macropinosomes as a result of 
their inherently leaky nature (Khalil et al., 2006b).  To this end, a succinct description is  
 
 
Figure 2.3: Schematic detailing different endocytic pathways of entry into cells.  




warranted.  Macropinocytosis is a non-selective form of endocytosis that internalises particles 
like liposomes by the actin-driven formation of membrane ruffles and the succeeding 
engulfment of fluid that results in the formation of large macropinosomes.  These 
macropinosomes are relatively leaky and allow the escape of lipoplexes thus avoiding 
lysosomal degradation (Khalil et al., 2006b; Vercauteren et al., 2012).    
 
 
Liposomes can be divided into four different classes as defined with respect to their 




Figure 2.4: Four classes of liposomes as defined by their functionality. 
                    
 
Conventional or anionic liposomes are characterised by their non-specific interactions with 
the environment (Lasic, 1997).  They are composed of neutral or anionic phospholipids.  This 
type of liposome encapsulates macromolecules such as plasmid DNA within their aqueous 
environment.  As a rule, they are not considered very efficient gene delivery vectors as they 
have relatively small packing capacities that limit the size of plasmid DNA that can be 



























Targeted liposomes have ligands or targeting moieties such as monoclonal antibodies, 
peptides, lectins, growth factors, glycoproteins, receptor ligands, cell penetrating peptides, 
simple molecules such as carbohydrates and bioactive small molecules such as folic acid 
attached to the liposomal surface allowing for targeting to a specific cell type or tissue and 
thus increasing the cellular uptake of the liposome by target cells (Lasic, 1997; Immordino et 
al., 2006; Shim et al., 2013; Allen and Cullis, 2013). 
 
Stealth or long-circulating liposomes are terms adopted to apply to liposomes sterically 
stabilised with polymers such as polyethylene glycol (PEG).  The incorporation of a lipid 
derivative of PEG, into the bilayer of liposomes have been reported to improve their stability, 
inhibit protein adsorption onto the surface of the liposome and prevent opsonisation in vivo. 
This limits the liposomal recognition by the reticuloendothelial system (RES), consequently 
leading to an increase in the liposome systemic circulation time (Gabizon, 2001; Garinot, et 
al., 2007; Allen and Cullis, 2013). 
 
 
2.2.2.5.1.  Cationic Liposomes  
 
Cationic liposomes were not extensively studied in the first 20 years of liposome research due 
to their apparent high toxicity (Lasic, 1997).  However since 1987 when Felgner and 
colleagues reported the first successful in vitro transfection with their synthesised cationic 
lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 
containing  a monovalent cationic head group and two hydrocarbon tails [Figure 2.5 (a)], a 
number of other cationic lipids have been produced and have proven to be significant tools 
for cellular delivery of nucleic acids, including DNA, oligonucleotides, siRNA, miRNA (Li 
and Ma, 2001; Singh, 1998; Shim et al.,2013).  These include, N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulphate (DOTAP) [Figure 2.5 (b)]; 
3β[N,N’,N’-dimethylaminoethane)-carbamoyl] cholesterol (DC-CHOL), 
dioctadecylamidoglycyl-spermine (DOGS) and more recently, N’,N’-dioctadecyl-N-4,8-
diaza-10-aminodecanoyl glycine amide to name a few.  All cationic lipids have a common 
structure, a positively charged polar head group, one/two hydrophobic chains or steroid 










Figure 2.5: Structure of cationic lipids, (A) DOTMA and (B) DOTAP  
                   (Martin et al., 2005; Immordino et al., 2006). 
 
 
A typical cationic gene delivery system comprises three components: the cationic lipid, a 
neutral helper lipid such as dioleoylphosphatidylethanolamine (DOPE) and a nucleic acid 
such as plasmid DNA, siRNA, oligonucleotides or miRNA (Huang et al., 1999; Ju et al., 
2016).  The cationic lipid together with a neutral co-lipid forms the cationic liposome.  These 
positively charged liposomes can interact with negatively charged DNA through electrostatic 
forces to form a cationic liposome-DNA complex, known as a ‘lipoplex’ (Felgner et al., 
1997).  Several studies have suggested that successful nuclear gene transfer involves: 1) 
packaging of nucleic acid, 2) nonspecific interaction between the nanosystem and the cell 
surface, 3) internalisation of nucleic acid by endocytosis, 4) nucleic acid molecule escape 
from endosomes and 5) translocation of the nucleic acid and subsequent expression in cell 
nuclei (Hui et al., 1996; Nayerossadat et al., 2012).  Hence, cationic liposomes have been 
fairly successful gene delivery vehicles since their first deployment in this role in 1987.  To 
date, numerous cationic liposomes have been synthesised and used for the delivery of nucleic 
acid molecules into cultured cells, in animals and even in patients undergoing phase I and II 
clinical trials (Lonez et al., 2008).   
 
Cationic liposomes are the most extensively employed non-viral gene transfer agents as they 
offer distinct advantages over other non-viral methods (Singh et al., 2006; Ju et al., 2016).   
They are easily prepared, there is virtually no size limitation on the DNA or nucleic acid to be 
transferred, and owing to their positive charge, they interact favourably with the negatively 




There are, however, several drawbacks related to the use of cationic liposomes in vivo.  These 
include low delivery efficiency, cytotoxicity, their undesired interaction with negatively 
charged serum proteins and components leading to opsonisation, complement activation and 
their rapid clearance from circulation and accumulation in cells of the mononuclear 
phagocyte system (MPS) or reticuloendothelial system (RES) (Rejman et al., 2004; Zalipsky 
et al., 1996; Shim et al., 2013). 
 
 
2.3.  SUB-CELLULAR ORGANELLE TARGETING 
 
Subcellular targeting is an expansion on traditional gene/drug therapy, which was discussed 
above.  This targeting involves engineered nanovector intracellular interactions, processing, 
and trafficking and is a rapidly emerging frontier of biomedical innovation (Huang et al., 
2011).   
 
Most methods of intracellular delivery focus on traversing the cellular membrane without 
identifying a specific intracellular target or controlling the distribution of the nanoparticle 
once inside the cell (Heller et al., 2012).  Biomedical nanotechnology advancement would be 
enhanced by nanocarriers that target a specific organelle, such as the nucleus, mitochondria, 
Golgi apparatus or the endoplasmic reticulum, all of which are promising targets for 
therapeutics (Kawamura et al., 2013).  The potential clinical effect of this type of 
nanoparticle subcellular targeting may be appreciated when taking into consideration the 
potential of effective gene therapies, molecular imaging devices and treatments for organelle-
specific diseases (Huang et al., 2011).  An example of this subcellular targeting is directing 
therapeutics such as nucleic acids to mitochondria, which is discussed in 2.3.1 
 
 
2.3.1.  Mitochondrial DNA Targeting 
 
The term Mitochondria comes from the combined Greek words mitos (filament) and 
chondrion (granule) and was coined in 1898 by Karl Benda, German doctor, to describe 
filamentous-type  cell organelles, which were first detected in the 1850s by Swiss 




The mitochondrion is a membrane-bound DNA containing intracellular organelle present in 
almost all eukaryotic cells.  Cell biology and mitochondrial biology have advanced 
considerably since Philip Siekevitz first coined the mitochondrion as the “powerhouse of the 
cell” in 1957 (Siekevitz, 1957).  This organelle is vital for the regulation of programmed cell 
death, as the cell's “arsenal” (Chen et al., 2015).  However, to state that this encompasses all 
that mitochondria does would be a gross oversimplification.  Milane et al. (2015) uses the 
analogy of the cell as a city, where the mitochondria can be regarded as: the electrical 
company due to it being the metabolic centre and involved in production of adenosine 
triphosphate (ATP),  the waste containment company with its involvement in reactive oxygen 
species (ROS) containment, the moving company with its assistance in cell movement and 
trafficking intracellularly and extracellularly, the department of defence with its association 
with inflammation, immunity, the stress response and cell danger response, the historical 
society with evolutionary tracking through mitochondrial DNA (mtDNA) and lastly the grim 
reaper through involvement in apoptosis regulation.  
 
Research studies about and on mitochondria have been ongoing with considerable success for 
over a century.  In fact, since the publication of two papers in 1988, one in Science and the 
other in Nature revealed that mutations in the mitochondrial genome could cause human 
disease, mitochondrial gene targeting in gene therapy is steadily emerging to show great 
potential (Horobin et al., 2007).  Mitochondrial research is currently one of the fastest 
growing disciplines in biomedicine, so much so that it has given rise to the development of 
new sub-disciplines such as Mitochondrial Medicine, Mitochondrial Pharmaceutics and 
Mitochondrial Pharmacology (Weissing et al., 2004).   
 
The uniqueness of mitochondria must first be considered before commencing on a discussion 
regarding gene or macromolecule delivery to the organelle.  Mitochondria are different from 
other subcellular organelles in that they are DNA-containing and comprise a complex two 
membrane structure.  Their primary function is energy production through the mitochondrial 
respiratory chain, which consists of four enzymatic complexes, namely complexes I, III and 
IV which are energy coupling centres.  These complexes, together with the electron carriers 
cytochrome c and ubiquinone, and complex V make up the oxidative phosphorylation 
(OXPHOS) system which synthesises ATP according to the cell’s needs (Salvado et al., 
2015).  Additionally, as mentioned above, mitochondria play important roles in a number of 




aging to apoptosis (Pearce et al., 2013; D’Souza et al., 2007).  This multitude of roles makes 
the mitochondrion a candidate of significant interest for organelle-specific delivery of 
exogenous materials such as DNA, drugs and other macromolecules (Horton et al., 2008).  
Importantly, the formation of the OXPHOS system is under the influence of two separate 
genetic systems, the nuclear and the mitochondrial genomes. As a consequence of this, 
genetic defects of either nuclear or mitochondrial DNA can compromise ATP production and 
potentially cause human pathology at any age, with any symptoms, and by any mode of 
inheritance (Pearce et al., 2013).   
 
 
2.3.2.  Mitochondrial Form and Function 
 
2.3.2.1.  Double Membrane and Matrix Space  
 
Mitochondria are composed a double membrane, both of which are largely composed of 
phospholipids arranged in bilayers with proteins embedded in them.  As there are two 
membranes, two distinct aqueous compartments are defined.  The space between the 
membranes is called the intermembrane space while the inner most one is called the matrix 
space (Figure 2.6). It has been suggested that the mitochondrion originated by, and is a result 
of endosymbiosis about 1.5 billion years ago (DiMauro, 2007).  Research on mtDNA 
supports this theory and show similarities between mitochondria and α-proteobacteria (Gray 
et al., 2004).  
 
The outer membrane, which has a lipid to protein ratio of 1:1 does not provide a barrier to 
small molecules (<5 kDa) which can simply diffuse through pores in the membrane formed 
by membrane-spanning channel proteins called porins (Mukhopadhyay and Weiner, 2007; 
Yamada and Harashima, 2008).  Larger molecules gain access past the outer membrane by 
using unique protein import machinery. An example of this would be the presequence 
mitochondrial targeting signal peptide (MTS) which delivers many proteins to mitochondria 
via protein import machinery (Yamada et al., 2007).  Other protein import pores on the outer 
membrane include the sorting and assembly machinery (SAM), and translocase of the outer 
membrane (TOM).  These provide passage for the majority of mitochondrial proteins that are 




As ATP synthesis via the OXPHOS system, β-oxidation of fatty acids and the TCA cycle all 
occur in the matrix space, the inner membrane, in contrast to the outer membrane, is highly 
impermeable i.e. it is far more selective regarding what enters the organelle.  This inner 
membrane is characterised by invaginations that fold back into pockets to form cristae to 
increase surface area so that the mitochondrial respiratory capacity can be significantly 
amplified.  It also has a high content of membrane proteins compared to the outer membrane 
and it further contains a unique lipid viz. the phospholipid, cardiolipin (Weissig, 2005; Von 
Stockum et al., 2016).  In order for specific compounds to reach the matrix space, proteins in 
the inner membrane function as transporters, with each having a specific ligand to shuttle 
across the membrane.  For example, the ATP/ADP carrier (AAC) allows ADP to cross the 
inner membrane, while simultaneously transferring ATP out of the matrix space.  In addition 
to metabolite transport proteins, the inner membrane also hosts mostly proteins that are 
components of the respiratory chain complex and ATP synthase (Mukhopadhyay and Weiner, 
2007; Yamada and Harashima, 2008).  The impermeability of the inner membrane is a 
necessity in creating a discrepancy in proton distribution between the mitochondrial matrix 
and the cytosol, which is the chief motive for ATP synthesis (Weissig, 2005).     
 
The mitochondrial matrix space formed within the inner membrane encompasses the 
mitochondrial DNA (mtDNA) which is a circular, double-stranded molecule of 
approximately 16,659 nucleotide base pairs (Figure 2.7).  The genome comprises 37 genes 
arranged end to end with no introns present (Pearce et al., 2013).  The 37 genes code for 13 
hydrophobic polypeptides, seven of them (ND1-ND6 and ND4L) form part of the 46 subunits 
of complex I, one (cytochrome b) is part of the 3 subunits of complex III, three (COX I, COX 
II and COX III) are found in the 13 subunits of complex IV and two (A6 and A8) are located 
in the 16 subunits of ATP synthase (Andalib et al., 2014; Salvado et al., 2015).  The other 24 
genes encode for 22 transfer RNAs and 2 ribosomal RNAs that are necessary for their protein 
expression within the organelle (Pearce et al., 2013).  The matrix space is also the site for 
other major biochemical pathways including the urea cycle, fatty acid oxidation and the TCA 
cycle.  The unique features of the inner membrane allows for simple diffusion of hydrophobic 
molecules.  Triphenylphosponium (TPP) ion, rhodamine 123 and JC1 are examples of 
cationic hydrophobic molecules that can cross the mitochondrial membrane. This property of 
TPP has been exploited by investigators to diffuse drugs attached to TPP across the 
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Figure 2.6: Graphical representation of human mitochondria depicting structural features    
















Figure 2.7: A schematic diagram of human mitochondrial DNA encoding 13 polypeptides    
                    (ND1-ND6, ND4L, CYT b, COX I-III, ATPase6 and ATPase8), rRNAs, and 22    
                    tRNAs.  The tRNas are depicted as single letter amino acid code.  







2.3.2.2.  Transporters and Translocators  
 
As mentioned above, for larger proteins to enter mitochondria, a translocator is required.  As 
the majority of mitochondrial proteins are coded for by nuclear genes, they have to be 
translocated to the organelle.  To achieve this, receptor-translocator complexes exist on both 
membranes to allow these proteins to enter mitochondria (Neupert and Herrmann, 2007). 
These mechanisms include the transfer system on the outer membrane abbreviated TOM 
(translocator outer membrane) and the TIM (translocator inner membrane) located on the 
inner membrane (Mukhopadhyay and Weiner, 2007).  These nuclear encoded proteins 
possess a N-terminal leader sequence that is recognised by the receptor-translocator 
complexes (Dolezal et al., 2006).  Attachment of this leader sequence to virtually any protein 
will enable this protein to be translocated into mitochondria.  Exploitation of this mechanism 
allows for fragments of DNA or RNA fused to the leader to be taken up by mitochondria 
(D’Souza et al., 2003).   
 
 
2.3.2.3.  Mitochondria and Apoptosis 
 
It is well known that mitochondria are involved in apoptotic programmed cell death.  
Cysteine proteases called caspases are the central mediators of apoptosis (Milane et al., 
2015).  These caspases can be activated to induce apoptosis by two general routes: the 
extrinsic and intrinsic pathways.  The extrinsic pathway is initiated by extracellular ligand 
binding to death receptors on the cell surface (Yamada and Harashima, 2008; Milane et al., 
2015).  The intrinsic pathway, also known as the mitochondrial or Bcl-2 inhibitable pathway, 
involves the destabilisation of the mitochondrial membrane, and release of mitochondrial 
apoptotic proteins such as cytochrome c, apoptosis inducing factor (AIF) and HtRA2.  This 
leads to a cascade of events in the cytosol and forming of an apoptosome which then activates 
the effector caspases that eventually leads to partial self-digestion of the cell and eventually 
cell death.  The proteins of the Bcl-2 family regulate the intrinsic pathway with proteins that 
are pro-apoptotic (Bax, Bak, Bid, Bad, Puma, Bim) and those that are anti-apoptotic (Bcl-2, 







2.3.2.4.  The Electron Transfer System and ATP Synthesis    
 
Mitochondria are the principal mediators of cellular energy production.  They produce 
adenosine 5′-triphosphate (ATP) though the process of oxidative phosphorylation 
(OXPHOS), which accounts for 80 to 90% of ATP generation in major mammalian tissues 
(Yamada and Harashima, 2008; Milane et al., 2015).  The mitochondrial respiratory chain or 
OXPHOS pathway consists of a group of five multi-protein enzyme complexes (complexes I-
V) and two electron carriers (coenzyme Q10 and cytochrome c) embedded in the inner 
mitochondrial membrane (Chinnery and Schon, 2011; Milane et al., 2015).  Reduced 
cofactors (NADH and FADH2) derived from the tricarboxylic acid cycle (TCA cycle; Krebs 
cycle) donate electrons to complex I and II and these electrons flow between the complexes 
down an electro-chemical gradient shuttled by the electron carriers and complexes III and IV.  
The freed energy is used by complexes I, III and IV to establish a proton gradient 
(chemiosmotic potential), that is utilised by complex V to generate the production of ATP 
from adenosine diphosphate (ADP) and inorganic phosphate (Chinnery and Schon, 2011; 
Milane et al., 2015).  Perhaps the most important mitochondrial function is the synthesis of 
ATP. Dysfunction of ATP production is associated with large number of mitochondrial 
diseases (Yamada and Harashima, 2008).  
 
 
2.3.3.  Diseases of Mitochondrial Origin and Mitochondrial Dysfunction in Disease  
 
Mitochondrial diseases comprise a heterogeneous group of metabolic disorders characterized 
by the common link of compromised energy production resulting from defects in 
mitochondrial OXPHOS system protein synthesis (Pearce et al., 2013).  The biochemical 
evidence of the concept of these mitochondrial diseases or dysfunctions such as loose 
coupling of oxidation and phosphorylation was first observed in Stockholm in 1962 by Luft 
et al. in a young lady with non-thyroid  hypermetabolism (Luft syndrome) (DiMauro, 2004a).  
The molecular age of mitochondrial diseases, as it was described by DiMauro (2004b), 
commenced in 1988 with a critical break-through regarding our future understanding of 
“mitochondrial myopathies” in the report of point mutations and pathogenic deletions in 





Mitochondrial diseases or disorders are considered unique from a genetic viewpoint because 
the respiratory chain is the only metabolic pathway in the cell that is under the dual influence 
of both the mitochondrial and nuclear genomes (DiMauro, 2004a).  
  
Since it was discovered that mtDNA mutations could cause human disease, a number of 
disorders have been reported to be associated with defects in the mitochondrial genome.  Up 
to 2007, 347 distinct mitochondrial disorders have been identified (Weissig et al., 2007). 
Mutations in mtDNA genes are a regular cause of mitochondrial cytopathy resulting in a 
large variety of clinical phenotypes connected to severe metabolic dysfunctions (Salvado et 
al., 2015).  In fact, the prevalence of mitochondrial disease is so high that according to the 
United Mitochondrial Disease Foundation, a child is born with mitochondrial disease or may 
develop one by age five every 15 minutes (Weissig et al., 2007).  Additionally, the 
prevalence of pathogenic mitochondrial DNA mutations was recently estimated to be 1 in 
200 adults (Tischner and Wenz, 2015).  In addition, mutations in mitochondrial genes are 
related to Parkinson, Huntington’s and Alzheimer’s diseases, diabetes and also have a greater 
susceptibility to develop cancer (Salvado et al., 2015).  
 
To date, over 300 pathogenic mutations have been identified in the human mtDNA 
(http://www.mitomap.org; accessed 20/05/2016).  These refer to point mutations in tRNA or 
rRNA genes, missense mutations in protein-coding genes and duplications or deletions (Niazi 
et al., 2012) (Table 2.4). 
 
Mitochondria contain an estimated 1500 proteins, of which only 13 are mitochondrial 
genome coded (Doyle and Chan, 2008).  Therefore, as stated above, mitochondrial diseases 
can arise from defects in both or either the nuclear and mitochondrial genomes.  Since both 
mitochondrial DNA and nuclear DNA (nDNA) encode constituents of the mitochondrial 
respiratory chain and ATP synthase, mitochondrial diseases typically affect tissues that are 
highly metabolically active with an elevated ATP demand such as muscular, cardiac, 
neuronal tissues and endocrine and renal systems (Murphy and Smith, 2000).  
 
Mitochondrial DNA diseases comprise a varied range of conditions that are usually 
progressive, and are often accountable for severe disorders and premature mortality.  Many 
complex and unidentified factors unfortunately contribute to the pathophysiology of mtDNA 




diverse and variable, so much so that an identical mutation produces immensely different 
phenotypes between two individuals, or, the same phenotype is caused by different 
mutations. Thus mitochondrial diseases are extremely heterogeneous and difficult to 
categorise into groups or classes (Doyle and Chan, 2008).  However, from a genetic 
perspective, mitochondrial diseases can be classified into two major categories: (i) primary 
mitochondrial diseases caused by mutations in the mitochondrial genome, which include 
homo- and heteroplasmic point mutations and large scale rearrangements or deletions; (ii) 
mitochondrial diseases caused by mutations in nuclear genes involved in mitochondrial 
function and the respiratory chain (Farrar et al., 2013; Viscomi et al., 2015).  It was 
suggested that a third (iii) category be included that comprises secondary disorders that arise 
from accumulation of mitochondrial damage over time, and could include neurodegenerative 
disorders that encompass mutations of either or both mitochondrial or nuclear DNA (Farrar et 
al., 2013).  
 
 
2.3.3.1.  Pathogenic Mitochondrial DNA Mutations and Mitochondrial Diseases  
 
Most eukaryotic cells except erythrocytes contain hundreds to thousands of mitochondria, 
depending on the energy demand of that cell or tissue (Milane et al., 2015).  Thus a typical 
cell would also contain hundreds or thousands of mtDNA copies.  This difference in mtDNA 
copy number per mitochondria, per cell or per tissue is termed polyplasmy (DiMauro, 2004a; 
Milane et al., 2015).  In normal tissue, all mtDNA molecules are identical and of the wild 
type (homoplasmy).  MtDNA mutations can occur in all copies of the genome and is called 
homoplasmic, or in only some copies which is termed heteroplasmic (where both mutated 
and wild type mtDNA co-exist within the cell).  In heteroplasmy, due to the number of copies 
of mtDNA in the  cell, the  ratio of mutated to wild type mtDNA molecules needs to increase 
to a level where the wild type mtDNA can no longer compensate for the biochemical defect, 
before the  mutated species can begin to manifest tissue dysfunction and clinical symptoms. 
This phenomenon is known as the threshold effect. This threshold level varies based on 
mutation and tissue type. Generally, single large scale mtDNA deletions re uire a lower 
threshold value (  60 ) of mutated to wild type mtDNA than point mutations which is 
normally greater than 80% (Mancuso et al., 2007; Tuppen et al., 2010; Pearce et al., 2013; 





In addition to cellular polyploidy, mitochondrial genetics differ from Mendelian genetics in a 
number of ways; firstly, mtDNA is exclusively maternally inherited because mitochondria are 
derived from the oocyte as mitochondria from spermatozoa degenerate soon after 
fertilisation, secondly, it deviates from the standard genetic code and lastly, during cellular 
division, the proportion of mutant mtDNA molecules in daughter cells may be distributed 
randomly and the phenotype may change accordingly. This phenomenon, called mitotic 
segregation, describes how certain patients with mitochondrial disorders may actually 
manifest different mitochondrial diseases at different stages of their lives (DiMauro, 2004a; 
Tuppen et al., 2010; Pearce et al., 2013). 
 
Mutations that occur in the mitochondrial genome can be maternally inherited or occur 
sporadically.  The mutation rate of mtDNA is disproportionately high and is approximately 
17-fold higher than in nuclear DNA, and it is highly vulnerable to mutation and oxidative 
damage (Mazunin et al., 2010).   This is due to a number of factors including, the specific 
structural organisation of the mitochondrial genome, its lack of histones, replication errors 
with insufficient repair mechanisms, mutations of nuclear genes whose protein products 
function in mitochondria and lastly, mtDNA damage and resultant mutations that arise from 
the availability of ROS from increased electron leak of the respiratory chain that is in close 
proximity to the mtDNA molecules (Mazunin et al., 2010; Andalib et al., 2014).  As 
mentioned above, there are commonly two types of mutations that occur in mtDNA: point 
mutations and mtDNA rearrangements.   
 
 
2.3.3.1.1.  Point Mutations  
 
Pathogenic mtDNA point mutations have been noted to occur in protein encoding, tRNA and 
rRNA genes, causing a wide range of diseases.  They are mostly maternally inherited and 
multisystemic, but some are sporadic and tissue specific (DiMauro, 2004a; Tuppen et al., 
2010).  Protein encoding genes account for two-thirds of the mtDNA sequence; however, the 
majority (> 50%) of pathogenic mtDNA point mutations causing human disease are located 
on mitochondrial tRNA genes, which only comprise 10% of the genome (Pearce et al., 2013).  
Phenotypically, these tRNA mutations, and to some extent the rRNA point mutations, may 
impair total mitochondrial translation by decreasing the availability of functional tRNAs and 




affect the function of the OXPHOS complex to which the corresponding protein belongs.  
Point mutations exhibit substantial clinical heterogeneity and are mostly heteroplasmic but 
homoplasmic mutations do occur (Tuppen et al., 2010).  Transfer RNA point mutations 
display a variety of clinical phenotypes such as, myopathies, encephalopathies, hearing 
impairment and diabetes mellitus (Pearce et al., 2013).  The most common mtDNA and best 
studied mitochondrial tRNA mutation is the A3243G mutation in tRNA
Leu(UUR)
 which was 
described by Goto et al. in 1990, and is responsible for 80% of patients with mitochondrial 
encephalopathy, lactic acidosis and stroke-like episode (MELAS) syndrome.  Patients often 
present with progressive encephalomyopathy characterised by repeated stroke-like episodes 
with seizures typically involving posterior cerebral areas, vomiting, exercise intolerance 
recurrent migraine-like headaches and lactic acidosis are other frequent clinical features 
(Pearce et al., 2013; Russell and Turnbull, 2014).  Although this mutation is famously known 
for its association with MELAS, a recent study showed that this mutation can also 
phenotypically manifest as maternally inherited diabetes and deafness (MIDD) or a 
combination of the MELAS/MIDD syndrome (Russell and Turnbull, 2014).  Other common 
mitochondrial diseases associated with mitochondrial tRNA mutations include myoclonus 
epilepsy with ragged red fibres (MERRF) and cardiomyopathy (DiMauro, 2004a; Pearce et 
al., 2013).  
 
Of the point mutations in protein encoding genes, Leber hereditary optic neuropathy (LHON) 
is the most common phenotype.  There are three primary LHON mtDNA mutations 
(G11778A, G3460A, and T14484C), which are present in at least 95% of LHON patients.  
This mitochondrial disease is characterised by acute or sub-acute impairment of vision in 
young adults, more commonly males, due to bilateral optic atrophy.  LHON is usually due to 
homoplasmic mtDNA mutation that is maternally inherited (DiMauro, 2004a; Tuppen et al., 
2010).  Other common mitochondrial diseases associated with mitochondrial protein 
encoding gene point mutations include maternally inherited Leigh syndrome (MILS) and 
NARP (neuropathy, ataxia, retinitis pigmentosa) (Table 2.4) (Tuppen et al., 2010).  
  
 
2.3.3.1.2.  MtDNA Rearrangement Mutations  
 
Rearrangements of mtDNA can be deletions or duplications, with deletions being more 




mutations are large scale deletions, which show a variable size range from 1.3 to 8 kb, and 
span several genes (Tuppen et al., 2010; Russell and Turnbull, 2014).  These large scale 
deletions are typically sporadic and occur early in development, with the identical deletion 
present in all cells within affected tissues. These deletions are thought to occur during 
replication and/or repair of the genome.   ecent studies have suggested that patients have a  5 
kb deletion in a similar area of the mitochondrial genome, the so called “common deletion”, 
and that the size of the deletion and its heteroplamsy is linked to disease severity (Mancuso et 
al., 2007; Tuppen et al., 2010; Russell and Turnbull, 2014).  The main clinical syndromes 
due to single large scale deletions are Kearns Sayre Syndrome (KSS), a multisystem disease, 
characterised by development of retinitis pigmentosa and chronic progressive 
opthalmoplegia; Pearson syndrome, a rare disorder of infancy associated with sideroblastic 
anaemia and exocrine pancreatic failure; and chronic progressive external ophthalmoplegia 
(CPEO), a phenotype characterised by progressive paralysis of the eye muscles leading to  
limitation of eye movements, palpebral ptosis and generalized weakness (Table 2.4).  CPEO 
is one of the most common manifestations of mtDNA disease in adults (Mancuso et al., 2007; 
Tuppen et al., 2010; Russell and Turnbull, 2014).   
 
 
2.3.3.2.  Pathogenic Nuclear DNA Mutations and Mitochondrial Diseases 
 
As noted above, there are about 1500 proteins that make up the OXPHOS system, of which 
only a minute portion is encoded by the mtDNA; the vast majority of these proteins are 
encoded by the nuclear genome.  As such, it is clear that mutations in nuclear DNA may 
cause mitochondrial diseases (Mazunin et al., 2010).  Nuclear DNA mutations have been 
discovered in a large number of genes either directly or indirectly connected to the respiratory 
chain.  Direct association refers to mutations in nDNA genes that encode the structural 
subunits of the respiratory chain complexes including subunits of complex I, III, IV, V and all 
subunits of complex II, as well as primary coenzyme Q10 (CoQ10) and cytochrome c.  
Indirect association refers to mutations in nDNA genes encoding proteins that are not 
constituents of the respiratory chain, but are required for the correct assembly and 
functionality of respiratory chain complexes in addition to other roles of mitochondria.  These 
include the assembly factor proteins of the respiratory complexes; proteins engaged in the 
mtDNA maintenance and replication machinery; components of the mtDNA transcription and 




pathways such as apoptosis and other enzymatic cycles viz. TCA cycle and fatty acid β-
oxidation (DiMauro, 2004a; Mazunin et al., 2010; Viscomi et al., 2015).  Mitochondrial 
disorders that occur because of defective nuclear encoded proteins comprise severe alcoholic 
liver disease, pyruvate dehydrogenase deficiency, human deafness dystonia syndrome and 
type 1 primary hyperoxaluria.  Numerous other mitochondrial diseases arise from mutations 
in nuclear encoded mitochondrial proteins, such as those involved in mtDNA maintenance/ or 
replication and mtDNA polymerase (Yamada and Harashima, 2008).  However, nuclear DNA 
mutations that cause mitochondrial diseases is beyond the scope of this investigation which 
focuses primarily on mtDNA defects.    
 
 
TABLE 2.4: Classification of common mtDNA mutations and associated disorders  




CPEO, chronic progressive external ophthalmoplegia; CYT b, cytochrome b; KSS, Kearns–Sayre syndrome; 
LHON, Leber hereditary optic neuropathy; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes; MERRF, myoclonic epilepsy with ragged-red fibers; MIDD, maternally-inherited 
diabetes and deafness; MILS, maternally-inherited Leigh syndrome; NARP, neuropathy, ataxia, and retinitis 
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Large-scale rearrangements  
 










































T14484C  (ND6) 
T8993C/G (ATPase 6) 
Point mutation or deletion (CYT b) 
 
MEALS, MIDD , PEO  
Encephalomyopathy  
Dementia, diabetes  
Myopathy, cardiomyopathy  
 
ME  F, myopathy, Leigh’s 
syndrome  
MERRF, cardiomyopathy  
MEALS  
Ataxia, Leigh’s syndrome  
Myopathy and diabetes  
SNHL  
KSS, CPEO, Pearson syndrome, 










2.3.3.3.  Mitochondrial Mutations, Cancer and Neurodegenerative Diseases  
 
Recently, mitochondrial genetics, specifically mtDNA mutations and/or polymorphism 
variance, have been related to several other common human diseases, including diabetes, 
autism spectrum disorders, neurodegenerative disorders including Alzheimer's disease (AD), 
Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) 
in addition to greater susceptibility to develop cancer (Moreira et al., 2010; Dowling, 2014).  
 
Neurodegenerative disorders are broadly characterised by the loss of adult neuronal cells 
through their dysfunction and eventual pre-emptive death (Milane et al., 2015).  Additionally, 
there have been multiple demonstrations of mtDNA defects in neurodegenerative disorders, 
comprising large-scale deletions, point mutations, nucleic acid modifications, and diminished 
mtDNA copies.  Impaired mtDNA gives rise to deficient mitochondrial key enzymes leading 
to defects in mitochondrial respiration, excessive ROS generation, increased mitophagy and 
ultimately apoptosis and cell death (Du and Yan, 2010). 
 
Studies have suggested that complex I defects and other mtDNA mutations or variations may 
result in mitochondrial dysfunction that leads to PD, however this tenuous association has yet 
to be definitively proven (Chaturvedi and Beal, 2013; Andalib et al., 2014).  Several reports 
have proposed that mtDNA defects such as reduced mtDNA ND6 transcript expression, 
decreased mtDNA copy numbers and point mutations in mtDNA encoded cytochrome c 
oxidase subunits I, II and III genes were observed in AD patients.  However these defects 
have not yet been identified as AD specific mutations that lead to pathogenesis.  A substantial 
body of evidence also suggests the involvement of mtDNA mutations in HD and ALS, but 
similar to the other neurodegenerative diseases mentioned above, these mutations have not 
been conclusively proven to cause pathogenesis (Chaturvedi and Beal, 2013).   
 
Mitochondrial DNA mutations such as insertions or deletions have been noted in many 
varieties of human cancer.  Atypical metabolic processes, increased ROS production, and 
failure to induce apoptosis in cancerous cells are believed to be as a result of these mutations, 
and are hypothesised to be involved in tumourigenesis in some cases (Chatterjee et al., 2006; 
Akouchekian et al., 2011; Yu, 2012).  Mitochondrial functional impairments have also been 
observed due to irregular expression of mtDNA encoded proteins as a result of defective 




elucidate the functional role of the different mitochondrial mutations in the initiation, 
progression and aetiology of human cancer (Chatterjee et al., 2006; Yu, 2012). 
 
 
2.3.4.  Strategies for Correcting Mitochondrial Defects  
 
Current therapies for treating mitochondrial diseases are palliative and supportive not 
curative.  These include supplementation with vitamins, anti-oxidants, CoQ10, creatine, l-
carnitine, controlled nutrition and exercise therapy; that ultimately only treat symptoms of the 
disorders (DiMauro and Mancuso, 2007; Tischner and Wenz, 2015).  The other common 
strategy that is employed is to force a shift in heteroplasmy i.e. decreasing the ratio of mutant 
to wild type mtDNA (DiMauro and Mancuso, 2007).  As mentioned above, in a 
heteroplasmic cell, the mutant and wild type mtDNA molecules exist in a particular ratio; 
above which mitochondrial diseases result.  This strategy can be achieved by use of agents 
such as restriction enzymes and peptide nucleic acids (PNA) that destroy mutant mtDNA 
molecules, or selectively inhibit their replication.  This leads to a decrease in the number of 
mutant mtDNA genomes, ultimately causing a shift in the ratio to below the threshold level 
(Doyle and Chan, 2008; Adhya et al., 2011; Tischner and Wenz, 2015).  However, there are 
several limitations to this therapy, viz. (i) it is a short-term solution, (ii) there are limited 
target mutations for restriction enzymes, (iii) there are insufficient binding sites for the PNA 
and (iv) it is only heteroplasmic specific and therefore not compatible with homoplasmic 
disorders (Doyle and Chan, 2008).   
 
As stated above, there is essentially no clearly defined genotypic-phenotypic relationship 
among mitochondrial DNA disorders.  Taking this into consideration and the existing largely 
inadequate and ineffective treatments outlined above, the development of mitochondrial gene 
therapy to treat mtDNA diseases represents a potentially exciting and promising approach.   
The underlying goal of this gene therapy is to rectify the defects of the OXPHOS chain itself, 
on a genetic level, the one commonly shared distinguishing feature among all mtDNA 
disorders.  It is a practical and valuable tool to treat a diverse and vast array of clinical 
phenotypes as the focal point is on the actual cause of the disorder.  The use of this 
therapeutic genetic intervention ultimately involves efficient and effective delivery of 




approaches to genetically modify the impaired proteins of the OXPHOS chain: the “indirect” 
method also known as allotopic expression and the “direct method”. 
 
2.3.4.1.  Allotopic Expression 
 
This indirect method of mitochondrial gene therapy involves the delivery of a wild type 
version of the mtDNA encoded gene that is mutated or impaired via an appropriate vector, to 
the nucleus of recipient cells.  This mtDNA gene would have to first be recoded from the 
mitochondrial code to a nuclear genetic code before delivery to the nucleus.  After 
transcription in the nucleus, the corresponding mRNA is translated in the cytosol and the 
protein imported into mitochondria (Figure 2.8).  In order to facilitate mitochondrial uptake, a 
N-terminal signal sequence or mitochondrial targeting sequence (MTS) is attached on the 
gene.  This allotopically expressed wild type protein is transported into the mitochondria, 
freed of the MTS peptide and incorporated into the specific subunit of the respiratory chain, 
in lieu of the original mutated gene product (D’Souza and Weissig, 2004; DiMauro and 
Mancuso, 2007; Adhya et al., 2011).  This allotopic expression has been demonstrated in 
vitro by Manfredi et al. (2002).   
 
Although the method has had some success, there are shortcomings.  In addition to the need 
to recode the wild type mitochondrial gene to be efficiently translated, and the need for the 
preprotein to be fused to a cleavable MTS peptide, the mitochondrial encoded proteins are 
highly hydrophobic, and the allotopic method might be limited to those that are amphiphilic 
enough to permit importation into the organelle via the protein import machinery (D’Souza et 
al., 2007; Adhya et al., 2011; Tischner and Wenz, 2015).  
 
 




2.3.4.2.  Direct Delivery of DNA/Macromolecules into Mitochondria  
 
Due to the central role of mitochondria in health and disease, as discussed in 2.3.2 and 2.3.3 
above, mitochondria are attractive targets for pharmaceutical and therapeutic intervention.   
However effective therapies for diseases, caused by mitochondrial DNA defects described in 
section 2.3.3.1, remain elusive as human mitochondria within living cells have limited 
accessibility to direct physical, biochemical and pharmacological manipulation. Hence, 
targeting of genetic material or drugs to the mitochondria could hold the promise of assisting 
to overcome these obstacles.  To make this vision a future reality, basic in vitro and in vivo 
research in the laboratory in search of new and improved vectors for mitochondrial 
gene/macromolecule delivery has to be undertaken and accomplished.  Hence this makes 
vector system design and development, and gene transfer efficiency of paramount 
importance.   
 
Adhya et al. (2011) suggested three conditions that must be satisfied in order for 
mitochondrial gene therapy to be successful.  Firstly, the method or vector system should be 
able to deliver nucleic acids to the inner most mitochondrial space, the mitochondrial matrix. 
For this to occur, the cargo must (i) be taken up by the recipient cell through a specific 
method of internalisation such as endocytosis; (ii) once internalised, the nucleic acid cargo 
must be preferably transported to mitochondria (mitochondriotropism) and not other 
intracellular organelles; (iii) the nucleic acid should be transported to the matrix where the 
mitochondrial genome and gene expression machinery is located.  Secondly, the nucleic acid 
cargo should have a significantly beneficial influence on mitochondrial function, and thirdly, 
the alteration of mitochondrial function through mitochondrial gene therapy should occur in 
vivo, and have a substantial constructive effect on the progress of the disorder or disease.   
 
In the multifaceted and complicated narrative of mitochondrial gene therapy, only the first 
condition has been marginally met, since this type of organelle-specific gene therapy is still 
in its infancy when compared to traditional nuclear gene therapy.  Current work is mostly 
centred on finding a suitable nanovector system that should ideally be mitochondriotropic (an 
agent or system that localises to the site of mitochondria), biocompatible, non-toxic, safe, 
stable, show low immunogenicity and have high therapeutic efficacy (Severino et al., 2015; 




mitochondria have been described but they are not ideal (Yamada and Harashima, 2012). 
These common vector systems will be discussed in brief.  
 
 
2.3.4.2.1.  Lipophilic Molecules 
 
Delocalised lipophilic cations are small membrane-permeable cationic molecules with 
delocalised positive charges that target the highly negative membrane potential of 
mitochondria and enter these organelles through electrostatic interactions (Zhang et al., 
2011).  Triphenylphosphonium (TPP), is the most common lipophilic cation that has been 
used for mitochondrial targeting.  TPP has been investigated extensively for the delivery of 
small bioactive molecules such as vitamin E (MitoVitE) and ubiquinol (MitoQ) and 
conjugated to other nanoparticles.  These particles are conjugated to TPP and gain entry into 
the organelle by exploiting the mitochondriotropism of TPPs delocalised charge which 
facilitates entry into the cell, and accumulation in the mitochondrial matrix (Doyle and Chan, 
2008; Milane et al., 2015).  Rhodamine 123 is another lipophilic cation that can selectively 
accumulate in the mitochondria of cells because of its delocalised charge centre.  However, it 
has mostly been used as flurophore in biological imaging, to visualise mitochondria and not 
extensively utilised as a mitochondriotropic residue for nanoparticles (Zhang et al., 2011; 
Milane et al., 2015).   
 
 
2.3.4.2.2.   Mitochondrial Targeting Sequences  
 
Mitochondrial targeting sequences (MTS), or as they are also known, mitochondrial leader 
sequences are presequences found on proteins encoded by the nuclear genome, translated in 
the cytosol and actively transported into mitochondria via the protein import machinery.  
These MTS peptides guide trafficking to and facilitate import into the mitochondria.  They 
are 10-80 amino acids in length, rich in positively charged and hydroxylated resides, contain 
no negatively charged residues, are located on the N-terminus of the precursor protein and 
they can be cleaved in 1 or 2  proteolytic steps once inside mitochondria (Yamada et al., 
2007; Doyle and Chan., 2008;  Zhang et al., 2011).  The use of a MTS peptide makes it 
possible to selectively deliver a variety of proteins, chemicals, oligonucleotides and linear 




peptide can be directly conjugated to plasmid DNA (pDNA) to co-localise with the 
mitochondria when delivered to mammalian cells by DQAsomes (D’Souza et al., 2005).  The 
use of MTS is the most studied approach to transport DNA into mitochondria.  Some of these 
approaches include direct coupling of MTS to the pDNA or indirect coupling whereby the 
MTS molecule is conjugated to a carrier such as PEI or PNA (peptide nucleic acids) (Won et 
al., 2011).  Flierl et al. (2003) described the use of MTS conjugated onto PNA-
oligonucleotide complexes to successfully localise these complexes into mitochondria.  These 
particles with MTS were targeted to mitochondria via the MTS import machinery.  The use of 
MTS as a mitochondriotropic vector is severely limited by the size and physiochemical 
properties of the cargo that it can import into mitochondria through the MTS translocator 
(Yasuzaki et al., 2010; Zhang et al., 2011).  However, the potential of MTS peptides may lie 
in their use as mitochondriotropic ligands coupled to an efficient carrier system like cationic 
liposomes.   
 
 
2.3.4.2.3.  Mitochondriotropic Vesicles 
 
2.3.4.2.3. (a)  DQAsomes  
 
Dequalinium is a dicationic amphiphilic compound with a delocalised charge centre that has 
been shown to accumulate in the mitochondria of living cells in response to the mitochondrial 
membrane potential.  Dequalinium and its derivatives are self-assembling molecules that 
resemble ‘bola’-form electrolytes.  These ‘bola’-form like amphiphiles are able to form 
liposome-like cationic vesicles, which the investigators termed ‘DQAsomes’ (Weissig et al., 
2001; D’Souza et al., 2003; Weissig et al., 2006).  The DQAsomes, based on the intrinsic 
mitochondriotropism of its constituents, were used to deliver DNA into, firstly, isolated rat 
mitochondria, following which, mitochondria of living cells.  DQAsomes have been further 
utilised to mediate delivery of both plasmid DNA and oligonucleotides, conjugated to the 
MTS peptide, to facilitate nucleic acid uptake via the mitochondrial protein import machinery 
(D’Souza et al., 2007; Doyle and Chan, 2008).  Employing immunofluorescence, and a 
combination of a variety of molecular-based and immunohistochemical techniques, it was 
finally demonstrated that DQAsomes are capable of transporting an artificial mini-
mitochondrial genome, into mitochondria of a range of cell culture models including a mouse 




one of the most promising candidates for future functional mitochondrial gene or drug 
delivery.   
 
2.3.4.2.3. (b)  MITO-Porter  
 
MITO-Porter is a liposome based carrier system that can deliver macromolecular cargoes into 
mitochondria via a membrane fusion mechanism.  It was pioneered by Yamada et al. (2008), 
and represents an advancement in mitochondrial gene and drug delivery due to the MITO-
Porter system’s success in delivering cargoes to the mitochondrial matrix.  It is composed of 
fusogenic lipids in an optimised ratio (9:2:1) of DOPE (Dioleoylphosphatidylethanolamine), 
SM (Sphingomyelin), and STR-R8 (Stearyl octaarginine).  The presence of octaarginine (R8) 
on the surface of the molecule, firstly, functions to facilitate cellular uptake and, secondly, its 
electrostatic interactions with mitochondria allow cargo entry while the lipid composition 
aids with liposome fusion with mitochondria, permitting matrix delivery (Yasuzaki et al., 
2010; Milane et al., 2015).  The investigators confirmed delivery to the mitochondrial matrix 
by preparing a MITO-Porter containing encapsulated propidium iodide, a membrane-
impermeable fluorescent dye that binds nucleic acids, to detect the mtDNA.  The 
fluorescence detected from the propidium iodide-mtDNA conjugates demonstrated that the 
MITO-Porter successfully delivered its cargo to the mitochondrial matrix (Yasuzaki et al., 
2010; Milane et al., 2015).   
 
The authors have expanded the MITO-Porter system to include DF-MITO-Porter, an 
improvement on the original, in which the cargo is coated with two mitochondria-fusogenic 
inner membranes and two endosome-fusogenic outer membranes, as well as octaarginine.  
This system was also proven effective in delivering molecular cargo to the mitochondrial 
matrix (Yamada et al., 2011).  The MITO-Porter and DF-MITO-Porter systems were further 
modified with a mitochondrial import signal of tRNA and MTS, respectively, to enhance 
mitochondrial targeting, which proved successful (Kawamura et al., 2013; Furukawa et al., 
2015).  Even though the MITO-Porter system has significantly progressed mitochondrial 
gene and drug delivery, there are still a number of questions regarding the harmfulness of the 
fusogenic lipid composition. Hence, the creation of safety and toxicity profiles would be 






2.3.4.2.3. (c)  Cationic Liposome-based Nanocarriers  
 
The success of phospholipid vesicles or liposomes, more specifically cationic liposomes, as 
gene delivery vehicles for chromosomal gene therapy have made them a potentially attractive 
vector for mitochondrial gene targeting.  Liposomes, as mentioned above, are comprised of 
lamellar phospholipid bilayers that surround aqueous compartments.  Their composition can 
be modified accordingly to control targeting, distribution, toxicity and nucleic acid/drug 
delivery (Knudsen et al., 2015).   
 
Cationic liposomes, as mentioned earlier are composed of cationic lipids, which are 
amphipathic molecules that usually consist of a hydrophobic head group attached via a linker 
or spacer to cholesterol derivatives or double hydrocarbon chains.  This lipid composition 
allows for the liposome surface to interact with the negatively charged molecules of nucleic 
acids to provide delivery of the cargo to target cells (Sanitt et al., 2016).  Liposomes and 
cationic liposomes are suggested to have immense translational potential for mitochondrial 
nucleic acid/drug delivery as they are largely considered biocompatible and non-toxic with 
many years of research in the field of liposomes and their use in drug delivery and gene 
therapy.  This makes liposomes pharmaceutically relevant and therefore the most investigated 
class of nanocarriers for mitochondrial targeted therapeutics (Durazo and Kompella, 2011; 
Shim et al., 2013).  This statement has proven accurate, so much so that the most successful 
mitochondrial targeted nanosystems to date, DQAsomes and MITO-Porter, being liposome 
based, with the MITO-Porter considered cationic as it contains octaarginine.  The versatility 
of liposomes lies in the fact that they can be easily modified to become mitochondriotropic, 
by the addition on the liposomal surface, of mitochondriotropic residues such as MTS, R8 
rhodamine 123 or TPP.  This was demonstrated by Boddapati et al. (2008) with the 
construction of stearyl triphenylphosphonium (STPP) functionalised liposomes for ceramide 
to specifically target the mitochondria.  Thus liposomes show great potential for future 
successful mitochondrial delivery of therapeutics. 
 
The chapters that follow detail an investigation into the physicochemical characterisation, 
cytotoxic profile, cellular uptake and mitochondrial localisation and targeting potential of 
novel cationic mitochondriotropic liposomes modified with MTS and octaarginine (R8) 
peptides.




MATERIALS AND METHODS 
 
3.1.  SYNTHESES AND LIPOSOME FORMULATON 
 
3.1.1.  Chemicals and Reagents   
 
Cholesteryl chloroformate (C28H45ClO2), 3-dimethylaminopropylamine (DMAPA, C5H14N2), 
and dioleoylphosphatidylethanolamine (DOPE, C41H78NO8P) were purchased from the 
Sigma-Aldrich Chemical Company (St Louis, MO, USA). Succinimidyl 3-(2-pyridyldithio) 
propionate (SPDP, C12H12N2O4S2) and N-γ-maleimidobutyryl-oxysulfosuccinimide ester 
(GMBS, C12H12N2O6) were obtained from Thermo Scientific (Waltham, MA, USA). 
Mitochondrial Targeting Sequence peptide [H-Met-Leu-Ser-Asn-Leu-Arg-Ile-Leu-Leu-Asn-
Lys-Ala-Ala-Leu-Arg-Lys-Ala-His-Thr-Ser-Met-Val-Arg-Asn-Phe-Arg-Tyr-Gly-Lys-Pro-
Val-Gln-Cys-OH (MTS, C168H286N54O42S3)] and octaarginine [H-Arg-Arg-Arg-Arg-Arg-
Arg-Arg-Arg-Cys-OH] (R8, C51H103N33O10S1) were acquired from GL Biochem, (Shanghai) 
Ltd. (Shanghai, China).  2-[4-(2-hydoxyethyl)-1–piperazinyl] ethanesulphonic acid (HEPES, 
C8H18N2O4S), dichloromethane (DCM, CH2Cl2), hydrazine (N2H4), chloroform (CHCl3), 
methanol (MeOH, CH4O), absolute ethanol (EtOH, C2H6O), sulphuric acid (H2SO4) and 
silica gel 60F254 chromatography plates were purchased from Merck (Damstadt, Hesse, 
Germany).  Ultrapure 18 MΩ water (Milli-Q50) was used throughout.  All other chemicals 
were of analytical purity grade or higher and purchased commercially.  
 
3.1.2.  Cationic Cholesterol-derived Cytofectin (CHOL-T) 
 
The first step in this study involved the synthesis of the cationic cholesterol derivative, 
CHOL-T (3β [N-(N’, N’-dimethylaminopropane)-carbamoyl] cholesterol), formulated from 
the starting material cholesteryl chloroformate.  This cytofectin is a positively charged 
amphiphilic molecule containing an amine cationic polar head group attached via a linker, 
and spacer region to a cholesterol derivative.  The resultant cationic lipid was incorporated 
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into the formulation of cationic liposomes for DNA binding, condensation and subsequent 
delivery.   
 
CHOL-T was prepared according to the protocol reported previously by Singh et al. (2001).  
Briefly, to a solution of cholesteryl chloroformate (90 mg, 0.2 µmols) in 1 ml DCM was 
added DMAPA (62.8 µl, 0.11 µmols) dropwise while stirring.  This synthesis reaction was 
allowed to proceed for 1 hour at room temperature (Figure 3.1) and monitored by thin layer 
chromatography (TLC) on silica gel 60F254 chromatographic plates developed in 
CHCl3:MeOH (9:1, 
v
/v) (results not shown).  The solvent (DCM and excess unreacted 
DMAPA) was subsequently removed by rotary evaporation under vacuum in a Büchi 
Rotavapor-R-300 (Büchi, Switzerland), leaving behind a thin film layer in the reaction vessel.  
This resultant residue was dissolved in absolute EtOH and allowed to crystallise overnight at 
4ºC.  The product was then recrystallised from EtOH, filtered under a stream of dry nitrogen 
gas and further dried by rotary evaporation under vacuum to yield the product as white 
coloured crystals.  Melting point determinations: 103 – 105°C.   
 
 
3.1.3.  Cholesterol-derived Cross-linking Agents  
 
This step involved the synthesis of two different hetero-bifunctional cross-linking agents, 3β-
[N-(hydrazino 3-{2-pyridyldithio} propionate)-carbamoyl] cholesterol (SP-CHOL) and 3β-
[N-(hydrazino-γ-maleimidobutyryl)-carbamoyl] cholesterol (GM-CHOL), conjugated to a 
cholesterol derivative to facilitate their incorporation into the liposome bilayer.  The two 
cross-linkers used were SPDP (succinimidyl 3-(2-pyridyldithio) propionate) and GMBS (N-γ-
maleimidobutyryl-oxysulfosuccinimide ester) and the cholesterol derivative was 
cholesterylformylhydrazide (MS04), a novel intermediary compound in the synthesis of the 
cationic cytofectin N, N-dimethylaminopropylaminylsuccinylcholesterylformylhydrazide 
(MS09) as reported by Singh and Ariatti (2006).  In brief, MS04 was prepared as follows: 
Solutions of cholesteryl chloroformate (1.13 g, 2.5 mmols) in CHCl3 (5 ml) and hydrazine 
(0.24 g, 7.5 mmols) in CHCl3:MeOH (3.6 ml, 5:1, 
v
/v) were prepared and cooled to 0°C.  The 
cholesteryl chloroformate solution was progressively added to the hydrazine solution and 
stirred for 1 h at room temperature (Figure 3.2).   The resultant reaction mixture was stored at 
room temperature for 24 h and subsequently concentrated under vacuum to form a crystalline 





Figure 3.1: Synthesis reaction scheme of CHOL-T from starting material cholesteryl chloroformate  
                    with the addition of DMAPA.         
 
                                              
product.  This was then further recrystallised in CHCl3:MeOH (125 mL, 4:1, 
v
/v), and the 
crystals were isolated by filtration and dried under vacuum.  Melting point: 225 – 227°C.  
The two solutions containing either MS04 (13.8 mg, 0.03 mmols) or MS04 (23 mg, 0.05 
mmols) in 500 µl CHCl3 and SPDP (14.3 mg, 0.045 mmols) or GMBS (14 mg, 0.05 mmols, 
respectively, in 500 µl CHCl3 were initially maintained at room temperature for 24 h in the 
dark and thereafter overnight at 4°C (Figure 3.3).  Thereafter, the solvents of both reaction 
mixtures were evaporated in vacuo and the resultant residues were dissolved in 150 µl CHCl3 
and compared by TLC against the starting materials on silica gel 60F254 plates developed in 
CHCl3:MeOH (95:5, 
v
/v).  Cholesterol-containing compounds were visualised as brown to 
purple spots upon spraying with H2SO4 (33%, 
v
/v) and heating to 100°C.  Bands presenting 
the respective products were scraped off, extracted with CHCl3:MeOH (2:1, 
v
/v) and filtered 
three times in vacuo through a sintered glass funnel.  The solvent of resultant filtrates were 
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Materials and Methods 
45 
 
evaporated and the residues once again dissolved in CHCl3:MeOH (2:1, 
v
/v), and passed 
through a pipette containing a cotton plug, into weighted round bottom flasks.  The solvent 
was evaporated by rotary evaporation using a Büchi Rotavapor-R300 and the products further 
dried using a pistol drier (Büchi-TO, Büchi, Switzerland) under vacuum to yield whitish 
coloured powdery products.  
SP-CHOL: 13.5 mg    GM-CHOL: 20.5 mg  
3β-[N-(hydrazino 3-{2-pyridyldithio} propionate)-carbamoyl]cholesterol:
 1
H NMR (300 
MHz, CDCl3) : δ 0.65 (s, 3H, C-CH3), 0.83 (d, 6H, J = 6.0 Hz, 26-H, 27-H, CH-(CH3)2), 0.89 
(d, 3H, J = 5.5 Hz, 21-H, CH-CH3), 0.98 (s, 3H, 19-H, C-CH3), 2.65 (t, 2H, J = 6.2 Hz, CO-
CH2), 3.07 (t, 2H, J = 6.1 Hz, S-CH2), 4.55 (m, 1H, 3α-H), 5.35 (d, 1H, J = 4.8 Hz, 6-H), 7,13 




H NMR (300 MHz, CDCl3) : 
δ 0.67 (s, 3H, C-CH3), 0.85 (d, 6H, J = 5.0 Hz, 26-H, 27-H, CH-(CH3)2), 0.91 (d, 3H, J = 6.5 
Hz, 21-H, CH-CH3), 1.00 (s, 3H, 19-H, C-CH3), 2.20 (d, 2H, J = 7.0 Hz, CO-CH2), 3.69 (d, 
2H, J = 6.1 Hz, N-CH3), 4.55 (m, 1H, 3α-H), 5.37 (d, 1H, J = 4.8 Hz, 6-H), 6.72 (s, 2H, 
CH=CH maleimido). 
 
3.1.4.  Mitochondriotropic Liposome Preparation  
 
All cationic liposomes were synthesised by the thin-film evaporation method adapted from 
that of Gao and Huang (1991).  In brief, stock solutions of the liposome components were 
individually prepared before liposomes formulation, according to the molar ratios outlined in 
Table 3.1.  The total reaction mixture contained 4 µmoles of lipid.  The cationic lipid, CHOL-
T was kept constant (2 µmols) in all liposomes, the remaining 2 µmols of each preparation 
comprised the neutral lipid, DOPE and either 5 or 10 mol% of SP-CHOL or GM-CHOL.  
Each cationic liposome lipid solution in CHCl3 was rotary evaporated to dryness at reduced 
pressure with a thin flow of moisture-free nitrogen gas at room temperature to produce a thin 
film deposit on the inside of the glass tube.  The samples were further dried under vacuum by 
a pistol drier to eliminate all traces of solvent.  Thereafter the thin film layers were rehydrated 
overnight at 4°C in 1 ml sterile HEPES buffered saline (HBS, 20 mM HEPES, 150 mM 
NaCl, pH 7.5). The hydrated lipid dispersions were then vortexed (Vortex Genie 2, Scientific 
Industries, Bohemia, USA) then sonicated (for 5 min at room temperature) using a 
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Transsonic T 460/H bath-type sonicator (Elma GmbH & Co., Singen, Germany), to generate 



















Figure 3.2: Synthesis reaction scheme of MSO4.  Cholesteryl chloroformate was converted to MSO4  
                    using hydrazine. 
 
 
TABLE 3.1: Lipid composition and molar ratios of components of cationic mitochondriotropic     
                     liposomes.  
Abbreviations: CHOL-T; 3β-[N-(N’, N’-dimethylaminopropane)-carbamoyl] cholesterol, DOPE; 
Dioleoylphosphatidylethanolamine, SP-CHOL; 3β-[N-(hydrazino 3-{2-pyridyldithio} propionate) carbamoyl] 
cholesterol, GM-CHOL; 3β-[N-(hydrazino-γ-maleimidobutyryl)-carbamoyl] cholesterol, MTS; mitochondrial 









 CHOL-T DOPE 
SP-CHOL/                                  
GM-CHOL 
  
SP-CHOL-MTS  2 1.8 0.2 2.50 MTS 
GM-CHOL-MTS 2 1.8 0.2 2.49 MTS 
SP-CHOL-MTS-R8  2 1.6 0.4 2.48 MTS + R8 
GM-CHOL-MTS-R8 2 1.6 0.4 2.46 MTS + R8 
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Figure 3.3: Synthesis reaction scheme of (A) 3β-[N-(hydrazino 3-{2-pyridyldithio} propionate)- 
                    carbamoyl] cholesterol (SP-CHOL) and (B) 3β-[N-(hydrazino-γ-maleimidobutyryl)-  
                    carbamoyl] cholesterol (GM- CHOL). MSO4 = cholesterylformylhydrazide, SPDP =  
                    succinimidyl 3-(2-pyridyldithio) propionate, GMBS = N-γ-maleimidobutyryl-  
                    oxysuccinimide ester and NHS = N-hydroxysuccinimide. 
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In order to make the cationic liposomes mitochondriotropic, the mitochondrial targeting 
signal (MTS) peptide was grafted onto the surface of the liposomes.  This was achieved by 
incubation of the MTS peptide (5 mg, 1.3 µmols) in 1 ml sterile HBS with the liposome 
preparations SP-CHOL-MTS and GM-CHOL-MTS which contain MTS only.  Each of these 
liposomes received 500 µl of the MTS solution and was subsequently incubated in the dark at 
room temperature overnight and thereafter for a further 24 h at 4°C.  Liposome preparations 
containing both MTS and octaarginine (R8) peptides, SP-CHOL-MTS-R8 and GM-CHOL-
MTS-R8, were formulated as above, with the exception that the MTS peptide was in 500 µl 
HBS, and included the addition  of an equimolar quantity of R8 (1.78 mg, 1.3 µmols) in 500 
µl HBS.  The MTS and R8 solutions were added alternately to the liposomes and thereafter 
incubated as above.  Following incubation periods, liposomes were then dialysed against 
HBS over 3 days with 3 additional buffer changes to eliminate any unbound peptides.  The 





3.2.  CHARACTERISATION OF LIPOSOMES AND LIPOSOME-DNA        
        COMPLEXES  
 
3.2.1.  Chemicals and Reagents 
 
E. coli strain JM109 was obtained from Promega Corp. (Dübendorf, Zürich, Switzerland). 
Molecular biology grade UltraPure™ agarose was ac uired from Invitrogen (Carlsbad, CA, 
USA). The gel loading buffer components (glycerol, bromophenol blue, xylene cyanol), 
ethidium bromide (EtBr), ethylenediaminetetraacetic acid (EDTA disodium salt, 
C10H16N2O8), sodium dodecyl sulphate (SDS, C12H25SO4Na), Tris [(hydroxymethyl)-
aminomethane, C4H11NO3] and sodium dihydrogen phosphate (NaH2PO4) were purchased 
from Merck (Darmstadt, Hesse, Germany). Uranyl acetate dehydrate, depleted of 
radioactivity, was obtained from Ted Pella Inc. (Redding, CA, USA).  Label IT
®
 Tracker™ 
TM-Rhodamine and Fluorescein kits were purchased from Mirus (Madison, WI, USA).  
Gamma-irradiated foetal bovine serum (FBS) was supplied by Highveld Biological (Pty) Ltd. 
(Lyndhurst, Gauteng, RSA).  Ultrapure 18 MΩ water (Milli-Q50) was used throughout.  All 
other chemicals were of analytical purity grade or higher and purchased commercially.  
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3.2.2.  Plasmid DNA  Preparations 
 
3.2.2.1.  Amplification of pCMV-luc  DNA 
 
Plasmid pCMV-luc (6.2kbp) (Figure 3.4), driven by the cytomegalovirus (CMV) promoter, 
was purchased from Plasmid Factory (Bielefeld, North Rhine-Westphalia, Germany).  The 
plasmid was amplified using E. coli strain JM109, grown in LB medium at 37°C and shaken 
at 150 rpm for 24 h.  The plasmid was then isolated according to the Promega protocol.  DNA 
purity and concentration was determined spectroscopically using the NanoDrop 2000c 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA).  The isolated plasmid DNA 
was run on a 1% agarose gel against a control pCMV-luc DNA sample to confirm purity and 
identify the different forms of DNA.  The plasmid preparations displaying an OD
260
/280 value 
of 1.8 or higher were used.  Working stock concentrations of 0.25 µg/µl were prepared with 
ultrapure 18 MΩ water (Milli-Q50) and stored at ‒20°C. 
 
Figure 3.4: Plasmid map of  pCMV-luc vector.  The pCMV-luc vector contains the cDNA of  
                    the firefly luciferase (luc) gene and a beta-lactamase for ampicillin resistance   
                    (Amp
r




3.2.2.2.  Fluorescent Labelling of Plasmid DNA 
 





 TM-Rhodamine and Fluorescein kits respectively.  Briefly, 325 µl sterile 





 reagent were added together in a 1.5 µl microcentrifuge tube and incubated at 37ºC 
for 1 h.  The reaction mixture was quickly centrifuged after 30 min to minimise the effect of 
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evaporation and to maintain the concentration of reaction components at appropriate levels.  




 reagent was removed by 
ethanol precipitation with the addition to the reaction mixture of 0.1 volume of 5 M NaCl and 
2 volumes of ice cold 100% ethanol which was mixed well and further incubated for 1 h at  
-80ºC.  Thereafter, the reaction mixture was centrifuged at 4ºC for 10 min to pellet out the 
labelled DNA.  This labelled DNA pellet was washed with 500 µl 70% ethanol, further 
centrifuged and air dried to remove all traces of ethanol.  The resultant dried pellet was 
resuspended in 100 µl sterile ultrapure 18 MΩ water (Milli-Q50).  Labelled DNA purity and 
concentration was determined spectroscopically using the NanoDrop 2000c 
spectrophotometer, and DNA stored at ‒20°C. 
 
 
3.2.3.  Preparation of Mitochondriotropic Liposome-DNA Complexes   
 
Liposome preparations were vortexed for 2 min and thereafter sonicated for 5 min prior to 
use.  The plasmid DNA (0.5 or 1 µg of pCMV-luc) was mixed with varying amounts of the 
appropriate liposome suspension to attain specific ranges of mass (
w
/w) or N/P (
+
/-) ratios.  
These suspensions were brought up to a volume of 10 µl with sterile HBS, vortexed for 30 s 
and allowed to incubate for 30 min at room temperature to afford DNA binding and complex 
formation.  Lipoplexes were freshly prepared before each assay.   
 
 
3.2.4.  DNA Binding Studies of Mitochondriotropic Liposomes and Nuclease Protection  
          Assays 
 
3.2.4.1.  Gel Retardation Assay 
 
In this study, liposome-DNA complex formation was monitored by gel retardation or 
electrophoretic mobility shift assays, that were originally devised by Fried and Crothers for 
studying protein-DNA interactions (Scott et al., 1994).  Lipoplexes were freshly made, as 
described in 3.2.3 above, by incubating 0.5 µg pCMV-luc DNA with increasing amounts of 
cationic liposome preparations at various mass ratios (liposome-pDNA, 
w
/w) as shown in 
Table 3.2, brought up to a total volume of 8 µl with HBS (pH 7.4), vortexed gently and 
allowed to mature for 30 min at room temperature.  Following the incubation period, 2 µl of 
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gel loading buffer (50% glycerol, 0.05% bromophenol blue, 0.05% xylene cyanol) was added 
to all the samples.  The samples (10 µl) were then subjected to electrophoresis on 1% agarose 
gels (0.2 g agarose, 18 ml deionised 18 MΩ water, 2 ml of 10 x running buffer, 
w
/v),  
containing 1 µg/ml EtBr,  in a Mini-Sub
®
 electrophoretic system (BioRad Laboratories, 
Richmond, USA) containing electrophoresis buffer (36 mM Tris-HCl, 30 mM sodium 
dihydrogen phosphate, 10 mM EDTA pH 7.5) at room temperature for 90 minutes at 50 volts.  
The gels were viewed and analysed under UV300nm transillumination and images captured 
using the Vacutec Syngene G:Box BioImaging system (Syngene, Cambridge, UK).         
 
TABLE 3.2: Mitochondriotropic liposome mass range assayed for DNA binding studies.   
                      pCMV-luc DNA was kept constant at 0.5 µg for each lipoplex tested. 
 
 
3.2.4.2.  Nuclease Protection Assay 
 
DNA degradation is known to be a major limiting factor in the application of gene transfer, 
and any non-viral gene delivery vector used has to be able to effectively protect the DNA 
cargo from nuclease digestion and degradation.  The role of mitochondriotropic lipoplexes in 
protecting the pDNA from attack by serum nucleases was assessed by in vitro nuclease 
protection assays using agarose gel electrophoresis.  Three mass ratios (
w
/w), as determined 
after analysis of gel retardation studies, of cationic mitochondriotropic liposomes (Table 3.3) 
were added to a constant amount of  pCMV-luc DNA (1 µg).  This was made up to a volume 
of 10 µl with HBS.  The samples were allowed to incubate for 30 minutes at room 
temperature, as described in section 3.2.3.  Foetal bovine serum (FBS) was thereafter added 
to the complexes to a final concentration of 10%.  Two controls were employed, a positive 
control containing pCMV-luc DNA only with no liposome or FBS and a negative control 
comprising naked pCMV-luc DNA and FBS.  The reaction mixtures were then incubated for 
4 h at 37ºC in a digital temperature-controlled water bath (TriLab Scientific, Johannesburg, 
Mitochondriotropic 
Liposome 
Liposome Test Range (µg) 
SP-CHOL-MTS  0 11.5 12 12.5 13 13.5 14 14.5 
GM-CHOL-MTS 0 6.5 7 7.5 8 8.5 9 9.5 
SP-CHOL-MTS-R8  0 2 2.5 3 3.5 4 4.5 5 
GM-CHOL-MTS-R8 0 1 1.5 2 2.5 3 3.5 4 
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Gauteng, RSA).  After the incubation period, ethylenediaminetetraacetic acid (EDTA) was 
added to the samples to a final concentration of 10 mM and sodium dodecyl sulphate (SDS) 
to a final concentration of 0.5% (
w
/v), to terminate the enzymatic reaction and disassociate the 
lipoplexes, respectively.  The samples were then incubated for a further 20 minutes at 55ºC.  
Thereafter, gel loading buffer (4 µl) was added and the samples subjected to electrophoresis 
on a 1% agarose gel for 120 minutes at 50 volts and imaged as described in section 3.2.4.1 
for the band shift assays. 
 
TABLE 3.3:  Varying amounts of mitochondriotropic liposome preparations and corresponding  
                       charge ratios tested for nuclease protection, MTT, AlamarBlue®, imaging, sizing   
                       and fluorescent assays.  pCMV-luc DNA was constant at 1 µg. 
 
 
3.2.4.3.  Ethidium Bromide Intercalation Assay 
 
The mitochondriotropic liposome-DNA association was further explored to determine the 
ability of the liposomes to efficiently compact DNA by the dye displacement or ethidium 
bromide intercalation assay.  This assay was conducted on a GloMax
®
-Multi Detection 
System (Promega BioSystems, Sunnyvale, CA, USA) set at excitation and emission 
wavelengths of 520 nm and 600 nm, respectively.  Initially 2 µl (0.2 µg) of an ethidium 
bromide stock solution (100 µg/ml) was added to 100 µl of HBS in a single well of 96-well 
FluorTrac flat-bottom black plate to establish a baseline measurement that was recorded as a 
relative fluorescence of 0.  Subsequently, 4.8 µl (1.2 µg) of pCMV-luc DNA was added to 
the mixture and a representative 100% relative fluorescence was ascertained.  Following this, 
1 µl (± 0.8 – 2.5 µg) aliquots of a given liposome preparation were systematically added to 
the mixture until a plateau in fluorescence readings was achieved.  In order to promote 
uniform dispersion and to ensure an accurate reading, the suspension was mixed for 5 
seconds prior to each measurement recording.  The results obtained were plotted relative to 
the 100% fluorescence value.  This procedure was conducted for all liposome preparations. 
Mitochondriotropic Liposome Liposome Amount (µg)  and Charge Ratio (N/P) (+/-) 
SP-CHOL-MTS  27    (7.2) 28    (7.5) 29    (7.7) 
GM-CHOL-MTS 17    (4.5) 18    (4.8) 19    (5.1) 
SP-CHOL-MTS-R8   7     (1.9)  8     (2.1)  9     (2.4) 
GM-CHOL-MTS-R8 5     (1.4) 6     (1.6) 7     (1.9) 
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3.2.5.  Imaging and Sizing 
 
3.2.5.1.  Characterisation of Particles by Transmission Electron Microscopy (TEM) 
 
The structural and physical features of the mitochondriotropic liposomes and lipoplexes were 
examined using cryogenic-transmission electron microscopy (cryo-TEM).  Liposomes were 
vortexed for 2 min and sonicated for 5 min prior to use, after which the liposome preparations 
were diluted 1:5 (
v
/v) with HBS to promote fluidity of the samples to be imaged.  Aliquots of 
diluted samples (1 µl) were placed onto 200-mesh Lacey Formvar carbon coated copper grids 
(Ted Pella Inc., Redding, CA, USA), contrasted 1:1 (
v
/v) with 4% uranyl acetate negative 
stain and allowed to stand for 3-5 min, and the excess liquid was blotted off with Whatman 
No. 5 filter paper paper (Sigma-Aldrich Chemical Co., St. Louis, MO, USA).  The grids were 
immediately vitrified by plunging into liquid propane (-180°C) cooled by liquid nitrogen, 
using an injector spring-loaded Leica Microsystems EM CPC Cryo system (Leica, Vienna, 
Austria).  The rapid freezing of the samples by the liquid propane protects against ice crystal 
formation and freeze-thaw damage.  Grids containing samples were maintained in liquid 
nitrogen and mounted in a cyrotransfer system (Gatan Inc., München, Bavaria, Germany).  
Samples were examined at -170°C on a Cryo-TEM JEOL JEM-1010 electron microscope 
(Jeol, Tokyo, Japan) operating under low electron dose to minimise electron beam radiation 
damage at an accelerating voltage of 100 kV.  Images were captured using a Soft Imaging 
Systems (SIS) MegaView III side-mounted 3 megapixel digital camera and subsequently 
visualised and selected using SIS iTEM software (Olympus, Münster, North Rhine-
Westphalia, Germany) for final image processing. Mitochondriotropic liposome-DNA 
complexes were also examined by cryo-TEM.  Lipoplexes were prepared as described in 
section 3.2.3 above, according to their optimal binding capacities.  The lipoplex dispersions 
were diluted 1:5 (
v
/v) with HBS to promote fluidity and were observed and imaged using the 
protocol as described above.  
 
 
3.2.5.2.  Particle Size and Zeta Potential Analysis 
 
Mitochondriotropic liposomes and lipoplexes preparations were studied for size and zeta 
potential determination using an innovative technique called Nanoparticle Tracking Analysis 
(NTA), facilitated by the Nanosight NS500 (Malvern Instruments, Malvern, Worcestershire, 
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UK) containing a sample chamber of around 0.25 ml, a laser wavelength of 430 nm and a 
sCMOS camera.  For data capturing and analysis, the NTA 3.2 analytical software was used.  
Liposomes were vortexed for 2 min and sonicated for a further 5 min, thereafter the 
dispersions were diluted 1:1000 with 3% sterile HBS.  Lipoplex preparations were prepared 
as described in section 3.2.3 and according to Table 3.3.  The different lipoplexes were 
diluted 1:100 with 3% sterile HBS.  The lipoplexes were also additionally subjected to 
analysis with 3% sterile HBS containing 5% FBS (
v
/v).  All liposome and lipoplex sample 
preparations were mixed thoroughly prior to analysis. 
 
 
3.3.  IN VITRO CELL CULTURE STUDIES 
 
3.3.1.  Chemicals and Reagents 
 
Eagle’s Minimum Essential Medium (EMEM) with L-glutamine (4.5 g/l) together with the 
trypsin-versene mixture and antibiotics (100x) comprising penicillin (10 000 U/ml), 
streptomycin (10 000 µg/ml) and amphoterin B (25 µg/ml) were purchased from Lonza 
BioWhittaker (Verviers, Liège, Belgium).  Foetal bovine serum (FBS) was purchased from 
HyClone (Cramlington, Norththumberland, UK).  3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide (MTT, C18H17N5S), dimethyl sulphoxide (DMSO, 
(CH3)2SO) phosphate buffered saline (PBS) tablets, acridine orange (AO, C17H19N3) and 
isopropanol (C3H8O) were acquired from Merck (Darmstadt, Hesse, Germany). AlamarBlue
®
 
cell viability reagent was obtained from Invitrogen (Carlsbad, CA, USA).  Invitrogen, 
Molecular Probes
®
 (Eugene, OR, USA) supplied MitoTracker
®
 Green FM (C34H28Cl5N3O).  
Cell lysis buffer (5 x) was purchased from Promega Corporation (Madison, WI, USA).   All 
sterile tissue culture plastic ware and consumables were obained from Corning Incorporated 
(New York City, NY, USA).  Ultrapure 18 MΩ water (Milli-Q50) was used throughout.  All 
other chemicals were of analytical purity grade or higher and purchased commercially.   
 
 
3.3.2.  Routine Cell Culture and Cell Maintenance  
 
Human embryonic kidney cells (HEK293) was obtained from the Anti-Viral Gene Therapy 
Unit, Medical School, University of the Witwatersrand, human hepatocellular carcinoma 
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cells (HepG2) and  human epithelial colorectal adenocarcinoma cells (Caco-2)  was 
purchased from Highveld Biological (Pty) Ltd. (Kelvin, Gauteng, RSA), and human cervical 
adenocarcinoma cells that stably express the firefly luciferase gene (HeLa-Tat luc) were 
provided by the Department of Physiology, University of KwaZulu-Natal, Westville, South 
Africa. 
 
The different cell lines were propagated using 5 ml of complete EMEM supplemented with 
10% (
v
/v) foetal bovine serum (FBS) and antibiotics (100 U/ml penicillin, 100 µg/ml 
streptomycin, 0.25 µg/ml amphotericin B) in 25 cm
2
 culture flasks at 37°C in an incubator 
(ThermoElectron Corp. Steri-Cult CO2 incubator, HEPA Class 100) under a humidified 
atmosphere. All cell culture procedures including preparation of complete medium and 
routine maintenance of cells were carried out aseptically in an Airvolution Class II biosafety 
cabinet (United Scientific (Pty) Ltd. Goodwood, Cape Town, RSA). 
 
 
3.3.2.1.  Reconstitution of Cells 
 
Initially, ampoules of cryopreserved HEK293, HepG2, Caco-2 and HeLa-Tat luc cells were 
removed from the biofreezer (-80ºC) and placed in a 37ºC water bath to thaw.  Once thawed, 
the vials were disinfected with ethanol, aseptically opened, the suspensions transferred to 
sterile centrifuge tubes and subjected to centrifugation (3000 rpm for 2 min) to pellet cells.  
The resultant supernatants containing DMSO were discarded and the pellets resuspended in 1 
ml pre-warmed fresh complete medium (EMEM + 10% FBS + antibiotics).  These 1 ml 
suspensions were transferred to cell culture flasks containing 5 ml complete medium (EMEM 
+ 10% FBS + antibiotics) and the flasks placed in a 37ºC incubator.  The medium was 
changed every two to three days and the different cell lines monitored daily using an inverted 
light microscope (Nikon TMS-F 6V, Tokyo, Japan), until they reached confluence.  
 
 
3.3.2.2.  Propagation and Subcultivation of Cells 
 
Once the cells were at or near confluence, they were trypsinised to aid in propagation of the 
cell lines.  Trypsin is a proteolytic enzyme that acts by digesting the proteins that allow cells 
to adhere to the culture flask.  Briefly, spent medium from the culture flask was discarded 
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into a sterile waste bottle and the cells washed with sterile 5 ml phosphate buffered saline 
(PBS, pH 7.5) by gently shaking the culture vessel.   Thereafter, the PBS was removed and 1 
ml of pre-warmed trypsin-versene was added to dislodge the cells from the culture flask.  
This process was allowed to proceed for approximately 1-2 min at room temperature or 37ºC 
and observed under an inverted phase contrast light microscope until the cells had rounded 
off.  Subsequently, 2 ml of complete medium was added to the flask to stop the trypsinisation 
procedure, following which, the cells were completely dislodged by firm tapping against the 
palm.  The resultant cell suspension was either then seeded into multiwell plates for the 
various experimental assays or split at a desired ratio into culture flasks, each containing 5 ml 
of complete medium.  These flasks were incubated at 37ºC and growth medium changed 
when necessary ensuring maintenance of pH and elimination of waste products.  Once cells 
had reached confluence, they were again trypsinised and split as desired or alternately 
cryopreserved for future use. 
 
 
3.3.2.3.  Cryopreservation of Cells   
 
Cells at or near confluence were trypsinised as described above.  The resulting cell 
suspension was centrifuged at 1000 rpm for 5 minutes. The pelleted cells were resuspended 
in 0.9 ml complete medium (EMEM + 10% FBS + antibiotics) and 0.1 ml of the 
cryoprotective agent such as dimethylsulfoxide (DMSO), which lowers the freezing point of 
the medium and ensures a slower cooling rate, thereby lowering the risk of ice crystal 
development causing cell damage.  This suspension was gently vortexed to promote 
homogeneity and was then aliquoted into 2 ml cryogenic vials.  Vials containing cells were 
frozen at a rate of -1C per minute in a Nalgene™ Mr Frosty Cryo 1C freezing container 
containing isopropanol to a temperature of -70°C.  The cryogenic ampoules of frozen cells 
were thereafter stored in a -80ºC biofreezer (Nuaire, Lasec Laboratory and Scientific 
Equipment, Ndabeni, Cape Town, RSA) for short term storage or in liquid nitrogen for long 
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3.3.3.  Cytotoxicity Studies  
 
3.3.3.1.  MTT Growth Inhibition Assay 
 
The cytotoxicity of the mitochondriotropic liposome formulations were quantified by the 
MTT reduction assay in the HEK293, HepG2, Caco-2 and HeLa-Tat luc cell lines.  Confluent 
cells were separately trypsinised, seeded into a 48-well plate at a seeding density of 2.1 – 2.6 
x 10
4 
cells/well and incubated in 0.25 ml complete medium at 37ºC for 24 hours to allow for 
cells to adhere to the wells and grow to semi-confluence.  The liposome-DNA complexes 
correlating with the sub-optimal, optimal and supra-optimal DNA binding ratios as 
determined from retardation studies were set up as in Table 3.3 and these lipoplexes were 
prepared as outlined in section 3.2.3.  Cells were prepared by firstly removing the medium 
and replacing it with 0.25 ml fresh complete medium.  Thereafter, the reaction complexes 
were added to the wells containing cells, and cells incubated at 37ºC for 48 hours.  The assays 
were carried out in triplicate.  Positive controls comprising untreated cells were also included 
in the assay.  Following the incubation period, the spent medium in each well was discarded 
and replaced with 0.2 ml growth medium and 0.2 ml MTT reagent (5 mg/ml in sterile PBS, 
pH 7.4).  The plates were allowed to incubate for a further 4 h at 37ºC.  Thereafter, the 
medium containing MTT was extracted and 0.2 ml of DMSO was added to each well to allow 
for the solubilisation of the formazan crystals.  Subsequently, absorbances were read on a 
Mindray MR-96A microplate reader (Vacutec, Hamburg, Germany) at 570 nm.  Cell viability 
(%) was directly correlated to absorbance and was calculated as follows:  
% cell survival = [OD570 Treated cells] / [OD570 Control] x 100. 
 
 
3.3.3.2.  AlamarBlue® Assay  
  
Overall cellular metabolism of viable cells was quantified by use of the AlamarBlue
®
 assay.  
This assay was used to determine the in vitro cell viability of HEK293, HepG2, Caco-2 and 
HeLa-Tat luc cells when exposed to mitochondriotropic lipoplexes tested.  Cells were 
trypsinised as described above, seeded into 48-well plates (2.2 – 2.5 x 10
4 
cells/well), 
incubated and allowed to attach to the wells.  After 24 hours, medium was replaced with fresh 
growth medium (0.25 ml) and test lipoplexes (Table 3.3), prepared as outlined in section 
3.2.3, were added in triplicate to cells in the wells.  Controls comprising untreated cells (as in 
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3.3.3.1) were also included in the assay.  The plates were incubated for 48 hours at 37ºC, 
after which, 25 µl (10%, 
v
/v) of 10x AlamarBlue
®
 reagent was added to the cells containing 
growth medium which were further incubated for 4 h at 37ºC.  Following the incubation 
period, a GloMax
®
-Multi Detection System (Promega BioSystems, Sunnyvale, CA, USA) 
operated by Instinct software was used to measure fluorescence in 96-well FluorTrac flat-
bottom black plates at excitation and emission wavelengths of 570 nm and 585 nm, 
respectively.  The percentage of AlamarBlue
®
 reduction was calculated as follows: 
 [(λ570 Test – λ585 Test) / (λ570 Control – λ585 Control)] x 100 
 
 
3.3.4.  Apoptosis Detection by Acridine Orange and Ethidium Bromide (AO/EB)   
          Staining 
 
As most of cell death that occurs when cells are exposed to liposomes is apoptotic, this assay 
was used to detect apoptosis in vitro by the dual staining method using ethidium bromide and 
acridine orange (AO/EB).  HEK293, HepG2, Caco-2 and HeLa-Tat luc cells were trypsinised 
as described above, seeded into 48-well plates (1.9 – 2.3 x 10
4 
cells/well), incubated and 
allowed to attach to the wells.  After 24 hours, medium was replaced with fresh growth 
medium (0.25 ml) and test mitochondriotropic lipoplexes at the optimal liposome-DNA ratios 
(Table 3.3) were prepared as described in section 3.2.3 and added into the wells.  Controls 
containing cells only were also employed.  The plates were incubated for 24 hours at 37ºC 
after which, medium was discarded and the cells stained with 20 µl of EB/AO solution (100 
µg/ml of AO and EtBr in a 1:1 ratio) per well for 5 minutes.  Following the incubation, the 
cells were washed with PBS and viewed using an inverted fluorescence microscope 
(Olympus CKX41, Tokyo, Japan) at 490 nm (excitation λ) and 516 nm (emission λ). 
 
 
3.3.5.  Detection of Mitochondrial Localisation by Fluorescent Studies  
 
3.3.5.1.  Fluorescence Microscopy  
 
Confluent cells (HEK293, HepG2, Caco-2 and HeLa-Tat luc) were separately trypsinised, 
seeded into 48-well plates at seeding densities of 1.9 – 2.1 x 10
4 
cells/well and incubated in 
0.25 ml complete medium at 37ºC for 24 hours to allow for cells to adhere to the wells and 
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grow to semi-confluence.  Thereafter, the spent medium was replaced with fresh complete 
medium.  Test mitochondriotropic lipoplexes at the optimal liposome-DNA ratios (Table 3.3) 
were prepared as illustrated in section 3.2.3 with rhodamine-labelled pCMV-luc DNA (1 µg) 
and added into wells.  Controls comprising untreated cells and untreated cells with naked 
rhodamine-DNA were also included in the assay.  The culture plates were incubated for 24 
hours at 37ºC following which, the medium was discarded and the cells stained with  200 µl 
50 nM MitoTracker
®
 Green FM (made up in serum-free growth medium) and allowed to 
incubate for 1 h at 37ºC.  Thereafter, the stain was decanted; cells washed with PBS (pH7.5) 
to remove excess stain and then viewed using an inverted fluorescence microscope (Olympus 
CKX41, Tokyo, Japan).  MitoTracker
®
 Green FM was observed at 490 nm (excitation λ) and 
516 nm (emission λ) while rhodamine-labelled pCMV-luc DNA was examined at 546 and 
576 nm representing the excitation and emission wavelengths, respectively. 
 
 
3.3.5.2.  Quantitative Evaluation of Mitochondrial Targeting Activity 
 
 This method was adapted from Yamada and Harashima (2013).  A homogenate solution was 
obtained from a total of 5 x 10
6
 of cultured cells (HEK293, HepG2, Caco-2 and HeLa-Tat 
luc).  The cells were trypsinised to dislodge them from the surface of the flasks.  Thereafter, 
cells were washed with ice-cold PBS, resuspended in mitochondrial isolation buffer [MIB, 
(250 mM sucrose; 2 mM Tris-HCl)] and subjected to 20 strokes in a Dounce homogeniser on 
ice to yield a homogenate.  Aliquots (10 µl) of lipoplexes (containing 1 µg of fluorescein-
labelled pCMV-luc DNA) were prepared at the optimal liposome-DNA ratio (
w
/w) as 
illustrated in section 3.2.3 for each of the cationic mitochondriotropic liposome formulations.  
These were added in triplicate to the homogenates of the different cell lines in 90 µl of MIB, 
and the suspensions incubated for 30 minutes at 25°C.  The resultant solution was designated 
Sample A.  Following the incubation period, a differential centrifugation technique was used 
to obtain each organelle fraction from the homogenates.  All steps were carried out on ice.  
Controls comprising untreated cells only and cells only containing naked fluorescein-DNA 
were also included in the assay.  The homogenate solution was centrifuged at 700 x g at 4°C 
for 10 minutes and the resultant pellet, denoted P fraction which contained nuclei and fracted 
cells were resuspended in 100 µl MIB.  The supernatant was further centrifuged at 16 000 x g 
at 4°C for 10 minutes and the resulting pelleted fraction was resuspended in  was resuspended 
in 100 µl MIB to give the mitochondrial fraction.  Sample A and the mitochondrial fraction 
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were solubilised by 1 x cell lysis buffer and the fluorescence intensities were measured in 96-
well FluorTrac flat-bottom black plates at excitation and emission wavelengths of 492 nm 
and 518 nm respectively, using the GloMax
®
-Multi Detection System operated by Instinct 
software.  Mitochondrial targeting activity (%) was calculated as follows:   
Mitochondrial targeting activity (%)  =  Fmt/FA  x 100, 




3.4.  STATISTICAL ANALYSIS 
 
All data are presented as mean ± standard deviation (SD, n = 3). One-way analysis of 
variance (ANOVA) was performed for all analyses followed by Dunnett and Tukey-Kramer 
post hoc tests for multiple comparisons between groups.  All statistical analyses were 
performed using a 95% confidence interval and was considered significant when the P value 















RESULTS AND DISCUSSION 
 
4.1.  SYNTHESES AND LIPOSOME FORMULATON 
 
4.1.1.  Cationic Cholesterol-derived Cytofectin (CHOL-T) 
 
3 β [N-(N’, N’- dimethylaminopropane)-carbamoyl] cholesterol (CHOL-T) was previously 
successfully synthesised from cholesterol chloroformate (Singh et al., 2001).  This cationic 
lipid has the general structure of most cationic lipids used today, i.e. it has four basic 
components: a hydrophobic lipid anchor, spacer arm, linker bond and a positively charged 















Figure 4.1: Structure of cationic lipid CHOL-T, showing the four components. 
 
The cationic lipid in this study has a cholesterol ring anchor, a carbamoyl linker bond and a 
monovalent dimethylamino cationic head group.  This lipid is amphiphilic and as such has 
both hydrophilic and lipophilic properties.  The lipophilic portion, which is the cholesterol 
anchor, not only brings rigidity and stability to the liposome structure but it also seems to 
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influence membrane fluidity, the consequent effects on lipid mixing within the bilayers as 
well as determining other physical properties of the lipid bilayer (Huang et al., 1999; Lesage 
et al., 2002).  The hydrophilic segment is generally a charged head group, and in this 
cytofectin the cationic head group has an amine (R3NH
+
) functionality.   
 
The linker bond of this cholesterol derivative is a carbamoyl bond and influences the 
chemical stability and biodegradability of the cationic lipid (Huang et al., 1999).  The spacer 
arm length that joins the hydrophilic and hydrophobic portions may play a role in promoting 
DNA interaction with the charged head group i.e. a longer spacer arm would result in a 
decrease of steric hindrance between the polar head group and the hydrophobic cholesterol 
ring system (Singh, 1998).   
 
The type of head group plays an important role in determining the transfection efficiency and 
cytotoxicity of the formulated liposomes.  Monovalent cationic lipids, like CHOL-T, 
condense DNA less strongly than multivalent cationic lipids in vitro; however the presence of 
too many positive charges on the head group may result in an extremely secure interaction 
with the DNA and the subsequent decrease in transfection activity as this impedes the 
disassociation of the pDNA at the molecular level (Huang et al., 1999).  Cholesterol 
derivatives with a tertiary amino group, such a CHOL-T, generally have stronger transfection 
activities than quaternary derivatives (Farhood et al., 1992).  The terminal tertiary amino 
functionality of CHOL-T extends 6 Å from the 3-position of the fused 
perhydrocyclopentanophenanthrene ring system and additionally, a carbamoyl linkage 
connects the hydrophobic cholesteryl moiety and the 3-carbon propane spacer element (Singh 
et al., 2011).  This cholesterol-derived cytofectin formed the major structural constituent of 
the mitochondriotropic liposomal vesicles manufactured for this investigation.    
 
 
4.1.2.  Cholesterol-derived Cross-linking Agents  
 
To make typical cationic liposomes mitochondriotropic, the mitochondrial targeting sequence 
(MTS) and octaarginine (R8) peptides were attached to the surface of the liposomes.  To 
facilitate this attachment, the liposomes needed to possess a lipid with a hydrophobic anchor, 
a spacer arm and a reactive head group that will bind to the peptides, incorporated into the 
liposomal bilayer.  To this end, two different cholesterol-derived cross-linking agents were 
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synthesised namely, 3β-[N-(hydrazino 3-{2-pyridyldithio} propionate)-carbamoyl] 
cholesterol (SP-CHOL) and 3β-[N-(hydrazino-γ-maleimidobutyryl)-carbamoyl] cholesterol 
(GM-CHOL) (Figure 4.2).  The thin layer chromatographs confirmed the presence of the 

















Figure 4.2: Structures of cholesterol-derived cross-linking agents (A) 3β-[N-(hydrazino 3-{2- 
                    pyridyldithio} propionate)-carbamoyl] cholesterol  (SP-CHOL) and (B) 3β-[N-   




Sulphuric acid (33%, 
v
/v) was sprayed onto the thin layer chromatograms to aid in colour 
development and visualisation.  Dehydration of sterols such as free cholesterol and MS04 by 
the acid, results in a brown to purple colour.  The reaction mixture (RM) as shown in Figure 
4.3 (A and B) shows the product, some unreacted MS04 as well as N-hydroxysuccinimide 
(NHS) which is released by the reaction (Figure 3.3).  The product lanes contained the 
desired crystalline products confirming that the purification process was successful. 
(A) 
(B) 




Figure 4.3: Representative TLC chromatographic plate illustrating the synthesis of (A) SP-CHOL and  
                    (B) GM-CHOL showing the stating material MS04, reaction mixture (RM) and as well as     
                    the purified products.  The retention factor (Rf) of the reactants was calculated as the     
                    distance from point of application of analyte  (mm) /distance from application line to     
                    solvent front (mm), as follows: Plate A – MS04 0.3, RM product = 0.05, SP-CHOL = 0.2;    
                    Plate B – MS04 = 0.4, RM product = 0.3, GM-CHOL = 0.4 
                    Solvent system: CHCl
3





MS04 is the first step intermediary in the synthesis of the cationic cytofectin N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09).  An excess amount 
of hydrazine, which acted as an electron/amino group donor activated the carbonyl group on 
cholesteryl chloroformate, which formed the hydrophobic anchor, yielding the product, 
cholesterylformylhydrazide (MS04), which contained the newly formed carbamoyl bond. 
This reaction was accompanied by the release of HCl (Figure 3.2).  Thus MS04 lipid 
structure comprised a cholesterol anchor, a carbomyl bond and a terminal amino group. 
 
The heterobifunctional cross-linkers used to synthesise the bioconjugates SP-CHOL and GM-
CHOL have two different reactive groups at either end.  SPDP contains NHS ester and 
pyridyldithiol reactive groups while GMBS comprises NHS ester and maleimide reactive 
groups.  Both these reagents’ cross-linking targets are amines through their NHS ester; and 
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the conjugation reaction with MS04, the NHS ester of both SPDP and GMBS reacts with the 
terminal amino group (-NH2) of the MS04 to produce the cholesterol-derived cross-linking 
agents, SP-CHOL and GM-CHOL respectively (Figure 3.3) with the subsequent release of 
NHS as a by-product of the reaction.  The cross-link formed by SPDP and MS04 is cleavable 
however the GMBS cross-link to MS04 is non-cleavable.  As noted by the structures of SP-
CHOL and GM-CHOL (Figure 4.2), they are essentially functionalised MS04 molecules with 
SP-CHOL containing a pyridyldithiol reactive group at one end and GM-CHOL boasting a 
maleimide reactive group at its end.  These reactive groups allow for binding or 
bioconjugation of other molecules such as the MTS and R8 peptides through the SH groups 
of the C-terminal cysteine residues.  SP-CHOL has a spacer arm of 6.8 Å containing a 
disulphide bond that extends from the amide bond to the pyridyldithiol reactive portion while 
GM-CHOL has a 7.3 Å alkane spacer arm length from said bond to its reactive maleimide 
segment.  The hydrophobic cholesterol anchor was utilised for its natural interaction with, 
and stable incorporation into liposomal bilayers.   
 
 
4.1.3.  Formulation of Cationic Mitochondriotropic Liposomes  
 
Conventional liposomes are lipid-based vesicular artificial macromolecular complexes 
usually composed of biodegradable, reusable amphiphilic molecules (Zhdanov et al., 2002).  
These molecules have a hydrophilic group, the polar head, and a hydrophobic portion, which 
is the non-polar tail.  Therefore these amphiphilic molecules self-assemble and form ordered 
structures, such as lipid bilayers, in aqueous solutions (Lasic, 1997).  These lipid bilayers 
exist such that the polar surfaces shield the non-polar interior.  However, as it is energetically 
unfavourable to have hydrophobic edges adjacent to water, the bilayer sheets self-close to 
form liposomes with the water both inside and outside the bilayer (Singh, 1998; Lasic, 1997) 
(Figure 4.4).  As mentioned earlier, conventional liposomes can be easily modified.  To this 
end, cationic lipids, which are positively charged amphiphilic molecules, can be incorporated 
into liposome structures to form cationic liposomes (Lonez et al., 2008; Wasungu and 
Hoekstra, 2006).    
 
Various methods have been utilised to prepare cationic liposomes.  These include the original 
hand-shaken preparation producing multilamellar vesicles (Bangham et al., 1965), ethanol or 
ether injection technique (Batzri and Korn, 1973; Campbell, 1995; Deamer and Bangham, 
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1976), reverse phase evaporation technique (Szoka and Papahadjopoulos, 1978), detergent 
depletion (Torchilin, 2003) and thin lipid film hydration (Gao and Huang, 1991).  The latter 
method was employed for the successful preparation of the four cationic mitochondriotropic 
liposomes utilised in this study.  Each of these four liposomes contained a constant 50% mole 
composition of the synthetic cationic cytofectin, CHOL-T to facilitate binding of negatively-
charged pDNA as well as varying mole percentage of the helper lipid, 
dioleoylphosphatidylethanolamine (DOPE).  The lipid composition of liposomes determines 
many physical features such as size, zeta potential and fluidity or rigidity of the bilayer as 
well as functional characteristics like cytotoxicity, binding capacity and transfection 
efficiency of the resultant liposomal vesicle.  Lipid derivatives containing cholesterol produce 
liposomes with good membrane stabilisation and well-organised structure due to the presence 
of the cholesterol portion of the lipid (Lesage et al., 2002; Briuglia et al., 2015).    The 
presence of cholesterol and its derivatives in liposomal bilayers has been shown to have a 
number of advantages: it improves vesicle resistance to excessive aggregation and protein 
binding; it improves serum stability of the vector even when exposed to high serum 
concentrations; the mechanical strength of these delivery vehicles is enhanced; and finally, it 
increases the packing density of lipids via “ordering and condensing” effects which leads to a 
more ordered membrane structure and subsequently results in reduced permeability of the 
liposomal bilayer to non-electrolyte and electrolyte solutes (Yang et al., 2013; Magarkar et 
al., 2014; Briuglia et al., 2015).   
 
The other major ingredient in all liposome preparations was the cephalin 
dioleoylphosphatidylethanolamine (DOPE).  DOPE is a neutral zwitterionic phospholipid and 
is often used in liposome preparations as a helper or co-lipid.  It tends to form a heterodimer 
with the cationic lipid through the interaction between the negatively charged phosphate on 
DOPE and the tertiary ammonium group on the cationic lipid (Felgner et al., 1994).  This 
helper lipid is also required to stabilise cationic liposome formulations as the cationic lipids 
tend repel each other (Dass, 2004).  It is thought that this lipid improves cationic lipid 
mediated nuclear transfection efficiency by promoting the conversion of the lamellar lipoplex 
phase into a non-lamellar or inverted hexagonal phase (HII) (Wasungu and Hoekstra, 2006; 
Kim et al., 2015).  DOPE has a small head group and two bulky fatty acyl chains that give it 
a conical molecular shape (Figure 4.4).  This shape favours robust intermolecular interactions 
between the phosphate and amine groups of its polar head, which explains why this lipid and 
other phosphatidylethanolamines are unable to organise themselves into bilayers by 
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themselves and instead prefer the HII phase (Monteiro et al., 2016).  It is this feature of DOPE 
that contributes to its fusogenic capacity that allows this neutral lipid to assist in endosomal 
membrane destabilisation and the subsequent release of DNA from the endosome during 
nuclear transfection (Li and Ma, 2001; Percot et al., 2004).  This natural fusogenic 
characteristic of DOPE is also exploited in mitochondrial targeted delivery of 
macromolecules such as DNA, proteins or drugs where DOPE-containing mitochondriotropic 
liposomes fuse with the mitochondrial membrane in order to facilitate delivery of cargoes 
(Yamada and Harashima, 2013; Kawamura et al., 2013a; Furukawa et al., 2015).  It is for 
these favourable reasons that the fusogen DOPE was incorporated into the cationic 
mitochondriotropic liposomes used in this study.  
 
To display MTS and R8 peptides on the surface of the liposome, 5 or 10 mol% of either SP-
CHOL or GM-CHOL was also incorporated in the liposomal bilayer.  The reactive groups 
(pyridyldithiol on SP-CHOL and maleimide on GM-CHOL) at the end of these lipid 
derivatives react with cysteine on MTS and cysteine on R8 when the liposomal suspensions 
are incubated with these peptides, thus enabling the binding of the respective peptides onto 
the liposomal surface and generating the resultant cationic mitochondriotropic liposomes.    
As mentioned earlier, MTS peptide has been shown to selectively deliver a wide range of 
proteins, chemicals, linear DNA and ODNs to mitochondria (Flierl et al., 2003; Yamada and 
Harashima, 2013).  It was further reported by Yamada and Harashima (2013) that MTS was 
an efficient ligand for the selective mitochondrial delivery of the nanoparticle under 
investigation in cell homogenates, by virtue of their accumulation in the mitochondrial 
fraction.  MTS peptide was added at 5 mol% of total lipid content as it was found that at 
higher concentrations, the MTS molecule caused excessive increases in surface charge and 
aggregation (Yamada and Harashima, 2013).  Based on this evidence, it is expected that MTS 
has the potential to be an effective ligand for selective mitochondrial delivery, via 
mitochondrial import machinery, of the cationic mitochondriotropic liposomes in this study.    
 
Octaarginine (R8) is a synthetic cationic cell penetrating peptide (CPP) that has been used 
extensively as vectors or ligands for the intracellular delivery of a variety of therapeutic 
molecules such as nucleic acids, proteins, peptides, fluorochromes, nanoparticles, micelles, 
small molecular drugs and liposomes (Yamada et al., 2008; Biswas and Torchilin, 2013; 
Layek et al., 2015; Boisguérin et al., 2015).  Liposomes modified with high-density R8 have 
been shown to be internalised predominantly by macropinocytosis, a form of fluid-phase 
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endocytosis that allows vectors to more efficiently escape macropinosomes due to their 
inherent leaky nature, and thus evade lysosomal degradation (Khalil et al., 2006a; Yamada et 
al., 2008 Huang et al., 2011).  It is thought that R8 and other CPPs mediate macropinocytosis 
by electrostatic interactions with anionic phospholipids and negatively charged sulphated 
proteoglycans such as glycosaminoglycans of cell membranes (Layek et al., 2015; Boisguérin 
et al., 2015; Imani et al., 2015).  R8 mimics the TAT peptide derived from human 
immunodeficiency virus (HIV-1 protein) which has been shown to deliver some cargo to 
mitochondria, while Yamada and Harashima (2008) observed that R8 modified liposomes 
enhanced binding to mitochondria (Yamada et al., 2011).  Thus, in this study, 5 mol% R8 
surface modification of cationic mitochondriotropic liposomes, which is considered high 
density, was utilised primarily as a cellular uptake device as well as a possible mitochondrial 
targeting device.    
 
 
4.1.4.  Mitochondriotropic Liposome-DNA Complex Formulation    
 
The term ‘lipoplexes’ was first used by Felgner et al. (1997) to describe the complex formed 
by the interaction of plasmid DNA  (pDNA) with cationic liposomes or lipids.  These so-
called ‘lipoplexes’ have proven to be a viable alternative in the search for new DNA delivery 
agents. 
 
The exact mechanism involved in the formation of cationic liposome-DNA constructs and 
structure of the lipoplexes is still not fully understood.  What is known however, and holds 
true today is that complexation is achieved by simply mixing and incubating the cationic 
liposome preparation and the pDNA (Felgner et al., 1987).  This process is dependent on a 
number of factors including charge ratio, type of cationic lipid, liposome concentration and 
nature of preparation, plasmid size and temperature to name a few (Barenholz, 2001; 
Wasungu and Hoekstra, 2006; Tros de Ilarduya et al., 2010).  It is generally accepted that the 
cationic liposomes interact with pDNA through charge-charge attraction (Li and Ma, 2001). 
Cationic liposomes, when mixed with DNA, react by spontaneous self-assembly forming 
lipoplexes (Figure 4.4).  The first step in this process involves an electrostatic interaction 
between the positively charged amine headgroup of the cationic lipid and the negatively 
charged phosphate backbone of the pDNA resulting in the formation of a liposome-DNA 
complex, a process during which the liposomes tend to retain their original shape
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Figure 4.4: Schematic structure and composition of the cationic liposome (+) used in this study and its electrostatic interaction with anionic DNA (‒) to  
                    form a  liposome-DNA complex called a lipoplex.
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This is an exothermic, rapid and reversible reaction (Ropert, 1999; Tros de Ilarduya et al., 
2010) (Figure 4.4).  The second step is irreversible, slower and endothermic involving the 
rearrangement and fusion of the liposome and pDNA such that the pDNA is compacted or 
condensed in a way that it is effectively shielded by the lipids of the liposome (Zhdanov et 
al., 2002; Wasungu and Hoekstra, 2006; Tros de Ilarduya et al., 2010).   
 
Originally there were essentially two hypothetical models of liposome-DNA interactions that 
have been elucidated by the use of fluorescence, atomic force and electron microscopy 
techniques.  These two models were the electrostatic model or ‘external’ model and the 
coated electrostatic or ‘internal’ model (Singh, 1998; Smith et al., 1993; Ma et al., 2007). The 
original electrostatic model was proposed by Felgner and Ringold in 1989 and is based on the 
probability that electrostatic forces underlie the successful interactions between DNA and 
cationic lipids where the DNA is adsorbed onto the surface of the cationic liposomal vesicle 
gaining a ‘beads on a string’ structure.  The coated electrostatic model suggests that the DNA 
is coated by lipid bilayers due to the DNA being entrapped between the bilayers during 
liposome-DNA interactions (Ma et al., 2007; Tros de Ilarduya et al., 2010).  As cationic 
liposomes and thus lipoplexes are frequently heterogeneous in terms of composition, 
preparation, size and shape, many varieties of morphologies have been reported such as 
spaghetti and meatballs structures, sliding columnar phase and map-pin structures.  However, 
x-ray diffraction studies have shown two prevailing types of structures in plain lipoplexes, 
viz. multilamellar structure L
C
α where DNA monolayers are sandwiched between lipid 
bilayers characterised by regular spacing [Figure 4.5 (A)]; and the second is the inverted 
hexagonal structure H
C
II or ‘honeycomb’ phase with DNA encapsulated within lipid 
monolayer tubes [Figure 4.5 (B)] (Tros de Ilarduya et al., 2010; Dan, 2015; Motta et al., 
2016).  It has been reported that lipid properties of the bilayer determine which of the two 
above structures the resultant lipoplexes will form (Dan and Danino, 2014).  Cationic 
lipoplexes may exhibit colloidal stability in three main zone allocations: zone A which has a 
negative N/P ratio and contains lipoplexes with uncondensed DNA surrounding them; zone B 
which comprises essentially uncharged complexes and is a region of colloidal instability and 
zone C which is a region of stable, positively charged lipoplexes with highly condensed DNA 




















Figure 4.5: Schematic of the two most common lipoplex structures 
                    (A) lamellar structure (L
C
α) where DNA is sandwiched between lipid bilayers, and  
                    (B) inverted hexagonal structure (H
C
II) where DNA is coated with lipid monolayer  




4.2.  CHARACTERISATION OF LIPOSOMES AND LIPOSOME-DNA        
        COMPLEXES 
 
4.2.1.  DNA Binding Studies of Mitochondriotropic Liposomes and Nuclease Protection  
          Assays 
 
As noted above, lipoplexes are formed by the mixing of cationic liposomes and anionic DNA, 
driven by electrostatic interactions between the two molecules.  Characterisation of these 
resultant lipoplexes was conducted to determine the optimum binding ratios of the liposome-
DNA complexes for in vitro analyses and mitochondrial localisation.  Lipoplex formation was 
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4.2.1.1.  Gel  Retardation Assay 
 
The gel retardation or electrophoretic mobility shift (EMS) assay was originally devised by 
Fried and Crothers for studying protein-DNA interactions (Scott et al., 1994; Hellman and 
Fried, 2007).  It was adapted for cationic liposome studies and the underlying principal of this 
assay is that the formation of complexes between plasmid DNA and cationic liposomes 
results in the retardation of the DNA electrophoretic migration.  Agarose gel electrophoresis 
was used to demonstrate the binding efficiency or complex formation between the pDNA and 
the cationic liposomes.  The amount of liposome-associated pDNA that is retained in the 
wells increases with increasing liposome concentration until complete DNA complexation is 
achieved, and the charge ratio (N/P) corresponding to this complexation can be thus 
estimated (Percot et al., 2004).  This is the minimum mass of cationic liposome that is 
required to completely compact and bind a constant amount of pDNA, thereby forming a 
cationic lipoplex capable of gene delivery.  Complete retardation suggests that the negative 
charges of the pDNA are completely titrated by the positive charges of the cationic 
mitochondriotropic liposomes.  This yields electroneutral complexes that cannot migrate 
through the agarose gel matrix and can be seen fluorescing in the wells.  At higher liposome-
DNA ratios, precipitates may form and float out of the sample wells thus evading detection 
even after ethidium bromide staining (Singh, 1998).  Naked pDNA, in the absence of 
liposome, would migrate in the gel matrix, however in the presence of increasing 
concentrations of cationic mitochondriotropic liposome; the anionic pDNA was neutralised 
resulting in complete DNA compaction by the liposomes and hence no further migration was 
observed and pDNA was finally retained in the wells.  As can be seen from the results 
(Figure 4.6) all cationic liposome preparations successfully bound the pDNA, at various 
weight or N/P ratios.  
 
The control lane containing 0.5 µg of naked or uncomplexed pCMV-luc generated the 
expected three conformations, i.e. supercoiled helical (migrates the furthest), linear and 
nicked circular (migrates the least).  It was observed that all mitochondriotropic lipoplexes 
retarded the same amount of pDNA (0.5 µg) at varying liposome-DNA or N/P ratios 
regardless of the fact that all liposomal preparations comprised a constant amount (2 µmols) 
of  the cationic lipid, CHOL-T.  It can hence be suggested that the difference seen in binding 
efficiencies of the various lipoplexes was possibly attributed to the cholesterol-derived cross-
linking agents, and the MTS and R8 peptides attached to the surface of the various liposomes.   






























Figure 4.6: Gel retardation analysis of the binding interaction of varying amounts of cationic      
                    mitochondriotropic liposome preparations in a total of 10 µl reaction mixture while  
                    pCMV-luc DNA was kept constant at 0.5 µg per well.   
                    (A) SP-CHOL-MTS, (B) GM-CHOL-MTS, (C) SP-CHOL-MTS-R8 and (D) GM-  
                    CHOL-MTS-R8.  Samples from left to right are as follows, lane 1: 0.5 µg of naked    
                    pDNA (0 µg of cationic liposome); lanes 2 – 8: the respective liposome-DNA  
                    complexes prepared using various liposome mass (µg) as indicated.  Numbers in red   
                    and arrows indicate the point of electroneutrality.    
  
 
             
B)     
(A)  
   0    11.5  12   12.5   13  13.5  14   14.5 
(C) 
    0      2     2.5     3    3.5     4    4.5    5 
(D) 
   0      1    1.5     2     2.5     3     3.5    4 
Liposome mass (µg) 
   0    6.5     7     7.5    8     8.5     9    9.5 
(B) 
Results and Discussion 
74 
 
From the results obtained (Figure 4.6 and Table 4.1), it can be seen that mitochondriotropic 
liposomes containing SP-CHOL required more liposome to bind 0.5 µg pDNA compared to 
their respective GM-CHOL containing counterparts.  SP-CHOL and GM-CHOL have lipid 
anchors that form part of the lipid bilayer of the liposome and the reactive portion of these 
agents structurally protrude out of the bilayer of the liposomes.  The MTS and R8 peptide 
molecules attach to these bilayer projecting reactive portions of the respective agents to form 
the mitochondriotropic liposomes.  SP-CHOL has a spacer arm of 6.8 Å while GM-CHOL 
has an arm length of 7.3 Å.  This slight difference in spacer length could possibly account for 
the higher N/P ratios needed by SP-CHOL containing liposomes to retard DNA migration 
relative to the GM-CHOL containing liposome preparations.  The shorter arm length of SP-
CHOL means that MTS molecules in SP-CHOL-MTS and both MTS and R8 peptides in SP-
CHOL-MTS-R8 bind to the liposome somewhat closer than would be observed in GM-
CHOL containing liposomes, GM-CHOL-MTS and GM-CHOL-MTS-R8.  This could 
possibly cause a shielding or masking effect whereby the positive charges of the liposomes 
are essentially blocked or shielded by the bound peptides thereby decreasing the ‘available’ 
overall positive charge or cationic cytofectin of the liposome and thus interfering with the 
binding of the cationic liposomes to the negatively charged DNA.  A similar shielding effect 
was observed in a study by Meyer et al. (1998) in which the polymer blocked negative 
charges of liposome-bound oligodeoxyribonucleotides.  The marginally larger spacer arm 
length of GM-CHOL could have ensured that the peptides bind to the liposome sufficiently 
further away such that the shielding effect is negated or reduced and the ‘available’ cationic 
charge is largely unaffected.    
 
Another trend observed was that mitochondriotropic liposome preparations that contained the 
R8 peptide, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 showed significantly lower 
amounts of liposome needed to bind 0.5 µg pDNA and hence lower N/P ratios in contrast to 
liposomes containing MTS only.  R8, as noted above, is a cationic peptide molecule and as 
such when bound to the liposomes, it lends its positive charge to those liposomes thus 
increasing the overall theoretical cationic charge of the liposomal preparations.  This could 
have consequently resulted in the requirement of lower amounts of those liposomes to 
completely bind the same amount of pDNA leading to the decreased N/P ratios detected.  
Additionally, MTS (33 amino acids) is a substantially larger peptide than R8 (8 amino acids).  
In liposome preparations that contain MTS only, SP-CHOL-MTS and GM-CHOL-MTS, 
MTS could exclusively bind to the reactive portions of the SP-CHOL and GM-CHOL thus 
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perhaps partially masking the positive charges of the liposomes because of its considerable 
size.  In liposomes containing MTS and R8, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8, 
MTS peptides are in competition with R8 molecules to bind the reactive portions thus it is 
conceivable that fewer MTS peptides attach to the liposomes and this could have lessened 
any shielding influence that MTS peptides may have induced.  
 
TABLE 4.1: Liposome-DNA ratios at which all plasmid DNA is lipoplex – associated (optimal ratio)   
                      and corresponding charge ratios for gel retardation and ethidium bromide intercalation  
                      assays. 
 
 
The data obtained has been used to facilitate the design of lipoplexes intended for 
cytotoxicity and mitochondrial localisation studies described in chapter three.   
 
 
4.2.1.2.  Nuclease Protection Assay and Stability in Serum 
 
Serum has been widely proposed as one of the key barriers to cationic liposome meditated 
gene transfer with many studies having demonstrated the numerous adverse effects of serum 
on lipoplexes (Zhang and Anchordoquy, 2004; Betker et al., 2013a).  Serum is a complex 
suspension derived from blood plasma.  It comprises various proteins such as albumin, 
lipases, electrolytes, nucleases, lipoproteins and other exogenous constituents but does not 
contain any blood cells and fibrinogens.  Serum has been reported to wield its inhibitory 
effect by interaction with cationic lipoplexes which results in alteration of their biophysical 
properties leading to possible decreases in lipoplex association with cells and consequent 
transfection efficiency as well as influencing the intracellular processing of lipoplexes 
(Madeira et al., 2008; Kim et al., 2014).  In recent times, there have been observations and 




















SP-CHOL-MTS  14 28:1 7.5:1 33:1 11.3:1 
GM-CHOL-MTS 9 18:1 4.8:1 21:1 5.5:1 
SP-CHOL-MTS-R8  4 8:1 2.1:1 9:1 2.4:1 
GM-CHOL-MTS-R8 3 6:1 1.6:1 7:1 2.0:1 
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lipoproteins, glycoproteins, apolipopriteins, immunoglobulins and albumin that associate 
with nanoparticles upon their interaction with biological fluids or serum (Caracciolo et al., 
2010; Betker et al., 2013b).  The association of these serum proteins with the lipoplex surface 
forms a protein rich layer called a protein corona (Caracciolo et al., 2010; Betker et al., 
2013b; Kim et al., 2014; Caracciolo, 2015).  The protein corona can have detrimental effects 
on the cationic lipoplex which leads to aggregation, structural reorganisation and/or 
destabilisation of complexes.  Aggregation results in size increases and modifications in zeta 
potential while structural reorganisation and destabilisation affects electrostatic interactions 
with cell membranes and could also induce the dissociation of DNA from the complexes 
exposing the DNA to nucleases present in the serum and thus probable degradation (Xu and 
Anchordoquy, 2008; Marchini et al., 2009; Caracciolo et al., 2010; Yang et al., 2013).  The 
formation of the protein corona around the lipoplex due to its interaction with serum, and its 
subsequent processing by the cells requires further investigation, as this key interaction may 
serve as an important predictive archetype for the possible in vivo efficiency of the 
nanoparticle.  Hence stability in serum, both in vitro and in vivo and the ability of the lipid 
vector to protect and shield its DNA cargo is a major concern.  DNA degradation is known to 
be a chief limiting factor in the application of gene transfer and any synthetic vector used has 
to be able to effectively protect the DNA cargo (Obata et al., 2009).  The integrity of DNA in 
serum containing media is vitally important in gene delivery systems.  Nucleic acid 
degradation by serum nucleases such as DNase I and other endonucleases is of particular 
concern as inefficient protection of DNA by a gene delivery vehicle is an undesirable trait in 
vector systems (Obata et al., 2009).   
 
The role of the formulated lipoplexes in protecting the DNA from attack by serum nucleases 
was assessed by in vitro nuclease protection assays using agarose gel electrophoresis (Figure 
4.7).  In theory, DNA associated with cationic liposomes is able to withstand the degradative 
effects of serum nucleases as the DNA is condensed and compacted into highly organised 
supramolecular structures (Figure 4.8) together with the liposomal vesicles, whereas DNA 
unprotected by a cationic lipid coating is rapidly degraded (Singh et al., 2006; Caracciolo et 
al., 2010).  As mentioned above, serum can also cause disruption of lipoplex structure 
resulting in DNA release and subsequent degradation.  Therefore, liposomes have a dual role 
of not only protecting DNA from serum, but additionally forming a resilient, serum-resistant 
interaction with DNA so as to tolerate any adverse effects of serum on its structure. 
 

















Figure 4.7: Nuclease protection assay of cationic mitochondriotropic liposome-DNA complexes of  
                   (A) SP-CHOL-MTS, (B) GM-CHOL-MTS, (C) SP-CHOL-MTS-R8 and (D) GM-  
                   CHOL-MTS-R8 in a total of 10 µl reaction mixture while pCMV-luc DNA was kept  
                   constant at 1 µg per well.  Samples from left to right are as follows, lane 1: 1 µg of  
                   untreated naked pCMV-luc DNA (control 1); lane 2: 1 µg of FBS-treated naked pCMV-  
                   luc DNA (control 2); lanes 3 – 8: the respective liposome-DNA complexes prepared at   
                   different liposome mass (µg) as indicated.  
 
 
Two controls were included in this investigation, namely, control 1: untreated naked marker 
pCMV-luc DNA displaying 3 species of DNA: an abundant high-mobility band, representing 
the compact supercoiled helical form (Figure 4.8); an intermediate band, showing the linear 
form and the least mobile band, indicating the nicked circular form; and control 2: naked 
unprotected pCMV-luc DNA treated with 10% FBS, to evaluate the degree of serum nuclease 
digestion on treated unprotected DNA compared to DNA in association with cationic 
mitochondriotropic liposomes.  As observed from the results obtained, all mitochondriotropic 
liposome preparations were able to effectively protect their associated pDNA cargo from 
possible degradation by nucleases present in FBS across all liposome-DNA mass ratios (w/w) 
tested compared to the unprotected fully digested pDNA (control 2).  
 
Cholesterol is known to increase the mechanical strength of membranes, affecting membrane 
elasticity and enhancing the packing density of phospholipids by ‘ordering and condensing’ 
effects.  This leads to a reduced permeability of membranes to solutes, water, small 
Liposome mass (µg) 
    (A)                (B)                 
   0       0      27    28     29     17     18     19 
    (C)                (D)                 
   0       0        7      8       9       5       6      7 
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molecules and ions (Róg et al., 2009; Caracciolo et al., 2010; Magarkar et al., 2014; Briuglia 
et al., 2015).  Due to these properties, cholesterol or cholesterol-derived lipids are often 
incorporated into liposomal preparations.  It has also been reported that the preservation of 
liposomal stability in the presence of serum could also be attributed to the increased packing 
of phospholipids by cholesterol which inhibits their removal by high-density lipoproteins 
(Caracciolo et al., 2010).  Furthermore, cholesterol-based liposomal preparations have been 
shown to resist serum-induced aggregation and dissociation possibly through the rigidity 
imparted by containing cholesterol in their structures; and additionally, cholesterol is 
effective in decreasing the quantity of serum proteins that adsorb to lipoplexes (Betker et al., 
2013a; Betker et al., 2013b; Kim et al., 2014; Briuglia et al., 2015).  Thus, cholesterol 
derivatives used in the formulation of mitochondriotropic liposomes in this study contributed 
to the conservation of liposomal integrity and stability in the presence of serum.  As indicated 
by the gel patterns, it can be assumed that all cationic mitochondriotropic liposomes at the 
sub-optimal, optimal and supra-optimal ratios tested, were able to offer considerable 
protection of their pDNA cargo by forming stable liposome-DNA complexes.   
 
SP-CHOL-MTS and GM-CHOL-MTS seemed to have afforded the best protection of pDNA 
across all ratios tested as the recovered DNA from these lipoplexes seemed to be almost 
completely intact when compared to banding patterns of the control marker DNA.  SP-
CHOL-MTS-R8 and GM-CHOL-MTS-R8 lipoplexes, however, seem to have undergone 
very minor partial DNA conformational change as there appeared to a slight increase in the 
relative amount of linear and decrease in amount of supercoiled helical DNA detected 
compared to the undigested control.  Overall, these findings indicate that the cationic 
mitochondriotropic liposomes prepared in this study are suitable gene transfer vehicles as 
serum treatment of liposome-DNA complexes did not enhance nuclease accessibility, and 
liposomes afforded complete protection to their pDNA cargo from the nucleases.  
 





















Figure 4.8: Schematic representation of DNA supercoiling followed by formation of anticlockwise  
                    (–) -coiling and clockwise (+) -coiling of circular DNA needed for condensation and   





4.2.1.3.  Ethidium Bromide Intercalation Assay 
 
The quantitative binding efficiency of cationic mitochondriotropic liposomes to pDNA as 
well as the corroboration of optimal ratios attained from retardation studies was investigated 
utilising a fluorescence quenching method based on ethidium bromide (EtBr), a monovalent 
cationic  double-stranded DNA-intercalating dye (Geall and Blagbrough, 2000; Tros de 
Ilarduya et al., 2002).  Ethidium bromide interacts with double-stranded DNA by occupying 
an effective binding site between two base pairs.  An enhanced fluorescence is detected when 
EtBr binds to DNA due to the phenanthridium moiety of this agent intercalating DNA, an 
observation first reported by LePecq and Paoletti in 1967 (Geall and Blagbrough, 2000; 
Duarte et al., 2011).  EtBr intercalation into DNA molecular modelling studies have shown 
that this binding results in a helical screw axis displacement of approximately +1 Å in the 
DNA structure which causes base pairs in the immediate vicinity to twist by 10°.  This 
twisting consequently results in an angular unwinding of -26° and an 8° tilt in intercalated 
base pairs relative to each other (Figure 4.9) (Sobell et al., 1977; Geall and Blagbrough, 
2000).   Free EtBr in solution exhibits very low fluorescence in aqueous solvents owing to the 
excited-state proton transfer to water however when EtBr intercalates DNA, it enters the 
hydrophobic environment surrounding the DNA molecule which consequently drastically 
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slows down the rate of proton transfer to water molecules thus causing a resultant significant 

















Figure 4.9: Diagram showing (A) Ethidium bromide and (B) the process of intercalation, illustrating  
                    the lengthening and untwisting of the DNA helix.  




As mentioned above, displacement of EtBr from DNA was employed in this study as 
confirmatory evidence of the binding ability of the cationic liposomes to pDNA.  In 
accordance with the principle of the assay, EtBr fluorescence is intensely enhanced upon 
intercalating base pairs of DNA and is quenched when displaced by higher affinity 
compounds or by compaction and condensation of the DNA structure.  The experimental 
parameter examined is the progressive decrease in fluorescence consequent to the increase in 
the concentration of cationic mitochondriotropic liposomes added i.e. as more liposome is 
added, resulting in DNA condensation; more EtBr molecules are displaced and replaced by 
the liposome resulting in a gradual decrease in fluorescence recorded (Xu et al., 1999; Duarte 
et al., 2011; Banerjee et al., 2013).  In agreement with this, all cationic mitochondriotropic 
liposome preparations were able to successfully displace intercalated ethidium bromide from 
pCMV-luc DNA.  This was demonstrated by the continual decrease in fluorescence upon the 
Ethidium bromide stacked  
between base pairs  
(A) 
(B) 
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stepwise addition of cationic liposomes to the reaction mixture as illustrated in Figure 4.10 
where percentage relative fluorescence was plotted as a function of micrograms of cationic 
mitochondriotropic liposomes.  Varying amounts of cationic liposomes were added to the 
reaction mixture, forming a liposome-DNA complex, until the fluorescence values reached a 
plateau, commonly referred to as the point of inflection.  This point represents the liposome-
DNA ratio at which the liposome maximally displaced the ethidium bromide and completely 
bound as well as condensed the pDNA.  The liposome-DNA mass (
w
/w) and N/P ratios 
representing these points are indicated in Table 4.1.  Ethidium bromide fluorescence 
decreased with an increase in the amount of cationic liposomes added, indicating that this 
increase led to a greater degree of DNA condensation and protection.  This action 
substantiates that DNA was compacted and condensed by the cationic liposomes to form 
lipoplexes, and this interaction is significantly stronger than that present between EtBr and 
DNA.  As can be seen from the graphs, GM-CHOL containing liposomes produced a greater 
level of fluorescence decline compared to their SP-CHOL containing counterparts.  This 
could possibly be because the shorter length of SP-CHOL which might produce a shielding 
effect, preventing interaction with DNA.   Furthermore, R8 containing liposomal preparations 
[Figure 4.10 (B)] needed far less liposome to completely condense and displace EtBr until 
fluorescence decay plateaued, than the MTS only liposomes [Figure 4.10 (A)].  This is in 
keeping with the results obtained from the gel retardation assays conducted which showed 
that SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 required considerably lower amounts of 
liposome to bind 0.5 µg of pDNA.  It could therefore be suggested, as mentioned in section 
4.2.1.1, that the presence of R8 increases the overall theoretical cationic charge of these 
liposomes and probably enhanced their pDNA binding and compaction efficiencies.   
 
Approximated percentage fluorescence decline for each mitochondriotropic liposome was: 
37% (SP-CHOL-MTS), 39% (GM-CHOL-MTS), 33% (SP-CHOL-MTS-R8) and 42% (GM-
CHOL-MTS-R8).  GM-CHOL-MTS-R8 displaced the most amount of EtBr while SP-
CHOL-MTS-R8 displaced the least demonstrating the weakest compaction of pDNA.  High 
degrees of EtBr displacement and the inferred high compaction denote that DNA is tightly 
bound to the liposome which can be seen as either favourable or unfavourable for transfection 
or, in this study, mitochondrial localisation.  Strong DNA-liposome binding and compaction 
would provide adequate protection and enable the liposome-DNA complex to securely 
transport its bound cargo to the target site but could prove detrimental if the bound  
 
































Figure 4.10:  EtBr intercalation displacement assay where percentage relative fluorescence was  
                       plotted as a function of µgrams of liposome (A) MTS only liposomes and (B) MTS and  
                       R8 liposomes.  Cationic mitochondriotropic liposome was systematically added to an  



























































Results and Discussion 
83 
 
DNA could not be timeously released to transfect the cell and subsequently be expressed.  
Conversely, weak DNA-liposome binding and compaction efficiency could result in 
disassociation of the lipoplex and likely degradation of the DNA cargo before it reaches its 
target cell.   Thus, it seems that an intermediary degree of DNA-lipid compaction and binding 
strength, such as demonstrated by all the cationic mitochondriotropic liposomes tested, would 
be most beneficial to efficient transfection or mitochondrial localisation.  A comparison of 
the liposome-DNA mass (
w
/w) and N/P ratios obtained here to that demonstrated by gel 
retardation assays (Table 4.1) display some minor discrepancies.  A potential reason for these 
differences is that retardation studies are based exclusively on charge neutralisation i.e. the 
point at which the negative charges of the DNA are completely titrated by the positive 
charges of the cationic liposome whereas this assay is based on DNA condensation and 
compaction by the cationic liposome as well as charge neutralisation.   
 
 
4.2.2.  Imaging and Sizing 
 
4.2.2.1.  Characterisation of Particles by Transmission Electron Microscopy (TEM) 
 
The nanostructure of cationic mitochondriotropic liposomes and lipoplexes were directly 
visualised by cryo-TEM which allows for the analysis of morphology and structure at the 
nanometer level.  Additionally, cryo-TEM permits the examination of a sample in a frozen-
hydrated state, i.e. very near its native state and with avoidance of fixation (Kuntsche et al., 
2011; Helvig et al., 2015).  As organic materials are known to give poor contrast in cryo-
TEM, combining negative staining with cryo-TEM allows for an improvement in contrast 
(Kuntsche et al., 2011).  In the most basic terms, TEM can be envisaged as an inverted light 
microscope where the ‘light source’ is an electron beam.  This beam is concentrated by a 
system of electromagnetic lenses onto the sample surface after which the transmitted 
electrons are further magnified and focused by magnetic lenses to generate a projected image 
on a viewing screen (Bibi et al., 2011; Kuntsche et al., 2011).  Sample preparation for cryo-
TEM involves application of a droplet of diluted sample onto the grid, followed by use of a 
negative stain and finally the sample is plunge-frozen in a coolant resulting in the sample 
preparation being embedded in a layer of electron-transparent vitrified amorphous ice which 
is maintained in liquid nitrogen (Alfredsson, 2005; Friedrich et al., 2010).  The negative stain 
attaches to the phosphate portion of phospholipids, poorly accessing the liposomal bilayer 
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which results in a darkly coloured outline of the liposome or lipoplex whilst the inner 
compartment is comparatively white (Bibi et al., 2011; Ruozi et al., 2011).  
 
Figures 4.11 and 4.12 illustrate the cryo-TEM micrographs of cationic mitochondriotropic 
liposomes and lipoplexes, respectively.  Overall, the morphologies observed for all liposome 
preparations were generally spherical; however some revealed a deformable nature with the 
presence of twisted and invaginated structures detected.  This could be possibly attributed to 

























Figure 4.11: Transmission electron micrographs of cationic mitochondriotropic liposomes as follows:   
                      (A) SP-CHOL-MTS, (B) GM-CHOL-MTS, (C) SP-CHOL-MTS-R8 and (D) GM- 
                      CHOL-MTS-R8. Bar = 100 or 200 nm. 
 100 nm   200 nm 
 200 nm  100 nm 
(A) (B) 
(C) (D) 

























Figure 4.12: Transmission electron micrographs of cationic mitochondriotropic lipoplexes [prepared  
                      at optimal binding liposome-DNA or N/P ratios as determined by electrophoretic  
                      mobility shift assays]. (A) SP-CHOL-MTS 7.5:1, (B) GM-CHOL-MTS 4.8:1, (C) SP-   




The micrographs describe heterogeneous vesicles in which the negative stain makes it 
possible to highlight the existence of closed bilayer structures with free internal space.  Some 
degree of vesicular structure distortion was identified; which could perhaps be artefacts due 
the interaction between the sample and the negative stain or dehydration as a result of 
exposure of samples to a vacuum in the viewing procedure.  Additionally, processes like slow 
freezing and possible thawing may result in morphological changes accompanied by a 
reorganisation of the vesicle structure and thus inaccurately represented images (Kuntsche et 
 200 nm  100 nm 
   200 nm  100 nm 
(A) (B) 
(C) (D) 
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al., 2011; Ruozi et al., 2011).  In general, all liposomes appear to be unilamellar in nature 
with the exception of SP-CHOL-MTS [Figure 4.11 (A)] which seems to show a multi-
lamellar structure however, this could be either single-walled or unilamellar vesicles that 
layered atop one another or invaginated/folded unilamellar structures giving the illusion of 
multi-lamellarity (Almgren et al., 2000).  Moreover, all cationic mitochondriotropic liposome 
preparations display a certain degree of clustering with some singular liposomes on the 
periphery of images.  The images of the corresponding lipoplexes (Figure 4.12) revealed 
numerous largely unclear ill-defined multi-lamellar aggregates which appear to be intact and 
layered over each other.  These aggregates are characteristic of lipoplexes and it has been 
suggested that oligonucleotides used in the formation of lipoplexes act as intermembrane 
bridges preventing the electrostatic repulsion of liposomal membranes hence forming 
aggregated lipoplexes (Alfredsson, 2005).  The formation of lipoplexes was corroborated by 
the existence of large, intact aggregate assemblies.  The presence of R8 did not seem to have 
any obvious morphological effects on either liposomes or lipoplexes.  Although TEM does 
provide some information on the sizes of the liposomes and their complexes, we resorted to 
Nanoparticle Tracking Analysis (NTA) (4.2.2.2), which provides a more accurate picture on 
size distribution.  
 
4.2.2.2.  Particle Size and Zeta Potential Analysis 
 
Particle size is a morphological parameter in nanoparticle development that is of great 
importance not only in its role in determining transfection efficiency but also in influencing 
circulatory half-lives and evasion of the reticuloendothelial system (RES) during in vivo 
applications.  Lipoplex or nanoparticle size is thought to impact transfection effectiveness or, 
in this study,  mitochondrial localisation by influencing the nature of the entry pathway of 
complexes into the cell by endocytosis i.e. either clathrin- or caveolin-mediated endocytosis 
or macropinocytosis (Ross and Hui, 1999; Ma et al., 2007; Marchini et al., 2009; Akbarzadeh 
et al., 2013).  Another feature of liposome-DNA complexes that is of significance is the zeta 
potential of the particle which is defined as a measure of the surface charge of given particles 
in a medium or suspension and which is further related to their stability by electrostatic forces 
(Figure 4.13).  Zeta potential therefore acts as an indicator of the colloidal stability of the 
lipoplexes in suspension and can potentially affect the pharmacokinetic properties of the 
nanocomplexes during their interaction with cells (Xu, 2008; Griffiths et al., 2011; Honary 
and Zahir, 2013a).  
















Figure 4.13: Schematic diagram of zeta potential for nanoparticles depicting the potential difference  
                      as a function of distance from the charged surface of a particle suspended in a  
                      dispersion medium. 
                      http://www.pharmainfo.net/characterization-nanoparticles/zeta (accessed 08/04/2015) 
 
 
The cationic mitochondriotropic liposomes and their corresponding optimal liposome-DNA 
complexes were evaluated for size and zeta potential by Nanoparticle Tracking Analysis 
(NTA).  NTA is a relatively new technique that allows for the simultaneous multi-parameter 
analysis of nanoparticles in liquid suspensions for direct, real-time visualisation and 
examination of concentration, size and zeta potential.  NTA utilises the well-understood 
principles of sizing by measuring both light scattering and Brownian motion of samples in 
liquid suspension to calculate the nanoparticle diffusion constant which is applied to estimate 
a spherical hydrodynamic diameter of the particle (Gross et al., 2016; NanoSight, 2015a).  
The measurement principles and methodology of NTA is extensive (Figure 4.14), but in 
short, the sample in suspension is pumped into a sample chamber where a laser beam 
(wavelength 430 nm) is passed through a prism edged glass flat within the sample chamber 
where the particles under investigation in the path of this beam scatter light in such a manner 
that they can easily be visualised and recorded at 90° via a 20x magnification microscope 
objective onto which is mounted a sCMOS camera.  The camera then captures a video of the 
particles (Figure 4.15) moving under Brownian motion within the field of view of 
approximately 100 µm x 80 µm x 10 µm.  This real-time video is then analysed on a frame-
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by-frame basis and each particle centre is individually and simultaneously visualised and 
tracked by specific image tracking, evaluation and processing software (NTA 3.2 analytical 
software).  The software tracks many particles individually and using the Stokes-Einstein 
equation (Figure 4.14) calculates their sphere equivalent hydrodynamic diameters.  NTA 
tracks nanoparticles within a range of 10 – 1000 µm.  As NTA permits each particle to be 
sized individually, irrespective of the others, the resulting data is not an intensity weighted 
mean but an absolute high resolution particle size analysis (NanoSight, 2015a, 2015b).  The 
NTA instrument measures zeta potential in a way similar to sizing with certain additions.   
An electrophoresis system, facilitated by two platinum electrodes in the sample chamber, 
allows a variable electric current to be applied to the nanoparticle sample suspension causing 
motion of the particles under the influence of the electric field.  The electrophoretic velocity 
of the particle movement is recorded, tracked and quantified in the same way as Brownian 
motion allowing for the resultant zeta potential to be calculated on a particle by particle basis 
(Griffiths et al., 2011; NanoSight).  A representative NTA report is found in Appendix A.   
 
Mean particle size distribution and zeta potential of the cationic mitochondriotropic 
liposomes and corresponding optimal liposome-DNA complexes are summarized in Table 
4.2.  As can be seen in these results, the hydrodynamic diameters calculated by NTA revealed 
nano-sized liposomes in the range of 121.0 – 246.55 nm.  Their corresponding lipoplex sizes 
were in the 129.7 – 200.35 nm range while in the presence of 5% FBS, these same lipoplexes 
displayed a diminished size range of 55.35 – 132.75 nm.   
 
TABLE 4.2: Mean particle size and zeta potential for liposomes and optimal liposome-DNA ratios. 
 
 
Abbreviations: SE; standard error 
a 
Lipoplexes were diluted 1:100 with 3% filter-sterilised HBS.  
b 





Mean Particle Size and Zeta Potentials  (n=2) 
Liposome Lipoplex (3% HBS)
a














(mV)  ± SE 
SP-CHOL-MTS  142.6  ±13.55 -29.05  ±2.05 175.8  ±15.02 -16.50  ±0.54 129.35  ±14.9 -18.70  ±1.0 
GM-CHOL-MTS 121.0  ±11.6 -38.95  ±1.1 200.35  ±26.8 -17.90  ±0.85 132.75  ±33.5 -13.25  ±0.25 
SP-CHOL-MTS-R8  246.55  ±11.3 -25.30  ±0.1 150.25  ±12.4 -17.35  ±0.55 55.35    ±2.80 -20.85  ±0.75 
GM-CHOL-MTS-R8 226.05  ±67.2 -28.70  ±1.9 129.7  ±10.26 -19.05  ±0.65 55.50    ±2.25 -14.50  ±0.8 




Scattered laser beam 
from particles 
Laser beam  
(Approx. 50 µm wide) 
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Metalised surface 
Sample chamber containing 
particles in liquid suspension  
 
Figure 4.14: Schematic of the optical configuration used in NTA and two-dimensional Stokes- 
                      Einstein equation. The sample in the chamber is illuminated by a laser beam. The   
                      particle movement is recorded via light scattering by a sCMOS camera and the software    
                      tracks each particle and determines the diffusion coefficient of the Brownian motion.  
                      Combining Stokes–Einstein equation and two dimensional mean square displacement,   
                      the particle size is then calculated as the mean-squared displacement (x, y)
2
, KB as the   
                      Boltzmann’s constant, T as the absolute temperature, t as the measurement time, η as  
                      the viscosity and d as the hydrodynamic diameter.  















Figure 4.15: Screen shot from video showing light scatter from liposomal particles moving under  
                      Brownian motion. 
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The different diluents used also showed an impact on the sizes and zeta potential of the 
formulations (Table 4.2). The presence of 5% FBS in the diluent medium clearly had an 
effect on the liposome-DNA complex size resulting in more diminutive lipoplexes with only 
SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 liposome-DNA complexes displaying a 
significant (P<0.05) decrease in size.  These two R8 containing liposomal suspensions also 
showed larger sizes for the free liposomes, in contrast to their MTS only containing 
counterparts.  Furthermore, the lipoplexes in 3% HBS that they generated were comparatively 
smaller in size than their liposomes, whereas the MTS only liposomal suspensions, SP-
CHOL-MTS and GM-CHOL-MTS, produced relatively larger lipoplexes in 3% HBS 
compared to their respective free liposome sizes.  This could be attributed to the presence of 
R8 which could have made the liposomes bulkier but when combined with DNA to form 
lipoplexes, the compaction and condensation that would have occurred, in part because of the 
cationic charge of R8, caused a shift to smaller nanoparticle sizes.  This was reinforced by the 
results of the gel retardation assays (Table 4.1) where lower amounts of these liposomes were 
needed to completely bind a constant amount of DNA.  These gel retardation assays also 
indicated that far greater amounts of MTS only containing liposomal suspensions were 
required to bind the same amount of DNA and this probably contributed to the larger sized 
lipoplexes observed for these liposomes. 
 
Previous studies have inferred a direct correlation between lipoplex size and their 
effectiveness in transfection (Zuhorn et al., 2002; Ross and Hui, 1999).  Although, some 
authors believe that there to be little or no association with the size of lipoplexes and 
transfection efficiency, there is general consensus that lipoplex size definitely plays a role in 
determining the entry pathway into cells, the so-called size-dependent entry mechanism of 
lipoplexes (Zuhorn et al., 2002; Ma et al., 2007; Marchini et al., 2009).  Studies have 
revealed that lipoplexes larger than 300 nm were preferentially internalised by caveolae-
mediated pathways while smaller ones mainly entered cells via clathrin-mediated endocytosis 
(Marchini et al., 2009; Ramezani et al., 2009).  Furthermore, there also seems to be little 
consensus on which size array is optimal to garner effective entry into the cells or produce 
efficient transfection or a combination of both.  Conflicting reports have been published 
claiming larger complexes are better for improved transfection while others suggest that 
smaller lipoplexes are superior (Ma et al., 2007; Marchini et al., 2009; Masotti et al., 2009; 
Wang et al., 2012).  For mitochondrial localisation/delivery, studies have shown that 
liposomes and liposome-DNA complexes are relatively successful at a variable size range of 
Results and Discussion 
91 
 
below 100 µm to about 300 µm (Khalil et al., 2006a; Yamada and Harashima, 2013; 
Kawamura et al., 2013a).  The cationic mitochondriotropic lipoplexes used in this study are 
proposed to enter cells via a combination of clathrin-mediated endocytosis and 
macropinocytosis, a non-specific form of endocytosis that allows for a broad range of 
particles sizes, up to 5 µm, to be internalised (Hirota and Terada, 2012).  Therefore, the 
concept of size of the liposome-DNA complex might not be most vital or limiting parameter 
in determining efficient mitochondrial localisation in vitro but could have significant 
importance in vivo by affecting circulation times of the nanocomplexes.  
 
The zeta potential is the overall charge that a nanoparticle acquires in a particular medium.  It 
is a measure of the electric potential at the slipping/shear plane between the attached layer of 
diluent molecules surrounding the nanoparticle and the bulk solution (Figure 4.13).  It states 
the potential difference between the bound layer of fluid attached to the dispersed particle and 
the dispersion medium.  Thus, zeta potential can be defined as the electrokinetic value 
correlating a realistic level of surface charge (Honary and Zahir, 2013a).  A higher level of 
zeta potential is desired as nanoparticles with zeta potential values greater than +25 – 30 mV 
or less than -25 – -30 mV typically have superior degrees of stability owing to their high 
mobility in solution and greater electrostatic repulsion between nanoparticles thus minimising 
aggregation effects (Griffiths et al., 2011).  From the results obtained (Table 4.2), it was 
firstly observed that all samples had zeta potentials that were negative and secondly, that free 
liposomes had higher zeta potential values than their corresponding lipoplex formulations in 
both 3% HBS and 5% FBS implying that the liposomes had greater colloidal stability than 
the lipoplexes.  There is also a change in zeta potential detected in lipoplexes sampled in 
HBS only compared to those in 5% FBS and HBS.  This change is significant (P<0.05) for 
GM-CHOL-MTS, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 liposome-DNA complexes 
but not SP-CHOL-MTS lipoplexes.  These changes in zeta potential could likely be attributed 
to effects of serum on the nanocomplexes with the possible binding of serum proteins to the 
complexes, forming a protein corona around the formulations.  The ionic strength of the 
diluent is one of the important factors affecting the zeta potential, with increasing ionic 
strength resulting in increased zeta potential.  As to the negative charge observed by the 
lipoplexes, previous literature has suggested that this might not be a huge deterrent to cellular 
binding and subsequent internalisation of the liposome-DNA complexes as studies have 
shown that nanoparticles with negative zeta potential have been successful in cellular uptake 
through the formation of nanoparticle clusters and the process of non-specific nanoparticle 
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adsorption on the cell membrane (Honary and Zahir, 2013a).  Additionally, Honary and Zahir 
(2013b) indicated that both cationic and anionic charges are known to enhance the delivery of 
liposomes to cells and that negatively charged particles showed lower cytotoxicity and longer 
circulation half-times in rats than positively charged ones.  Furthermore, nanoparticles with a 
high positive charge can combine with plasma proteins in the blood system in vivo and hence 
increase cellular toxicity.  Thus, these liposomes and lipoplexes with negative zeta potentials 
were low in cytotoxicity as evidenced from the MTT and AlamarBlue
®
 assays (4.3.2.1-
4.3.2.2).  Lastly, Xu (2008) stated that as zeta potential is a parameter that involves not only 
nanoparticle but also their environment, the zeta potential values measured may differ greatly 
from their true values in the experimental or test environment and therefore may be trivial to 
practical usefulness.   
 
 
4.3.  IN VITRO CELL CULTURE STUDIES  
 
4.3.1.  Cell Lines  
 
Human embryonic kidney cells (HEK293), human hepatocellular carcinoma cells (HepG2), 
human epithelial colorectal adenocarcinoma (Caco-2) and human cervical adenocarcinoma 
cells that stably express the firefly luciferase gene (HeLa-Tat luc) were used in this study 
(Figure 4.16).  HEK293 cell are semi-adherent cells that grow as a monolayer in culture.  
These cells were derived by the exposure of mechanically sheared fragments of DNA of 
adenovirus type 5 (AD5) to the human primary embryonic kidney cell culture of an aborted 
embryo (Thomas and Smart, 2005; Stepanenko and Dmitrenko, 2015).  The HepG2 cell line 
is one of several cell lines isolated from the liver biopsies of hepatoblastoma and 
hepatocellular carcinomas (Aden et al., 1979).  They are epithelial in morphology and are 
known to exhibit the same biosynthetic capabilities as well as several genotypic and 
phenotypic characteristics of normal liver parenchymal cells and thus produce a large number 
of serum proteins such as albumin, transferrin, α-fetoprotein, fibrinogen and β-lipoprotein to 
name but a few (Knowles et al., 1980; Santos et al., 2016).  The Caco-2 cell line is a 
continuous line of heterogeneous epithelial cells cultivated through research conducted by Dr. 
Jorgen Fogh (Fogh and Trempe, 1977).  It is a well-known and widely accepted in vitro 
model of the human intestinal epithelium that in culture, spontaneously differentiate resulting 
in a monolayer of cells that display numerous morphological and functional characteristics of 
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mature enterocytes (Liu and Chen, 2004; Sambuy et al., 2005).  HeLa cells were the first 
immortal cell line to be cultured.  They were discovered by Dr George Gey in 1951 and were 
taken from a biopsy sample of cervical carcinoma from a patient named Henrietta Lacks 
(Lucey et al., 2009).  HeLa cells are adherent, large and triangular in shape and they tend to 
proliferate unusually rapidly in a single layer.  The HeLa-Tat luc cells used in this study were 
stably transfected with the TAT protein together with reporter plasmid LTR-luc under the 
control of HIV-1 LTR promoter.  It therefore stably expresses the firefly luciferase gene but 






















Figure 4.16: Cell lines used in this study: (A) HEK293, (B) HepG2, (C) Caco-2 and (D) HeLa-Tat  
                      luc.  Here cells were viewed as a monolayer at semi-confluence under 100 x       
                      magnification with an inverted microscope (Olympus CKX41, Tokyo, Japan).   
 
 
When mammalian cells are cultured in vitro, the aim is to reproduce the cells’ original 
physiological environment as closely as possible.  In order to accomplish this, the appropriate 
(A) (B) 
(C) (D) 
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nutrient environment, temperature, gas and humidity levels need to be maintained.  To this 
end, the cell culture medium provides the nutrients needed such as vitamins, glucose, amino 
acids and salts as well as supplemented growth factors from FBS and it also helps in the 
regulation of the pH of the culture.  Most adherent cell lines grow as a single layer 
(monolayer) attached to the culture vessel and once the accessible surface is covered by cells, 
cell growth is reduced which leads to growth suppression and possible cell death.  To avoid 
this and keep cells healthy and optimally growing, it is necessary to passage or subdivide 
them regularly as well as replenish with fresh cell medium when required.   
 
All four cell lines were successfully reconstituted and cultured in complete medium (EMEM 
+ 10% FBS + antibiotics) over the period of study.  Initial cell growth was slow with cells 
only reaching confluence after 4 to 5 days.  This was expected as reconstituted cells have an 
initial growth rate that is slower than normal.  Eventually cell numbers increased probably 
due to the amplified levels of growth factors secreted by the propagating cells.  The cell lines 
were trypsinised and subdivided 1:3 or 1:2 splits every 3 to 4 days. 
 
 
4.3.2.  Cytotoxicity Studies  
 
Cell lines are well established as valuable alternative assay systems for toxicological analyses 
(Santos et al., 2016).  In this investigation, two cell viability assays viz. the MTT reduction 
and AlamarBlue
®
 assays were utilised to determine the levels of in vitro cytotoxicity that the 
cationic mitochondriotropic liposomal delivery systems had induced in the HEK293, HepG2, 
Caco-2 and HeLa-Tat luc cell lines.  Cells were exposed to the liposome-DNA complexes 
correlating to the sub-optimal, optimal and supra-optimal DNA binding ratios and allowed to 
incubate for 48 hours.   
 
4.3.2.1.  MTT Growth Inhibition Assay 
 
This is a colorimetric assay that measures the reduction of yellow MTT in aqueous solution 
by reducing agents and dehydrogenases in viable metabolically active cells to yield purple 
formazan crystals that are water insoluble (Figure 4.17) (Stockert et al., 2012).  When cells 
are no longer viable, they lose their ability to reduce MTT into formazan and thus the colour 
detection gives an indication of the number of viable cells (Riss et al., 2013).  The formazan 
























Liposome Concentration (µg/10µl) 
HepG2 HEK293 Caco-2 HeLa-Tat luc(A) 
  ** 
**  ** 
is solubilised and its concentration as reflected by optical density values serves as indicator of 
viable cells.  Early literature speculated that MTT is reduced in the mitochondria of cells by 
mitochondrial succinic dehydrogenases and that this assay is a fitting indicator of 
mitochondrial function and activity however, recent evidence reveals that MTT is mainly 
metabolised in the cytoplasm by NADH, nicotinamide co-enzymes and other dehydrogenases 
associated with the plasma membrane, the endoplasmic reticulum and lysosome vesicles 
(Stockert et al., 2012; Angius and Floris, 2015).  Taking this into consideration, the MTT 
assay was only used to assess cell viability and not as an inference to mitochondrial activity 











Figure 4.17: Chemical structure of MTT and its reduced coloured insoluble formazan product.   
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Figure 4.18: In vitro MTT cytotoxicity analysis of cationic mitochondriotropic liposome-pCMV-luc  
                      DNA complexes toward HepG2, HEK293, Caco-2 and HeLa-Tat luc cell lines.  
                      Lipoplexes (containing 1 µg of pCMV-luc DNA) were prepared at various liposome- 
                      DNA ratios (
w
/w) as indicated above. (A) SP-CHOL-MTS, (B) GM-CHOL-MTS, (C)  
                      SP-CHOL-MTS-R8 and (D) GM-CHOL-MTS-R8. A control sample containing only  
                      cells was assumed to have 100% survival. Results are presented as a percentage of the  
                      control sample and represent the mean ± SD, n = 3. Statistical analysis was performed   
                      using one-way ANOVA followed by Dunnett multiple comparison post hoc test.   
                      *P<0.05  and **P<0.01 as compared to the control. 
 
 
Figure 4.18 (A-D) shows the plot of percentage cell viability as a function of liposome-DNA 
ratios (
w
/w).  As shown from the results obtained all cationic mitochondriotropic lipoplexes 
were relatively well tolerated, some more than others, over the lipid concentration range 
tested.  The general trend observed for most of the cell lines tested seems to reveal a decrease 
in cell viability with an increase in liposome-DNA ratios with the maximum reduction in 
viability observed at the highest (supra-optimal) lipoplex ratio for most of the liposome 
formulations in all four cell lines.  At higher liposome-DNA ratios and therefore higher N/P 
ratios, there is a slight decrease in viability observed.  A similar trend was observed by 
Masotti et al. (2009) in a study that investigated different cationic liposomes and 
commercially available liposomes.  This is expected as greater charge ratios are expected to 
be more harmful to cells with the excess free liposomes competing with the nanocomplexes 
for binding and subsequent uptake by target cells (Xu et al., 1999).  Of the four cell lines 
evaluated, HEK293 cells seem to be most susceptible to toxic effects (P<0.01) of all cationic 
mitochondriotropic lipoplexes, with significant decreases in viability exhibited.  The HeLa-
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Tat luc cell line was the most resilient demonstrating very little cytotoxicity for the different 
mitochondriotropic lipoplexes as well as across all the complex ratios.  The HepG2 and 
Caco-2 cell lines were intermediate in their response to the lipoplexes.  Overall, the results 
show that the cationic mitochondriotropic lipoplexes were well tolerated by all the cell lines 
over a range of liposome-DNA ratios (
w
/w) with cell survival staying over 60% across the 
board.  Cell viabilities of the cell line, HepG2, HEK293, Caco-2 and HeLa-Tat luc, 
respectively were as follows: SP-CHOL-MTS (90-85; 72-62; 110-88 and 103-96) %, GM-
CHOL-MTS (87-77; 83-64; 101-63 and 110-74) %, SP-CHOL-MTS-R8 (82-69; 93-80; 100-
61 and 114-73) % and GM-CHOL-MTS-R8 (74-60; 93-77; 83-75 and 104-91) %.  Of the 
lipoplex preparations, GM-CHOL-MTS-R8 prompted the greatest level of toxicity observed, 
in HepG2 cells, with 40% reduction in cell viability however it was very well tolerated in the 
other cell lines.  Therefore, from the results, there seems to be no clear indication of which 
liposome preparation caused the most cytotoxicity as they all affected the different cell lines 
dissimilarly with a liposomal formulation having a pronounced cytotoxic effect on one cell 
line but also causing an increase in cell numbers in another cell line.  Cationic lipids are 
known to be cytotoxic and level of toxicity is dependent on the structure of the cationic lipid.  
Cholesterol-based cationic lipids are known to exhibit lower toxicities compared to the lipids 
with aliphatic chains and additionally cationic lipids with a quaternary amine headgroup is 
more toxic compared to a tertiary one (Lv et al., 2006; Yang et al., 2013; Kim et al., 2014). 
DOPE-containing liposomes were also shown to display low toxicity in HepG2 cells (Lv et 
al., 2006).  It can therefore be suggested that the presence of the cationic cholesterol-derived 
cytofectin, CHOL-T and DOPE in the mitochondriotropic liposomal formulations tested 
probably influenced their biocompatibility and stability and led to the relatively low toxicities 







The perfect test for in vitro cytotoxicity should be one that is a rapid, simple, sensitive, 
efficient, consistent, cost effective and safe measurement of cell viability (O'Brien et al., 
2000).  Hence, the MTT assay falls short of some the above mentioned characteristics, 
prompting the additional use of the AlamarBlue
® 
assay to test the cationic mitochondriotropic 
lipoplexes for any harmful effects toward the cell lines utilised.  The MTT assay is a 
technique that is an indirect indicator of cell viability that monitors cell membrane integrity 
Results and Discussion 
99 
 
following drug or test compound exposure which can impede or damage the cell’s 
functioning and is thus considered a terminal assay which does not allow for the further 
investigations or follow-up using the same cell cultures (Al-Nasiry et al., 2007; Rampersad, 
2012).  The AlamarBlue
® 
assay, on the other hand, seems to fit all the requirements of the 
ideal in vitro cytotoxicity test; it is safe, sensitive, non-toxic for cells, one-step and cost-
effective.  AlamarBlue
®
 circumvents many of the issues that the MTT assay has and offers 
advantages over it as well, that include higher sensitivity, better stability and a non-toxic 
nature, solubility in medium and also allows for continuous monitoring of cultures (Al-Nasiry 
et al., 2007).  The active ingredient in AlamarBlue
®
 is resazurin, a water soluble, cell 
permeable redox indicator that is used to monitor the reducing environment of living cells 
and hence measure the proliferation of viable cells (Rampersad, 2012; Bonnier et al., 2015).  
Resazurin (oxidised form) is a blue, non-fluorescent dye that is reduced to the highly 
fluorescent, pink resorufin (Figure 4.19) which can be quantitatively measured either as 
colorimetric or fluorometrically, with the latter being the more sensitive.  Thus, similar to the 
MTT assay principal, by assessing the changes in the fluorescence of the dye, the number of 
metabolically active cells can be identified and measured with the quantity of resorufin 
product being proportional to the number of viable cells (Riss et al., 2013; Bonnier et al., 
2015).  AlamarBlue
®
 is reduced by mitochondrial reductases and cytochromes as well as 
other enzymes located in the cytosol and mitochondria such as diaphorases, 
NAD(P)H:quinone oxidoreductases and flavin reductase, to name a few.  Therefore 
AlamarBlue
®
 reduction may indicate damage of cellular metabolism and is not necessarily 
indicative of a break of the electron transport chain and mitochondrial dysfunction 










Figure 4.19: Chemical structure of non-fluorescent blue dye, resazurin and its reduction to strongly  
                      fluorescent pink resorufin by viable cells. Adapted from Stoddart (2011). 
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 cytotoxicity assay showing percentage (%) reduction of resazurin as cell  
                      viability in HepG2 (♦), HEK293 (■), Caco-2 (●) and HeLa-Tat luc (▲) cell lines as   
                      function liposome-pCMV-luc DNA ratios. Lipoplexes (containing 1 µg of pCMV-luc   
                      DNA) were prepared at various liposome-DNA ratios (
w
/w) as indicated above. (A) SP- 
                      CHOL-MTS, (B) GM-CHOL-MTS, (C) SP-CHOL-MTS-R8 and (D) GM-CHOL-MTS- 
                      R8. A control sample (       ) containing only cells were assumed to have 100% survival.  
                      Results represent the mean ± SD, n = 3. 
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Figure 4.20 displays the percentage reduction of AlamarBlue
®
 as a function of liposome-
DNA ratios (
w
/w), in HepG2, HEK293, Caco-2 and HeLa-Tat luc cell lines.  As can be seen 
by the results, all the mitochondriotropic lipoplexes across all liposome-DNA ratios were 
fairly well tolerated.  As with the MTT assay, there seems to be a decrease in cell viability 
with a corresponding increase in liposome-DNA ratios, with the maximum decline in 
viability observed at the highest (supra-optimal) lipoplex ratio for most (75%) of the 
liposome formulations in the four cell lines tested.  However, dissimilar to that observed in 
the MTT assay, the response of the different cells lines differed, with HepG2 cells displaying 
the most resistance to the cytotoxic effects of the lipoplexes.  In fact, it showed virtually no 
cytotoxicity in response to most of the liposomal formulations and in some cases proliferation 
of cells actually increased to higher than that of the control cells represented by (----) line in 
the graph.  HeLa-Tat luc and Caco-2 cell lines were the most susceptible while HEK293 cells 
were intermediate in their reaction.  Generally, this assay showed a much higher reduction of 
AlamarBlue
®
 for all liposomal formulations, and therefore a greater level of cell viability 
compared to the MTT assay probably owing to AlamarBlue
®
 assay’s superior degree of 
sensitivity.  Conversely, this assay also presented the most inhibitory effect with a 42% 
decrease in cell survival observed in HeLa-Tat luc cells for SP-CHOL-MTS at lipid-DNA 
ratio 
(w
/w) of 27:1.  GM-CHOL-MTS elicited the lowest overall cytotoxic response from all 
four cell lines. 
 
Both cytotoxicity assays demonstrated results that are consistent with other lipid-based gene 
delivery nanoparticles (Naicker et al., 2014).  The AlamarBlue
®
 has an advantage as it is 
more sensitive and non-toxic and thus probably more accurate than the MTT assay.  None the 
less, neither of these bioassays may be very predictive of in vivo outcomes and careful 
analysis of data is necessary. 
 
4.3.3.  Apoptosis Detection by Acridine Orange and Ethidium Bromide (AO/EB)   
          Staining 
 
Apoptosis is a type of genetically controlled programmed cell death whereby individual cells 
of multicellular organisms undergo self-destruction in reaction to an assortment of stimuli 
that includes an emergency response to viral infections, anomalous growth of cells, cells 
undergoing a period of stress or those that are severely damaged beyond repair.  Apoptosis is 
also responsible for the elimination of cells during normal development when they have 
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become redundant or once they have reached the end of their lifespan (Hong and Wu, 2002; 
Stoddart 2011; Liu et al., 2015).  The alternate mechanism of cell death is necrosis which is 
considered unprogrammed and results in the premature death of cells due to pathological 
conditions such as trauma and toxins and is additionally, almost always detrimental (Rock 
and Kono, 2008).  The process of apoptosis results in distinct morphological characteristics 
such as chromatin condensation, nuclear fragmentation, cell shrinkage, loss of membrane 
integrity and membrane blebbing that can be identified visually by the use of fluorescent 
microscopy and the differential uptake of fluorescent DNA binding dyes such as AO/EB dual 
staining (Cury-Boaventur et al., 2004; Ribble et al., 2005).   
 
Studies in adherent cells and macrophages have shown that cytotoxicities caused by 
liposomes are mostly attributed to apoptosis (Bednarek et al., 2002; Takano et al., 2003).  In 
this investigation, the MTT growth inhibition and AlamarBlue
®
 assays indicated cytotoxicity 
induced by the cationic mitochondriotropic liposomal preparations.  In an effort to evaluate 
whether cell death was mostly apoptotic or necrotic, the AO/EB dual staining technique was 
employed.  Mitochondriotropic liposome-DNA complexes prepared at optimal ratios were 
incubated for 24 hours with the HepG2, HEK293, Caco-2 and HeLa-Tat luc cell lines and 
thereafter stained with AO/EB, the results of which are illustrated in Figure 4.22.  Acridine 
orange is a vital nucleic acid selective fluorescent dye that stains both live and dead cells.  
Ethidium bromide, on the other hand, stains only cells that have lost their cytoplasmic 
membrane integrity thereby allowing EtBr to enter the cells to intercalate the DNA.  
Therefore, live cells appear evenly green with a circular nucleus in the centre of the cell while 
early apoptotic cells look green with bright yellow-green dots located on one side in the 
nuclei as a result of chromatin condensation and fragmentation.  Late apoptotic cells stain 
nuclei orange as the EtBr incorporates into the cells but these nuclei appear fragmented and 
condensed in contrast to necrotic cells that also stain orange but have a structurally normal 
nucleus reminiscent of viable cells and an increased cell volume (Ribble et al., 2005; 
Kasibhatla et al., 2006; Liu et al., 2015).  From the morphological observations made after 
evaluation of the fluorescent images, an apoptotic index (AI), which is defined as the 
percentage of apoptotic cells within the total population of cells, was calculated and plotted 
as a function of the respective cells lines, HepG2, HEK293, Caco-2 and HeLa-Tat luc (Figure 
4.21).  As can be seen from the results, HepG2 cells had the highest level of apoptosis 
observed followed by HEK293, Caco-2 and HeLa-Tat luc cells in this assay with all the 
mitochondriotropic lipoplexes displaying much greater levels of apoptosis than their 
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respective controls (P<0.05; P<0.01; P<0.001) which is to be expected.  No definitive trend 
can be observed as to which liposomal formulation has the greatest influence on apoptosis as 
all the lipoplexes had induced programmed cell death to varying degrees in the different cell 
lines.  These results do not exactly correlate with the cytotoxicity values obtained from the 
MTT and AlamarBlue
®
 assays, with some values obtained here comparatively much higher.  
This can be possibly explained by the fact that this assay does not examine any metabolic 
activity of cells to determine their viability, just morphological observations based on their 
death.  Ćurčić et al. (2012) suggested that differences in cell viability detected between 
metabolic activity-testing cytotoxicity assays, such as MTT, and apoptosis indicating assays 
such as the AO/EB dual staining, could be attributed to the fact that the former ones would 
detect cell death far earlier and the latter only identifies it later in the process.  This assay was 
therefore conclusive in proving that cell death induced by liposomes was apoptotic and not 
necrotic in nature.  However, the results as they relate to actual cytotoxicity of the liposomes 
should be regarded with caution as this assay’s principal purpose is to distinguish and 
quantify the type of cell death and morphological features related to that and not to determine 













Figure 4.21: Apoptotic index calculated as a percentage (%) from results of the AO/EB dual staining  
                      apoptosis assay.  SP-CHOL-MTS, GM-CHOL-MTS, SP-CHOL-MTS-R8 and GM- 
                      CHOL-MTS-R8 mitochondriotropic lipoplexes (containing 1 µg of pCMV-luc DNA)  
                      prepared at optimal binding ratios were incubated with HepG2, HEK293, Caco-2 and  
                      HeLa-Tat luc cell lines.  A control of untreated cells for each cell line was utilised.   
                      Results represent the mean ± SD, n = 2. Statistical analysis was performed using one- 
                      way ANOVA followed by Dunnett multiple comparison post hoc test. *(P<0.05)   
                      **(P<0.01) and ***(P<0.001) indicate a significant  difference compared to the  
                      respective controls. 
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Figure 4.22: Apoptosis assay using AO/EB dual staining and fluorescent microscopy illustrating  
                      morphological changes induced by SP-CHOL-MTS, GM-CHOL-MTS, SP-CHOL- 
                      MTS-R8 and GM-CHOL-MTS-R8 mitochondriotropic lipoplexes (containing 1 µg of  
                      pCMV-luc DNA) prepared at optimal binding ratios in HepG2, HEK293, Caco-2 and  
                      HeLa-Tat luc cell lines as indicated.  A control of untreated cells for each cell line was  
                      utilised.  L: Live cells stained green; EA: early apoptotic cells with condensed yellow- 
                      green nuclei; LA: late apoptotic cells stained orange with condensed nuclei; N: necrotic  
                      cells with uniform orange fluorescence and MB: membrane blebbing, a feature of  




4.3.4.  Evaluation of Cellular Uptake and Mitochondrial Localisation by Fluorescent  
           Studies  
 
 4.3.4.1.  Fluorescence Microscopy  
 




Kit.  The reagents in 
this kit covalently bind marker molecules such as rhodamine to nucleic acids in an 
uncomplicated one-step chemical reaction, which yields fully intact fluorescently-tagged 
DNA for in vitro tracking experiments.  This DNA was used to make up the optimal 
(electroneutral) liposome-DNA ratios, as determined by gel retardation assays, for each of the 
mitochondriotropic liposomes (SP-CHOL-MTS, GM-CHOL-MTS, SP-CHOL-MTS-R8 and 
GM-CHOL-MTS-R8), which were then incubated with the different cell lines for 24 hours. 
Thereafter, the cells were stained with MitoTracker
®
 Green FM, a cell-permeant probe that 
comprises a mildly thiol-reactive chloromethyl moiety that allows it to covalently bind to 
mitochondrial matrix proteins by interacting with free thiol groups of cysteine residues 
thereby labelling mitochondria.  As there are hundreds to thousands of mitochondria that are  
part of an extensive continuous and dynamic cytoskeleton in cells, MitoTracker
®
 Green 
would stain all of them and therefore make the entire cell appear green in images similar to 
that observed in the central panels of Figure 4.25.   
 
Prior to utilising fluorescent microscopy for this assay, confocal laser scanning microscopy 
(CLSM) was employed to attain higher resolution images so as to better evaluate the assay 
and its practical potential in attaining the desired result.  Representative images, similar to 
that of fluorescence microscopy were acquired (Figure 4.23), leading to the decision that 
fluorescent microscopy could indeed be used to garner the desired result.   
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The ability of the cationic mitochondriotropic liposomes to localise rhodamine-labelled 
pCMV-luc DNA (1 µg) intracellulary in the vicinity of mitochondria was examined in living 
HepG2, HEK293, Caco-2 and HeLa-Tat luc cell lines using fluorescent microscopy.  The 
intracellular targeting potential of the mitochondriotropic liposome-rhodamine-labelled 
pCMV-luc DNA complexes (red) was observed after staining mitochondria green with 
MitoTracker
®
 Green FM.  The yellowish fluorescence indicated in the merged fluorescent 
images represents the co-localisation of the rhodamine-labelled pCMV-luc DNA with the 
MitoTracker
®
 Green FM (Figure 4.25, right panels).  Controls containing cells only and cells 
only incubated with naked rhodamine-labelled pCMV-luc DNA were employed.  As can be 
seen there is no fluorescence detected in these control images.  This is an expected result as 
the cells alone should not have any discernible fluorescence and the naked rhodamine-tagged 
DNA would have been likely degraded by the serum nucleases present in the medium.  From 
the results, it appears that MitoTracker
®
 Green was effective in staining the mitochondria of 
cells because, as mentioned above, the hundreds of these organelles present in a cell would 
have picked up the dye and consequently made the whole cell seem green.  It can also be said 
that all mitochondriotropic lipoplexes were successful in the intracellular delivery of the 
rhodamine-DNA cargo.  This is evidenced by the red fluorescence seen in the left panels of 
Figure 4.25 where the DNA appears to be localised almost exclusively inside the cells and 
not in the matrix around the cells.  The artefacts that can be seen brightly fluorescing are 
remnants of the MitoTracker
®
 Green dye.  The proposed mechanism of cellular uptake for 
SP-CHOL-MTS and GM-CHOL-MTS liposomal formulations is non-specific clathrin-
mediated endocytosis (Figure 4.24) while SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 are 
purported to employ macropinocytosis via electrostatic interactions of cellular uptake device, 
R8, with the cell membrane (Figure 4.24).  Both these mechanisms appear to have been 
effective as the results clearly show that there is definite intracellular co-localisation observed 
in all cell lines and for all cationic mitochondriotropic liposome formulations, between the 
green fluorescence of MitoTracker
®
 Green and the red fluorescence of the rhodamine-
labelled DNA as depicted in the merged images in the right panels of Figure 4.25.  It also 
appears that all lipoplexes (SP-CHOL-MTS, GM-CHOL-MTS, SP-CHOL-MTS-R8 and GM-
CHOL-MTS-R8) prepared at optimal liposome-DNA ratios were efficient in firstly, 
enhancing cellular uptake in all four cell lines and secondly, effecting the co-localisation 
observed in the four cell lines tested even though these nanocomplexes were shown to have 
negative zeta potentials. It therefore seems that the zeta potential did not affect the 
performance of the complexes.  
Results and Discussion 
109 
 
This efficiency indeed posed an issue as it is virtually impossible to evaluate which one of 
them was most proficient.  Both MTS and R8 were shown to successfully target mitochondria 
using MITO-Porter and DF-MITO-Porter in a series of studies (Yasuzaki et al., 2010; 
Yamada et al., 2011; Yamada and Harashima, 2013; Kawamura et al., 2013a; Kawamura et 
al., 2013b)   Another concern encountered is that it is not possible to conclusively say that the 
rhodamine-DNA is localised exclusively to mitochondria as this cannot be elucidated by 
these images alone. This observation was also made by Santos et al. (2014) in their 
investigation of plasmid nanoparticles.  However, at this point it is fair to speculate that this 
microscopy study certainly supports the notion of the mitochondriotropic nanoparticles cell 
internalisation and directed selective delivery to the mitochondria.    To further investigate 




























Figure 4.23: Representative images showing intracellular co-localisation by CLMS. Left panel:  
                      mitochondria stained green byMitoTracker
®
 Green FM; Central panel: red fluorescence  
                      from rhodamine-tagged DNA delivered by the nanoparticles; Right panel: merged left  
                      and central panels.  Yellowish colour indicates co-localisation of the rhodamine-tagged  
                      DNA with the MitoTracker
®
 Green FM.  Bar = 10µm. 
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Figure 4.24: Schematic representation of mitochondrial delivery of MTS only and MTS and R8  
                      liposomes.  Lipoplexes enter the cell via endocytosis or macropinocytosis respectively.   
                      Disruption of endosome and macropinosome allows escape of respective liposome- 
                      DNA complexes which then translocate to the mitochondria to which it binds via MTS  
                      and a combination of MTS and R8.   
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Figure 4.25: Intracellular co-localisation by fluorescence microscopy of SP-CHOL-MTS, GM- 
                      CHOL-MTS, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 mitochondriotropic  
                      lipoplexes (containing 1 µg of rhodamine-labelled pCMV-luc DNA) prepared at optimal   
                      binding ratios in (A) HepG2, (B) HEK293, (C) Caco-2 and (D) HeLa-Tat luc cell lines.  
                      Two controls containing cells only and cells exposed to naked rhodamine-tagged DNA  
                      were used.  Left panel: red fluorescence from rhodamine-tagged DNA delivered by the  
                      nanoparticles; Central panel:  mitochondria stained green by MitoTracker
®
 Green FM;  
                      Right panel: merged left and central panels.  Yellowish colour indicates co-localisation  
                      of  the rhodamine-tagged DNA with the MitoTracker
®
 Green FM.  
                      Magnification = 200x. 
 
 
4.3.4.2.  Quantitative Evaluation of Mitochondrial Targeting Activity 
 





 Kit.  This fluorescein-tagged DNA (1 µg) was used to form mitochondriotropic 
lipoplexes at the optimal binding ratios of each of the four liposomal formulations (SP-
CHOL-MTS, GM-CHOL-MTS, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8).  These 
lipoplexes were then added to cell homogenates of the HEK293, HepG2, Caco-2 and HeLa-
Tat luc cell lines to examine their mitochondrial targeting ability.  Cell homogenates were 
used as they are a better model of living cells than isolated mitochondria since they contain 
other organelles (Yamada and Harashima, 2013).  In the previous experiment, living cells 
were used however no conclusive answer was acquired as to whether the presence of MTS 
and/or R8 increased the interaction between liposomes and mitochondria.  To satisfy this 
enquiry, it was decided that homogenates were a superior model system to living cells.  The 
ability of cationic MTS-modified liposomes (SP-CHOL-MTS and GM-CHOL-MTS) to 
selectively target mitochondria was evaluated by assessing the mitochondrial targeting 
activity of these nanoparticles.  The mitochondrial targeting activity of MTS and R8 modified 
liposomes (SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8) was also studied.  MTS peptide is 
well known to have a high mitochondrial targeting activity but it has not been tested with 
these novel liposomal formulations and in dual surface modification with R8. 
 
As mentioned above, lipoplexes prepared at the optimal binding ratios of these liposomes and 
comprising fluorescein-tagged DNA were incubated with the respective cell homogenates. 
The fluorescent level of the fluorescein-tagged DNA and therefore the liposomes themselves 
in the mitochondrial fraction was determined after subcellular fractionation by differential 
centrifugation.  This was calculated to be the mitochondrial targeting activity of the tested 
liposomes and is summarised in Figure 4.26.   





Figure 4.26: Evaluation of mitochondrial targeting of mitochondriotropic liposomes SP-CHOL-MTS,  
                      GM-CHOL-MTS, SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8 in four different cell  
                      homogenates. Lipoplexes (containing 1 µg of fluorescein-labelled pCMV-luc DNA)        
                      were  prepared at optimal binding ratios.  Two controls, comprising untreated cells and  
                      cells exposed to naked DNA were utilised. Results represent the mean ± SD, n = 3.  
                      Statistical analysis was performed using one-way ANOVA followed by Dunnett 
                      multiple comparisons post hoc test. *(P<0.05) and ***(P<0.001) indicate a significant    
                      difference.  
 
 
From the results, it was observed that both MTS alone and MTS in combination with R8 
definitely improved the mitochondrial targeting of nanoparticles that were larger than 150 nm 
(Table 4.2).  Lipoplexes prepared at optimal binding ratios of MTS only (SP-CHOL-MTS 
and GM-CHOL-MTS) and MTS and R8 (SP-CHOL-MTS-R8 and GM-CHOL-MTS-R8) 
liposomes displayed much greater mitochondrial targeting efficiencies (P<0.001) than the 
two controls employed in the HepG2, HEK293, Caco-2 and HeLa-Tat luc cell homogenates. 
The two controls showed little fluorescence, as was expected as the cells alone were 
untreated and the naked fluorescein-tagged DNA would have likely been degraded by 
nucleases.  In terms of the differences observed between the MTS only liposomes (SP-
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and GM-CHOL-MTS-R8), the MTS and R8 nanocomplexes seem to have a slight though not 
statistically significant advantage, except in the case of GM-CHOL-MTS-R8 in the Caco-2 
cell homogenates (P<0.05), over their MTS only counterparts.  This could be as a result of 
the R8, as recent studies reported that R8 also serves as a mitochondrial targeting device via 
electrostatic interactions with the mitochondria, which has a highly negative potential.  This 
gives R8 the ability to deliver certain cargoes to the mitochondria (Khalil et al., 2006a; 
Yamada et al., 2012).  However, in another study conducted by the same authors they 
postulated that R8 had non-specific binding to the mitochondria, and R8 modified liposomes 
performed poorly compared to MTS modified liposomes in mitochondrial targeting (Yamada 
and Harashima, 2013).  Conversely, in a more recent study, the authors once again suggested 
that R8 had mitochondrial targeting properties (Yamada et al., 2015).  
 
In line with these findings, in this study the presence of R8 together with MTS appeared to 
have a beneficial effect.  No significant difference was detected between the majority of the 
liposomes containing the SP-CHOL and GM-CHOL cholesterol-derived cross-linking agent, 
except in the case of GM-CHOL-MTS-R8 where a significant increase (P<0.05) can be noted 
in mitochondrial targeting activity of this liposome in the Caco-2 cell homogenates.  This 
could possibly be from the slightly longer spacer in the cross-linker structure that may give 
the MTS and R8 peptides attached to it an added advantage in mitochondrial targeting.  No 
significant difference was observed between the liposomes performances the different cell 
homogenates.  Interestingly, this assay does not indicate whether or not the delivered pDNA 
entered the mitochondria, just that it was targeted or localised to mitochondria which as 
suggested by Niazi et al. (2013) is adequate for mitochondrial gene therapy considering that 
these authors speculated that mitochondrial competence for DNA uptake is an intrinsic 
property of the organelle and has the potential capability to support mitochondrial 
transfection in living cells.  Overall, mitochondrial targeting and localisation analysis of this 
assay’s results revealed that both MTS only and a combination of MTS and R8 can function 
as mitochondrial targeting devices in combination with liposomes, leading to enhanced 
mitochondrial targeting of these novel liposomal formulations observed in a variety of cell 







5.1.  CONCLUDING REMARKS  
 
Mitochondria are organelles that are of mounting interest in pharmaceutical and nanomedical 
research, since it was discovered that dysfunction of these organelles contribute to numerous 
diseases and pathologies, each with a different clinical manifestation.  To date, not much is 
understood about these defects and their implications in mitochondrial diseases.  It is 
speculated that nanotechnology, specifically gene therapy will shed more light on these 
dysfunctions.  However, mitochondrial gene therapy is a field still in its early developmental 
stages, but has immense potential in finally elucidating, observing and manipulating the 
mitochondria and its genome to clarify its role in common diseases such as Alzheimer’s 
disease, Parkinson’s disease, cancer, neurodegeneration and ageing.  Additionally, it would 
serve to increase our understanding of defects and dysfunctions present in mitochondrial 
disease leading to more efficient treatment and possibly cure.  This stagnicity in 
mitochondrial research is, in part, due to the non-existence of an efficient, safe and 
biocompatible mitochondrial targeting nanovector.  Therefore, the development of a non-
toxic and effective mitochondrial targeting system is required but this still remains a fairly 
arduous challenge.  
 
This study evaluated the ability of four novel cationic mitochondriotropic lipid-based 
delivery systems to improve the efficacy of cellular uptake and mitochondrial localisation of 
model plasmid DNA in four different cell line models.  The cationic cytofectin, CHOL-T, 
together with the neutral lipid, DOPE; the cholesterol-derived cross-linkers, SP-CHOL and 
GM-CHOL, and the MTS and R8 peptides were able to form mitochondriotropic liposomes 
capable of successfully binding and additionally, protecting pDNA from the effects of serum 
nucleases.  The liposomes and their corresponding optimal lipoplexes also presented with 
relatively favourable particle sizes and zeta potential measurements as well as being 
morphologically spherical in shape.  These nanovectors were reproducible and stable to long-




In vitro cell culture studies examining the cytotoxicity profile of these novel liposomal 
formulations revealed them to be well tolerated by, and display minimal toxicity to, the  
HepG2, HEK293, Caco-2 and HeLa-Tat luc, cell lines tested.  Additionally, evaluation of the 
mechanism of cell death induced by these delivery vehicles indicated that apoptosis was the 
predominant process.  
 
Initial studies into the cellular uptake and co-localisation of the liposome-rhodamine tagged 
DNA complex with mitochondria in living cells was conducted using CLSM as a proof of 
principle of the technique and subsequent studies were performed utilising fluorescent 
microscopy.  Fluorescent images demonstrated that the mitochondriotropic liposomes did 
indeed overwhelmingly enhance cellular uptake, in the presence of serum, as can be inferred 
by the obvious and substantial co-localisation observed between green stained mitochondria 
of cells and the red rhodamine-tagged DNA delivered by the nanovectors, compared to the 
two controls employed which showed no detectable fluorescence.  However, the images 
could not provide detailed definitive evidence that the rhodamine-tagged DNA was 
exclusively localised specifically to mitochondria in these living cells. 
 
In an attempt to further elucidate mitochondrial localisation and targeting ability of the MTS 
only (SP-CHOL-MTS and GM-CHOL-MTS) and MTS and R8 (SP-CHOL-MTS-R8 and 
GM-CHOL-MTS-R8) liposomes, cell homogenates were employed.  Efficient accumulation 
of the MTS modified and MTS and R8 modified liposomes on mitochondria was confirmed 
using these various cell homogenate cocktails.  This strongly suggested that the presence of 
MTS on the liposomal surface did indeed significantly increase (P<0.001) the mitochondrial 
localisation and targeting ability of the liposomes as evidenced by the increased presence of 
fluorescence in the mitochondrial fraction of the homogenates for all cell lines tested.  The 
dual surface modification of MTS and R8 peptides of the liposomes appeared to perform 
better than their MTS only counterparts with the GM-CHOL-MTS-R8 liposomal preparation 
performing the best in terms of mitochondrial localisation and targeting.  So it can be 
assumed that R8 contributed to the mitochondrial targeting ability of the liposome.   This 
particular liposome also displayed low toxicity and high DNA compaction and binding 
affinity as indicated by the MTT, AlamarBlue
® 
and ethidium bromide intercalation assays 





These results reflect the potential of these four cationic mitochondriotropic liposomes in 
accomplishing cellular uptake and mitochondrial targeting and localisation.  These findings 
support the hypothesis that these MTS only and a combination of MTS and R8 modified 
liposomes have the ability for future corrective and restorative mitochondrial gene delivery.  
However, even though all four nanovectors proved to be competent at achieving cellular 
uptake and mitochondrial targeting to varying degrees, it can be reasoned that the GM-
CHOL-MTS-R8 liposome holds the most potential for further development and eventual 
establishment as a clinically applicable vector system for effective mitochondrial delivery of 
therapeutic genes and bioactive molecules.   
 
Possible limitations to this study include the lack of; firstly, an available mitochondria-
specific reporter gene system that will allow for easy expression and simple identification 
inside mitochondria and secondly, advanced bioassays that can definitely establish the 
presence of delivered DNA inside mitochondria.  The absence of these confirmatory assays 
greatly contributed to the inconclusive fluorescence microscopy results of this study that 
could not categorically determine if rhodamine-tagged DNA was exclusively co-localised to 
mitochondria in living cells.  Until these bioassays are developed, all mitochondrial targeted 
delivery systems have to rely on indirect methods of demonstrating mitochondrial targeting 
of DNA.   
 
Future studies include, improvement of the vector system, possibly by incorporating a 
fluorescent component into its structure so as to better visualise it in living cells and, 
evaluating the ability of these cationic mitochondriotropic liposomes to target mitochondria 
in an animal model in vivo.  Additional work to confirm mechanisms of cell internalisation 
and endosomal escape may be investigated to give a superior understanding of intracellular 
trafficking.  To conclude, taking into consideration their relatively non-toxic nature and 
stability in serum in vitro, these novel cationic mitochondriotropic liposomes appear to be a 
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Research studies about and on mitochondria have been carried out continuously and with 
considerable success for over a century.  In fact, since the publication of two papers in 1988, 
one in Science and the other in Nature revealed that mutations in the mitochondrial genome 
could cause human disease; mitochondrial gene targeting in gene therapy is steadily emerging 
to show great potential.  Mitochondrial research is currently one of the fastest growing 
disciplines in biomedicine, so much so that it has given rise to the development of new sub-
disciplines such as Mitochondrial Medicine, Mitochondrial Pharmaceutics and Mitochondrial 
Pharmacology.  There have been a number of studies and reports of successful biomolecule 
delivery to the mitochondria.  This review explores the experimental strategies currently 
being developed to deliver macromolecules including, model DNA and drug molecules to 
mitochondria, by discussing the theory underlying each strategy, and detailing the current 
progress made. Emphasis is made on the potential hurdles that must be acknowledged and 
overcome.   
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